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Guidelines summarize and evaluate all available evidence on a par-
ticular issue at the time of the writing process, with the aim of assist-
ing health professionals in selecting the best management strategies
for an individual patient with a given condition, taking into account
the impact on outcome, as well as the risk–benefit ratio of particular
diagnostic or therapeutic means. Guidelines and recommendations
should help health professionals to make decisions in their daily
practice. However, the final decisions concerning an individual
patient must be made by the responsible health professional(s) in
consultation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years
by the European Society of Cardiology (ESC) and by the European
Association for Cardio-Thoracic Surgery (EACTS), as well as by
other societies and organisations. Because of the impact on clini-
cal practice, quality criteria for the development of guidelines
have been established in order to make all decisions transparent
to the user. The recommendations for formulating and issuing
ESC Guidelines can be found on the ESC website (http://www.
escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/
Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines
represent the official position of the ESC on a given topic and are
regularly updated.
Members of this Task Force were selected by the ESC, includ-
ing representation from the European Heart Rhythm Association
(EHRA), and EACTS as well as by the European Stroke
Organisation (ESO) to represent professionals involved with the













medical care of patients with this pathology. Selected experts in
the field undertook a comprehensive review of the published evi-
dence for management (including diagnosis, treatment, preven-
tion and rehabilitation) of a given condition according to ESC
Committee for Practice Guidelines (CPG) policy and approved by
the EACTS and ESO. A critical evaluation of diagnostic and thera-
peutic procedures was performed, including assessment of the
risk–benefit ratio. Estimates of expected health outcomes for
larger populations were included, where data exist. The level of
evidence and the strength of the recommendation of particular
management options were weighed and graded according to
predefined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided dec-
laration of interest forms for all relationships that might be per-
ceived as real or potential sources of conflicts of interest. These
forms were compiled into one file and can be found on the ESC
website (http://www.escardio.org/guidelines). Any changes in
declarations of interest that arise during the writing period must
be notified to the ESC and EACTS and updated. The Task Force
received its entire financial support from the ESC and EACTS
without any involvement from the healthcare industry.
The ESC CPG supervises and co-ordinates the preparation of
new Guidelines produced by task forces, expert groups or con-
sensus panels. The Committee is also responsible for the
endorsement process of these Guidelines. The ESC Guidelines
undergo extensive review by the CPG and external experts, and
in this case by EACTS and ESO-appointed experts. After appropri-
ate revisions the Guidelines are approved by all the experts
involved in the Task Force. The finalized document is approved
by the CPG, EACTS and ESO for publication in the European
Heart Journal, Europace, and in the European Journal of Cardio-
Thoracic Surgery. The Guidelines were developed after careful
consideration of the scientific and medical knowledge and the
evidence available at the time of their dating.
The task of developing ESC and EACTS Guidelines covers
not only integration of the most recent research, but also the
creation of educational tools and implementation programmes
for the recommendations. To implement the guidelines, con-
densed pocket guideline versions, summary slides, booklets with
essential messages, summary cards for non-specialists and an
electronic version for digital applications (smartphones, etc.)
are produced. These versions are abridged and thus, if needed,
one should always refer to the full text version, which is freely
available on the ESC website. The National Societies of the ESC
are encouraged to endorse, translate and implement all ESC
Guidelines. Implementation programmes are needed because
it has been shown that the outcome of disease may be favour-
ably influenced by the thorough application of clinical
recommendations.
Surveys and registries are needed to verify that real-life daily
practice is in keeping with what is recommended in the guide-
lines, thus completing the loop between clinical research, writing
of guidelines, disseminating them and implementing them into
clinical practice.
Table 2: Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
Table 1: Classes of recommendations
Classes of 
recommendations
Suggested wording to 
use
Class I Evidence and/or general agreement 





divergence of opinion about the 
treatment or procedure. 
    Class IIa Weight of evidence/opinion is in Should be considered
    Class IIb
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement that 
the given treatment or procedure 
is not useful/effective and in some 
cases may be harmful. 
Is not recommended
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Health professionals are encouraged to take the ESC and
EACTS Guidelines fully into account when exercising their clinical
judgment, as well as in the determination and the implementa-
tion of preventive, diagnostic or therapeutic medical strategies.
However, the ESC and EACTS Guidelines do not override in any
way whatsoever the individual responsibility of health professio-
nals to make appropriate and accurate decisions in consideration
of each patient’s health condition and in consultation with that
patient and the patient’s caregiver where appropriate and/or
necessary. It is also the health professional’s responsibility to ver-
ify the rules and regulations applicable to drugs and devices at
the time of prescription.
2. INTRODUCTION
Despite good progress in the management of patients with atrial
fibrillation (AF), this arrhythmia remains one of the major causes
of stroke, heart failure, sudden death, and cardiovascular morbid-
ity in the world. Furthermore, the number of patients with AF is
predicted to rise steeply in the coming years. To meet the grow-
ing demand for effective care of patients with AF, new informa-
tion is continually generated and published, and the last few
years have seen substantial progress. Therefore, it seems timely
to publish this 2nd edition of the ESC guidelines on AF.
Reflecting the multidisciplinary input into the management of
patients with AF, the Task Force includes cardiologists with varying
subspecialty expertise, cardiac surgeons, stroke neurologists, and
specialist nurses amongst its members. Supplementing the evi-
dence review as outlined in the preamble, this Task Force defined
three Population, Intervention, Comparison, Outcome, Time
(PICOT) questions on relevant topics for the guidelines. The ESC
commissioned external systematic reviews to answer these ques-
tions, and these reviews have informed specific recommendations.
Further to adhering to the standards for generating recom-
mendations that are common to all ESC guidelines (see pream-
ble), this Task Force discussed each draft recommendation
during web-based conference calls dedicated to specific chap-
ters, followed by consensus modifications and an online vote on
each recommendation. Only recommendations that were sup-
ported by at least 75% of the Task Force members were included
in the guidelines.
We hope that these guidelines will help to deliver good care to
all patients with AF based on the current state-of-the-art evi-
dence in 2016.
3. EPIDEMIOLOGY AND IMPACT FOR PATIENTS
3.1 Incidence and prevalence of atrial fibrillation
In 2010, the estimated numbers of men and women with AF
worldwide were 20.9 million and 12.6 million, respectively, with
higher incidence and prevalence rates in developed countries
[1, 2]. One in four middle-aged adults in Europe and the US will
develop AF [3–5]. By 2030, 14–17 million AF patients are antici-
pated in the European Union, with 120 000–215 000 newly
diagnosed patients per year [2, 6, 7]. Estimates suggest an AF
prevalence of approximately 3% in adults aged 20 years or older
[8, 9], with greater prevalence in older persons [1] and in
patients with conditions such as hypertension, heart failure,
coronary artery disease (CAD), valvular heart disease, obesity,
diabetes mellitus, or chronic kidney disease (CKD) [7, 10–15].
The increase in AF prevalence can be attributed both to better
detection of silent AF [16–18], alongside increasing age and
conditions predisposing to AF [19].
3.2 Morbidity, mortality, and healthcare burden of
atrial fibrillation
AF is independently associated with a two-fold increased risk of
all-cause mortality in women and a 1.5-fold increase in men [20–
22] (Table 3). Death due to stroke can largely be mitigated by
anticoagulation, while other cardiovascular deaths, for example
due to heart failure and sudden death, remain common even in
AF patients treated according to the current evidence base [23].
AF is also associated with increased morbidity, such as heart fail-
ure and stroke [21, 24, 25]. Contemporary studies show that 20–
30% of patients with an ischaemic stroke have AF diagnosed
before, during, or after the initial event [17, 26, 27]. White matter
lesions in the brain, cognitive impairment [28–30], decreased
quality of life [31, 32], and depressed mood [33] are common in
AF patients, and between 10–40% of AF patients are hospitalized
each year [23, 34, 35].
The direct costs of AF already amount to approximately 1% of
total healthcare spending in the UK, and between 6.0–26.0 billion
US dollars in the US for 2008 [36, 37], driven by AF-related com-
plications (e.g. stroke) and treatment costs (e.g. hospitalizations).
These costs will increase dramatically unless AF is prevented and
treated in a timely and effective manner.
3.3 Impact of evidence-based management on out-
comes in atrial fibrillation patients
Figure 1 depicts the major milestones in the management of AF.
Despite these advances, substantial morbidity remains. Oral
Table 3: Cardiovascular morbidity and mortality associated
with atrial fibrillation
Event Association with AF
Death Increased mortality, especially cardiovascular 
mortality due to sudden death, heart failure or 
stroke. 
Stroke 20–30% of all strokes are due to AF.  A growing 
number of patients with stroke are diagnosed with 
‘silent’, paroxysmal AF.
Hospitalizations 10–40% of AF patients are hospitalized every year.
Quality of life Quality of life is impaired in AF patients independent 




Left ventricular dysfunction is found in 20–30% of all 
AF patients.  AF causes or aggravates LV dysfunction 
in many AF patients, while others have completely 




Cognitive decline and vascular dementia can 
develop even in anticoagulated AF patients. 
Brain white matter lesions are more common in 
AF patients than in patients without AF.
AF = atrial fibrillation; LV = left ventricular.













anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-
VKA oral anticoagulants (NOACs) markedly reduces stroke and
mortality in AF patients [38, 39]. Other interventions such as
rhythm control and rate control improve AF-related symptoms
and may preserve cardiac function, but have not demonstrated a
reduction in long-term morbidity or mortality [40, 41].
In contemporary, well-controlled, randomized clinical trials in
AF, the average annual stroke rate is about 1.5% and the annual-
ized death rate is around 3% in anticoagulated AF patients [40].
In real life, the annual mortality can be different (both higher and
lower) [42]. A minority of these deaths are related to stroke, while
sudden cardiac death and death from progressive heart failure
are more frequent, emphasizing the need for interventions
beyond anticoagulation [43, 44]. Furthermore, AF is also associ-
ated with high rates of hospitalization, commonly for AF man-
agement, but often also for heart failure, myocardial infarction,
and treatment-associated complications [34, 45].
3.4 Gender
In both developed and developing countries, the age-adjusted inci-
dence and prevalence of AF are lower in women, while the risk of
death in women with AF is similar to or higher than that in men
with AF [1, 46, 47]. Female AF patients who have additional stroke
risk factors (particularly older age) are also at greater risk than men
of having a stroke [48, 49], even those anticoagulated with warfarin
Figure 1: Timeline of findings from landmark trials in atrial fibrillation management, including treatment of concomitant conditions and prevention (green), anti-
coagulation (blue), rate control therapy (orange), rhythm control therapy (red), and atrial fibrillation surgery (purple).
Recommendations relating to gender
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[50] (see Chapter 9 for details). Women with diagnosed AF can be
more symptomatic than men and are typically older with more
comorbidities [51, 52]. Bleeding risk on anticoagulation is similar in
both sexes [49, 50, 53], but women appear less likely to receive spe-
cialist care and rhythm control therapy [54], while the outcomes of
catheter ablation or AF surgery are comparable to those in men [55,
56]. These observations highlight the need to offer effective diagnos-
tic tools and therapeutic management equally to women and men.
4. PATHOPHYSIOLOGICAL AND GENETIC
ASPECTS THAT GUIDE MANAGEMENT
4.1 Genetic predisposition
AF, especially early-onset AF, has a strong heritable component
that is independent of concomitant cardiovascular conditions
[58, 59]. A few young AF patients suffer from inherited cardio-
myopathies or channelopathies mediated by disease-causing
mutations. These monogenic diseases also convey a risk for sud-
den death (see Chapter 6). Up to one-third of AF patients carry
common genetic variants that predispose to AF, albeit with a rel-
atively low added risk. At least 14 of these common variants,
often single nucleotide polymorphisms, are known to increase
the risk of prevalent AF in populations [60–62]. The most impor-
tant variants are located close to the paired-like homeodomain
transcription factor 2 (Pitx2) gene on chromosome 4q25 [63, 64].
These variants modify the risk of AF up to seven-fold [64]. Several
of the AF risk variants are also associated with cardioembolic or
ischaemic stroke, possibly due to silent AF (see section 5.1) [62,
65, 66]. Changes in atrial action potential characteristics [67–70],
atrial remodelling, and modified penetration of rare gene defects
[61] have been suggested as potential mechanisms mediating
increased AF risk in carriers of common gene variants. Genetic
variants could, in the future, become useful for patient selection
of rhythm or rate control [71–74]. While genomic analysis may
provide an opportunity to improve the diagnosis and manage-
ment of AF in the future [75, 76], routine genetic testing for com-
mon gene variants associated with AF cannot be recommended
at present [77].
4.2 Mechanisms leading to atrial fibrillation
4.2.1 Remodelling of atrial structure and ion channel
function. External stressors such as structural heart disease,
hypertension, possibly diabetes, but also AF itself induce a slow
but progressive process of structural remodelling in the atria
(Figure 2). Activation of fibroblasts, enhanced connective tissue
deposition, and fibrosis are the hallmarks of this process [78–80].
In addition, atrial fatty infiltration, inflammatory infiltrates, myo-
cyte hypertrophy, necrosis, and amyloidosis are found in AF
patients with concomitant conditions predisposing to AF [81–84].
Structural remodelling results in electrical dissociation between
muscle bundles and local conduction heterogeneities [85],
favouring re-entry and perpetuation of the arrhythmia [86]. In
many patients, the structural remodelling process occurs before
the onset of AF [78]. As some of the structural remodelling will be
irreversible, early initiation of treatment seems desirable [87].
Table 4 gives an overview of the most relevant pathophysiologi-
cal alterations in atrial tissue associated with AF, and lists
corresponding clinical conditions that can contribute to these
changes.
The functional and structural changes in atrial myocardium
and stasis of blood, especially in the left atrial appendage (LAA),
generate a prothrombotic milieu. Furthermore, even short epi-
sodes of AF lead to atrial myocardial damage and the expression
of prothrombotic factors on the atrial endothelial surface, along-
side activation of platelets and inflammatory cells, and contribute
to a generalized prothrombotic state [88, 89]. The atrial and sys-
temic activation of the coagulation system can partially explain
why short episodes of AF convey a long-term stroke risk.
4.2.2 Electrophysiological mechanisms of atrial fibrilla-
tion. AF provokes a shortening of the atrial refractory period and
AF cycle length during the first days of the arrhythmia, largely
due to downregulation of the Ca2+-inward current and upregula-
tion of inward rectifier K+ currents [94, 95]. Structural heart dis-
ease, in contrast, tends to prolong the atrial refractory period,
illustrating the heterogeneous nature of mechanisms that cause
AF in different patients [96]. Hyperphosphorylation of various
Ca2+-handling proteins may contribute to enhanced spontaneous
Ca2+ release events and triggered activity [97, 98], thus causing
ectopy and promoting AF. Although the concept of Ca2+-han-
dling instability has been challenged recently [106, 107], it may
mediate AF in structurally remodelled atria and explain how
altered autonomic tone can generate AF [80, 105].
4.2.2.1 Focal initiation and maintenance of atrial fibrillation. The
seminal observation by Haissaguerre et al. [108]. was that a focal
source in the pulmonary veins can trigger AF, and ablation of this
source can suppress recurrent AF. The mechanism of focal activ-
ity might involve both triggered activity and localized reentry
[109, 110]. Hierarchic organization of AF with rapidly activated
areas driving the arrhythmia has been documented in patients
with paroxysmal AF [111, 112], but is less obvious in unselected
patients with persistent AF [113].
4.2.2.2 The multiple wavelet hypothesis and rotors as sources of
atrial fibrillation. Moe and Abildskov [114] proposed that AF can
be perpetuated by continuous conduction of several independ-
ent wavelets propagating through the atrial musculature in a
seemingly chaotic manner. As long as the number of wavefronts
does not decline below a critical level, they will be capable of
sustaining the arrhythmia. Numerous experimental and clinical
observations can be reconciled with the multiple wavelet
hypothesis [115]. All localized sources of AF (ectopic foci, rotors,
or other stable re-entry circuits) cause fibrillatory conduction
remote from the source, which is difficult to distinguish from
propagation sustaining AF by multiple wavelets, and either of
these phenomena may generate ‘rotors’ picked up by intracar-
diac [116, 117] or body surface [117] recordings.
5. DIAGNOSIS AND TIMELY DETECTION OF
ATRIAL FIBRILLATION
5.1 Overt and silent atrial fibrillation
The diagnosis of AF requires rhythm documentation using an elec-
trocardiogram (ECG) showing the typical pattern of AF: Absolutely
irregular RR intervals and no discernible, distinct P waves. ECG-
documented AF was the entry criterion in trials forming the













evidence for these guidelines. By accepted convention, an episode
lasting at least 30 s is diagnostic. Individuals with AF may be symp-
tomatic or asymptomatic (‘silent AF’). Many AF patients have both
symptomatic and asymptomatic episodes of AF [118–121].
Silent, undetected AF is common [120, 122], with severe conse-
quences such as stroke and death [123–125]. Prompt recording
of an ECG is an effective and cost-effective method to document
chronic forms of AF [126]. The technology to detect paroxysmal,
self-terminating AF episodes is rapidly evolving (see section 6.1
for a definition of AF patterns). There is good evidence that pro-
longed ECG monitoring enhances the detection of undiagnosed
AF, e.g. monitoring for 72 h after a stroke [27, 127], or even lon-
ger periods [18, 128]. Daily short-term ECG recordings increase
AF detection in populations over 75 years of age [129] (Web
Figure 1). Ongoing studies will determine whether such early
detection alters management (e.g. initiation of anticoagulation)
and improves outcomes.
Once the ECG diagnosis of AF has been established, further
ECG monitoring can inform management in the context of: (1) a
change in symptoms or new symptoms; (2) suspected progression
of AF; (3) monitoring of drug effects on ventricular rate; and (4)
monitoring of antiarrhythmic drug effects or catheter ablation for
rhythm control.
5.2 Screening for silent atrial fibrillation
5.2.1 Screening for atrial fibrillation by electro-
cardiogram in the community. Undiagnosed AF is common,
especially in older populations and in patients with heart failure
[130]. Opportunistic screening for silent AF seems cost-effective
in elderly populations (e.g. >65 years) [131], and similar effects
have been reported using single-lead ECG screening in other
at-risk populations [132, 133]. Screening of older populations
(mean age 64 years) yielded a prevalence of 2.3% for chronic
forms of AF in 122,571 participants using either short-term ECG
or pulse palpation (followed by ECG in those with an irregular
pulse) [134]. Previously undiagnosed AF was found in 1.4% of
Figure 2: Major mechanisms causing atrial fibrillation that can be considered when choosing therapy. The various aetiological factors (left) cause a complex array of
pathophysiological changes in the atria, including stretch-induced atrial fibrosis, hypocontractility, fatty infiltration, inflammation, vascular remodelling, ischaemia,
ion channel dysfunction, and Ca2+-instability. These changes enhance both ectopy and conduction disturbances, increasing the propensity of the atria to develop or
maintain AF. At the same time, some of these alterations are involved in the occurrence of the hypercoagulable state associated with AF. For example, hypocontractil-
ity reduces local endothelial shear stress, which increases PAI-1 expression, and ischaemia-induced inflammation enhances the expression of endothelial adhesion
molecules or promotes shedding of endothelial cells, resulting in tissue factor exposure to the blood stream. These changes contribute to the thrombogenic milieu in
the atria of AF patients. AF in itself can aggravate many of the mechanisms shown, which may explain the progressive nature of the arrhythmia.
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those aged >65 years, suggesting a number needed to screen of
70. These findings encourage the further evaluation of system-
atic AF screening programmes in at-risk populations.
5.2.2 Prolonged monitoring for paroxysmal atrial fibrilla-
tion. Paroxysmal AF is often missed [120]. Repeated daily ECG
recordings increased the detection of silent, asymptomatic parox-
ysmal AF in an unselected Swedish population aged >75 years
[120, 135]. Several patient-operated devices [136, 137] and
extended continuous ECG monitoring using skin patch recorders
[138] have been validated for the detection of paroxysmal AF (Web
Figure 1) [139]. The detection of asymptomatic AF by new technol-
ogies, such as smartphone cases with ECG electrodes, smart
watches, and blood pressure machines with AF detection algo-
rithms, has not yet been formally evaluated against an established
arrhythmia detection method [140].
5.2.3 Patients with pacemakers and implanted devices.
Implanted pacemakers or defibrillators with an atrial lead allow
continuous monitoring of atrial rhythm. Using this technology,
patients with atrial high rate episodes (AHRE) can be identified.
Depending on the risk profile of the population studied, such
AHRE are detected in 10–15% of pacemaker patients [141]. AHRE
are associated with an increased risk of overt AF [hazard ratio
(HR) 5.56; 95% confidence interval (CI) 3.78–8.17; P < 0.001] and
ischaemic stroke or systemic embolism (HR 2.49; 95% CI 1.28–
4.85; P = 0.007). The stroke risk in AHRE patients seems lower
than the stroke risk in patients with diagnosed AF, and not all
AHRE represent AF [142]. Strokes often occur without AHRE
detected within 30 days before the event [143–147].
Consequently, it is unclear whether AHRE imply the same thera-
peutic requirements as overt AF [148], and the benefit of OAC in
patients with AHRE is tested in ongoing clinical trials [e.g.
Apixaban for the Reduction of Thrombo-Embolism in Patients
Table 4: Pathophysiological alterations in atrial tissue associated with atrial fibrillation and clinical conditions that could contribute
to such alterations
AF = atrial fibrillation; CAD = coronary artery disease.













With Device-Detected Sub-Clinical Atrial Fibrillation
(ARTESiA) (NCT01938248) and Non vitamin K antagonist Oral
anticoagulants in patients with Atrial High rate episodes
(NOAH – AFNET 6) (NCT02618577)]. At present, pacemakers and
implanted devices should be interrogated on a regular basis for
AHRE, and patients with AHRE should undergo further assess-
ment of stroke risk factors and for overt AF, including ECG moni-
toring (Figure 3) [149].
5.2.4 Detection of atrial fibrillation in stroke survivors.
Sequential stratified ECG monitoring detected AF in 24% (95% CI
17–31) of stroke survivors [151], and in 11.5% (95% CI 8.9%–
14.3%) in another meta-analysis [17], with large variations
depending on the timing, duration, and method of monitoring.
AF detection is not uncommon in unselected stroke patients
(6.2%, 95% CI 4.4–8.3) [128], but is more likely in patients with
cryptogenic stroke implanted with loop recorders or who have
had ECG monitors for several weeks [18, 128, 152]. Cryptogenic
stroke is defined as a stroke in which the cause could not be
identified after extensive investigations [153]. A broader definition
is embolic stroke of undetermined source [154]. Several studies
have also found AF in patients in whom another competing
cause for stroke has been identified clinically (e.g. hypertension
or carotid artery stenosis) [27, 127]. Hence, prolonged ECG moni-
toring seems reasonable in all survivors of an ischaemic stroke
without an established diagnosis of AF.
5.3 Electrocardiogram detection of atrial flutter
Right atrial isthmus-dependent flutter has a typical ECG pattern
and ventricular rate [158]. The prevalence of atrial flutter is less
than one-tenth of the prevalence of AF [159]. Atrial flutter often
coexists with or precedes AF [160]. In typical, isthmus-dependent
flutter, P waves will often show a ‘saw tooth’ morphology, espe-
cially in the inferior leads (II, III, aVF). The ventricular rate can be
variable (usual ratio of atrial to ventricular contraction 4:1 to 2:1,
in rare cases 1:1) and macro re-entrant tachycardias may be
missed in stable 2:1 conduction. Vagal stimulation or intravenous
adenosine can therefore be helpful to unmask atrial flutter. The
management of atrial flutter is discussed in section 13.7. Left or
[150].
Figure 3: Management of AHRE detected by an implanted device.
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right atrial macro re-entrant tachycardia is mainly found in
patients after catheter ablation for AF, AF surgery, or after open
heart surgery [158].
6. CLASSIFICATION OF ATRIAL FIBRILLATION
6.1 Atrial fibrillation pattern
In many patients, AF progresses from short, infrequent epi-
sodes to longer and more frequent attacks. Over time, many
patients will develop sustained forms of AF. In a small propor-
tion of patients, AF will remain paroxysmal over several deca-
des (2–3% of AF patients) [161]. The distribution of paroxysmal
AF recurrences is not random, but clustered [162]. AF may also
regress from persistent to paroxysmal AF. Furthermore,
asymptomatic recurrences of AF are common in patients with
symptomatic AF [120].
Based on the presentation, duration, and spontaneous termi-
nation of AF episodes, five types of AF are traditionally distin-
guished: first diagnosed, paroxysmal, persistent, long-standing
persistent, and permanent AF (Table 5). If patients suffer from
both paroxysmal and persistent AF episodes, the more common
type should be used for classification. Clinically determined AF
patterns do not correspond well to the AF burden measured by
long-term ECG monitoring [163]. Even less is known about the
response to therapy in patients with long-standing persistent AF
or long-standing paroxysmal AF. Despite these inaccuracies, the
distinction between paroxysmal and persistent AF has been used
in many trials and therefore still forms the basis of some
recommendations.
There is some evidence suggesting that AF burden may influ-
ence stroke risk [44, 124, 164] and could modify the response to
rhythm control therapy [76, 165]. The evidence for this is weak.
Therefore, AF burden should not be a major factor in deciding
on the usefulness of an intervention that is deemed suitable for
other reasons.
6.2 Atrial fibrillation types reflecting different
causes of the arrhythmia
The risk of developing AF is increased in a variety of physio-
logical and disease states (Figure 2), and the historic term
‘lone AF’ is probably misleading and should be avoided [166].
Although the pattern of AF may be the same, the mechanisms
underpinning AF vary substantially between patients [167]
(Table 6). This suggests that stratifying AF patients by underly-
ing drivers of AF could inform management, for example, con-
sidering cardiac and systemic comorbidity (e.g. diabetes and
obesity [168]), lifestyle factors (e.g. activity level, smoking,
alcohol intake [169, 170]), markers of cardiac structural
Recommendations for screening for atrial fibrillation
AF = atrial fibrillation; AHRE = atrial high rate episodes; ECG = electro-





Table 5: Patterns of atrial fibrillation
AF = atrial fibrillation.
aThe distinction between paroxysmal and persistent AF is often not
made correctly without access to long-term monitoring [163]. Hence,
this classification alone is often insufficient to select specific therapies.
If both persistent and paroxysmal episodes are present, the predomi-
nant pattern should guide the classification.













remodelling (e.g. fibrosis [171–173] or electrocardiographic param-
eters of AF complexity [174]), or genetic background. Table 6 pro-
vides such a taxonomy, informed by expert consensus [76, 120,
175], but without much evidence to underpin its clinical use [176].
Systematic research defining the major drivers of AF is clearly
needed to better define different types of AF [176].
6.3 Symptom burden in atrial fibrillation
Patients with AF have significantly poorer quality of life than
healthy controls, experiencing a variety of symptoms including
lethargy, palpitations, dyspnoea, chest tightness, sleeping difficul-
ties, and psychosocial distress [32, 177–180]. Improved quality of
life has been noted with both pharmacological and interventional
therapies [181–185], but there are limited data to compare the
benefit of different treatments [32, 186]. Assessment of quality of
life is further constrained by a lack of cross-validation of the sev-
eral AF-specific quality of life tools [187–191]. With regard to
symptom assessment, EHRA suggested the EHRA symptom scale
(Table 7) to describe symptom severity in AF patients [192]. A
similar scale (the Canadian Cardiovascular Society Severity of
Atrial Fibrillation Scale) is used in Canada [193]. The EHRA scale
has been used and validated [194–199]. A modification was pro-
posed in 2014, subdividing EHRA class 2 into mild (2a) or moder-
ate (2b) impact [199]. As symptoms in class 2b (‘troubling’
symptoms) identified patients with a health utility benefit of
rhythm control in that study, this modification may provide a
threshold for potential treatment decisions, pending independent
validation. While some AF patients had no or minimal symptoms
(25–40%), many (15–30%) report severe or disabling symptoms
[194, 196]. The modified EHRA scale should be used to guide
symptom-orientated treatment decisions and for longitudinal
patient profiling.
Table 6: Clinical types of atrial fibrillationa
AF = atrial fibrillation; LV = left ventricular; LVH = left ventricular hypertrophy.
aIt is recognized that these types of AF will overlap in clinical practice, and that their impact for management needs to be evaluated systematically; modified
from the report on the fourth AFNET/EHRA Consensus Conference [76].
Table 7: Modified European Heart Rhythm Association
symptom scale (modified from Wynn et al. [199])
AF = atrial fibrillation; EHRA = European Heart Rhythm Association.
aEHRA class 2a and 2b can be differentiated by evaluating whether
patients are functionally affected by their AF symptoms. AF-
related symptoms are most commonly fatigue/tiredness and exertional
shortness of breath, or less frequently palpitations and chest pain
[42, 194, 200–202].
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7. DETECTION AND MANAGEMENT OF RISK
FACTORS AND CONCOMITANT
CARDIOVASCULAR DISEASES
Many cardiovascular diseases and concomitant conditions
increase the risk of developing AF (Table 8), recurrent AF, and
AF-associated complications. The identification of such condi-
tions, their prevention and treatment is an important leverage to
prevent AF and its disease burden. Knowledge of these factors
and their management is hence important for optimal manage-
ment of AF patients [203, 204].
7.1 Heart failure
Heart failure and AF coincide in many patients [215–217]. They
are linked by similar risk factors and share a common patho-
physiology [218]. Heart failure and AF can cause and exacerbate
each other through mechanisms such as structural cardiac
remodelling, activation of neurohormonal mechanisms, and rate-
related impairment of left ventricular (LV) function. Patients with
AF and concomitant heart failure, both with preserved ejection
fraction [LV ejection fraction (LVEF) >_50%] and reduced ejection
fraction (LVEF <40%) [219, 220], suffer from a worse prognosis,
including increased mortality [16, 221]. The recent ESC Guidelines
on heart failure [222] have also introduced a new category of
heart failure with mid-range ejection fraction (HFmrEF; LVEF 40–
49%), although data on AF patients in this group are limited.
Prevention of adverse outcomes and maintenance of a good
quality of life are the aims of management in all patients with AF
and concomitant heart failure, regardless of LVEF [223]. The gen-
eral approach to AF management does not differ between heart
failure patients and others, but a few considerations are worth-
while. Of note, the only therapy with proven prognostic value in
these patients is anticoagulation, and appropriate OAC should be
prescribed in all patients at risk of stroke (see Chapter 9).
7.1.1 Patients with atrial fibrillation and heart failure
with reduced ejection fraction. In addition to OAC, standard
heart failure therapy should be used in patients with heart failure
with reduced ejection fraction (HFrEF), as detailed in the ESC
Recommendation on use of the modified European Heart
Rhythm Association symptom scale
c




Table 8: Cardiovascular and other conditions independ-
















AF = atrial fibrillation; BMI = body mass index; CI = confidence interval;
FEV1 = forced expiratory volume in 1 second; HR = hazard ratio; OR =
odds ratio; RR = risk ratio.













Guidelines [222]. This includes angiotensin-converting enzyme
(ACE) inhibitors or angiotensin receptor blockers (ARBs), minera-
locorticoid antagonists, defibrillators, cardiac resynchronization
therapy [218], and combined angiotensin receptor neprilysin
inhibition (ARNI) in patients able to tolerate an ACE inhibitor or
ARB with ongoing symptoms [224].
Rate control of AF is discussed in detail in Chapter 9. In brief,
only beta-blockers and digoxin are suitable in HFrEF because of
the negative inotropic potential of verapamil and diltiazem. Beta-
blockers are usually the first-line option in patients with clinically
stable HFrEF, although a meta-analysis using individual patient
data from randomized controlled trials (RCTs) found no reduc-
tion in mortality from beta-blockers vs. placebo in those with AF
at baseline (HR 0.97, 95% CI 0.83–1.14) [23]. Digoxin is commonly
prescribed in clinical practice, but no head-to-head RCTs in AF
patients have been performed. In a meta-analysis of observatio-
nal studies, digoxin had a neutral effect on mortality in patients
with AF and concomitant heart failure (adjusted observational
studies HR 0.90, 95% CI 0.70–1.16; propensity-matched observa-
tional studies RR 1.08, 95% CI 0.93–1.26) [225]. Therefore, initial
and combination rate control therapy for AF in HFrEF should
take account of individual patient characteristics and symptoms;
beta-blocker initiation should be delayed in patients with acute
decompensated heart failure, and digoxin can accumulate and
provoke adverse effects in patients with kidney dysfunction (see
Chapter 10).
Patients with AF and HFrEF who present with severe symptoms
may require rhythm control therapy in addition to rate control
therapy. For patients who develop HFrEF as a result of rapid AF
(tachycardiomyopathy), a rhythm control strategy is preferred,
based on several relatively small patient cohorts and trials report-
ing improved LV function after restoration of sinus rhythm [185,
226–228]. The diagnosis of tachycardiomyopathy can be chal-
lenging, and at times requires the restoration of sinus rhythm
[229]. Catheter ablation may be a useful method to restore LV
function and quality of life in AF patients with HFrEF [185, 226–
228], but further data are needed. Figure 4 summarizes the
approach to patients with AF and heart failure.
7.1.2 Atrial fibrillation patients with heart failure with
preserved ejection fraction. The diagnosis of heart failure with
preserved ejection fraction (HFpEF) in patients with AF is prob-
lematic because of the difficulty in separating symptoms that are
due to HF from those due to AF. Although diagnostic differentia-
tion can be achieved by cardioversion and clinical reassessment
but should be reserved for symptomatic improvement as a spe-
cific therapy that improves prognosis in HFpEF is currently lack-
ing. Echocardiography can support the detection of HFpEF in
patients with symptomatic AF by providing evidence of relevant
structural heart disease [e.g. LV hypertrophy (LVH)] and/or meas-
urement of diastolic dysfunction. Reduced early diastolic myo-
cardial velocity e0 by tissue Doppler reflects impaired LV
relaxation, while the ratio of E/e0 is correlated with invasive
measurement of LV filling pressures [230–234]. Natriuretic pep-
tide levels are part of the diagnostic assessment of HFpEF [222],
although natriuretic peptide levels are elevated in AF patients
and the optimum diagnostic cut-off is still unknown [235]. The
management of patients with AF and concomitant HFpEF should
focus on the control of fluid balance and concomitant conditions
such as hypertension and myocardial ischaemia.
7.1.3 Atrial fibrillation patients with heart failure with
mid-range ejection fraction. HFmrEF is a recently defined
entity, describing patients with symptoms and signs of heart fail-
ure, LVEF 40–49%, elevated levels of natriuretic peptides, and
either LV hypertrophy, left atrial (LA) enlargement, or evidence of
diastolic dysfunction [222]. However, diagnosis is more difficult in
patients with AF, as natriuretic peptides are elevated in AF and
LA dilatation is common, regardless of concomitant heart failure.
LVEF is also variable and difficult to assess in AF patients because
of AF-induced reduction in systolic LV function and variable car-
diac cycle length. Further study of this group is required before
particular treatment strategies in AF patients with HFmrEF can be
recommended.
7.1.4 Prevention of atrial fibrillation in heart failure.
Retrospective analyses from large randomized trials have
reported a lower incidence of new-onset AF in patients
treated with ACE inhibitors/ARBs compared with placebo
[236–238]. The reduced incidence of AF with ACE inhibitors/
ARBs is less evident in patients with HFpEF [239] and is lost in
patients without heart failure [240–242]. Neprilysin inhibition
does not seem to add to this effect [224]. Beta-blocker therapy
was associated with a 33% reduction in the adjusted odds of
incident AF in HFrEF patients pre-treated with ACE inhibitors/
ARBs, reinforcing the importance of beta-blocker therapy in
HFrEF patients in sinus rhythm [23]. Eplerenone, a mineralo-
corticoid receptor antagonist, also reduced the risk of new-
onset AF in patients with LVEF <_35%, New York Heart
Association (NYHA) Class II, when added to ACE inhibitors/
ARBs and beta-blockers [243].
7.2 Hypertension
Hypertension is a stroke risk factor in AF; uncontrolled high
blood pressure enhances the risk of stroke and bleeding
events and may lead to recurrent AF. Therefore, good blood
pressure control should form an integral part of the manage-
ment of AF patients [247]. Inhibition of the renin–angiotensin–
aldosterone system can prevent structural remodelling and
recurrent AF [236, 244]. A recent analysis of the Danish health-
care database with long-term monitoring of the effect of dif-
ferent antihypertensive agents on the occurrence of overt AF
suggests a beneficial effect of ACE inhibitors or ARBs [245].
Secondary analyses of ACE inhibitors or ARBs in patients with
heart failure or LVH show a lower incidence of new-onset AF
[238, 246]. In patients with established AF, but without LV dys-
function or heart failure, ARBs do not prevent recurrent AF
better than placebo [240, 241]. ACE inhibitors or ARBs may
reduce recurrent AF after cardioversion when co-administered
with antiarrhythmic drug therapy compared with an antiar-
rhythmic drug alone [248, 249]. Meta-analyses driven by these
studies suggested a lower risk of recurrent AF [236–238, 250],
but at least one controlled trial failed to demonstrate benefit
[240, 251].
7.3 Valvular heart disease
Valvular heart disease is independently associated with incident
AF [252]. Approximately 30% of patients with AF have some
form of valvular heart disease, often detected only by
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echocardiogram [201, 253–255]. AF worsens prognosis in
patients with severe valvular heart disease [256], including those
undergoing surgery or transcatheter interventions for aortic or
mitral valve disease [257–262]. Valvular heart disease can be
associated with an increased thrombo-embolic risk, which prob-
ably also adds to the stroke risk in AF patients [263]. Similar to
heart failure, valvular disease and AF interact with and sustain
each other through volume and pressure overload, tachycardio-
myopathy, and neurohumoral factors [264–270]. When valve
dysfunction is severe, AF can be regarded as a marker for pro-
gressive disease, thus favouring valve repair or replacement
[271].
Traditionally, patients with AF have been dichotomized into
‘valvular’ and ‘non-valvular’ AF [272]. Although slightly differ-
ent definitions have been used, valvular AF mainly refers to AF
patients that have either rheumatic valvular disease (predomi-
nantly mitral stenosis) or mechanical heart valves. In fact,
while AF implies an incremental risk for thrombo-embolism in
patients with mitral valve stenosis [263, 273, 274], there is no
clear evidence that other valvular diseases, including mitral
regurgitation or aortic valve disease, need to be considered
when choosing an anticoagulant or indeed to estimate stroke
risk in AF [275]. Therefore, we have decided to replace the his-
toric term ‘non-valvular’ AF with reference to the specific
underlying conditions.
7.4 Diabetes mellitus
Diabetes and AF frequently coexist because of associations
with other risk factors [277–283]. Diabetes is a risk factor for
stroke and other complications in AF [284]. In patients with
AF, a longer duration of diabetes appears to confer a higher
risk of thrombo-embolism, albeit without greater risk of OAC-
related bleeding [285]. Unfortunately, intensive glycaemic con-
trol does not affect the rate of new-onset AF [284], while treat-
ment with metformin seems to be associated with a decreased
long-term risk of AF in diabetic patients [286] and may even
Figure 4: Initial management of patients presenting acutely with atrial fibrillation and heart failure. (Adapted from Kotecha and Piccini [218].)
Recommendations for patients with valvular heart disease and
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be associated with a lower long-term stroke risk [13]. Diabetic
retinopathy, a measure of disease severity, does not increase
the risk of ocular bleeding in anticoagulated patients [287].
7.5 Obesity and weight loss
7.5.1 Obesity as a risk factor. Obesity increases the risk for AF
(Table 8) [288–291] with a progressive increase according to
body mass index (BMI) [288, 290–292]. Obese patients may have
more LV diastolic dysfunction, increased sympathetic activity and
inflammation, and increased fatty infiltration of the atria [293–
295]. Obesity may also be a risk factor for ischaemic stroke,
thrombo-embolism, and death in AF patients [292].
7.5.2 Weight reduction in obese patients with atrial fibril-
lation. Intensive weight reduction in addition to the manage-
ment of other cardiovascular risk factors (in the range of 10–15
kg weight loss achieved), led to fewer AF recurrences and symp-
toms compared with an approach based on general advice in
obese patients with AF [203, 204, 296]. Improved cardiorespira-
tory fitness can further decrease AF burden in obese patients
with AF [297]. Although the findings in these studies have to be
confirmed, they underpin the positive effect of weight reduction
in obese AF patients.
7.5.3 Catheter ablation in obese patients. Obesity may
increase the rate of AF recurrence after catheter ablation [298–
301], with obstructive sleep apnoea as an important potential
confounder. Obesity has also been linked to a higher radiation
dose and complication rate during AF ablation [302, 303].
Notably, the symptomatic improvement after catheter ablation
of AF in obese patients seems comparable to the improvement
in normal-weight patients [298]. In view of the potential to
reduce AF episodes by weight reduction (see section 7.5.2.), AF
ablation should be offered to obese patients in conjunction with
lifestyle modifications that lead to weight reduction.
7.6 Chronic obstructive pulmonary disease, sleep
apnoea, and other respiratory diseases
AF has been associated with obstructive sleep apnoea [304, 305].
Multiple pathophysiological mechanisms can contribute to AF in
obstructive sleep apnoea, including autonomic dysfunction,
hypoxia, hypercapnia, and inflammation [96, 304–307].
Obstructive sleep apnoea exaggerates intrathoracic pressure
changes, which in itself and via vagal activation can provoke
shortening of the atrial action potential and induce AF. Risk fac-
tor reduction and continuous positive airway pressure ventilation
can reduce AF recurrence [308–312]. It seems reasonable to con-
sider obstructive sleep apnoea screening in AF patients with risk
factors. Obstructive sleep apnoea treatment should be optimized
to improve AF treatment results in appropriate patients. Servo-
controlled pressure support therapy should not be used in HFrEF
patients with predominantly central sleep apnoea (of which 25%
had concomitant AF) [313].
Patients with chronic obstructive pulmonary disease often
suffer from atrial tachycardias, which need to be differentiated
from AF by ECG. Agents used to relieve bronchospasm,
notably theophyllines and beta-adrenergic agonists, may pre-
cipitate AF and make control of the ventricular response rate
difficult. Non-selective beta-blockers, sotalol, propafenone,
and adenosine should be used with caution in patients with sig-
nificant bronchospasm, while they can safely be used in
patients with chronic obstructive pulmonary disease. Beta-1
selective blockers (e.g. bisoprolol, metoprolol, and nebivolol),
diltiazem, and verapamil are often tolerated and effective (see
Chapter 10).
7.7 Chronic kidney disease
AF is present in 15–20% of patients with CKD [316]. The definition
of CKD in most AF trials is relatively strict. Although an estimated
creatinine clearance (CrCl) rate of <60 mL/min is indicative
of CKD, a number of trials in AF patients have used CrCl <50
mL/min to adapt NOAC dosage, usually estimated using the
Cockroft–Gault formula. CrCl in AF patients can deteriorate over
Recommendation for obese patients with atrial fibrillation
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time [317]. The management of OAC in patients with CKD is dis-
cussed in section 9.2.4.
8. INTEGRATED MANAGEMENT OF PATIENTS
WITH ATRIAL FIBRILLATION
Most patients initially access the healthcare system through phar-
macists, community health workers, or primary care physicians.
As AF is often asymptomatic (“silent AF”), these healthcare profes-
sionals are important stakeholders to enable the adequate detec-
tion of AF and to ensure consistent management. The initial
assessment should be performed at the point of first contact with
the healthcare system, and is feasible in most healthcare settings
(when an ECG is available). We propose to consider five domains
in the initial assessment of patients presenting with newly diag-
nosed AF (Figure 5). These domains are:
1. Haemodynamic instability or limiting, severe symptoms;
2. Presence of precipitating factors (e.g. thyrotoxicosis, sepsis, or post-
operative AF) and underlying cardiovascular conditions;
3. Stroke risk and need for anticoagulation;
4. Heart rate and need for rate control;
5. Symptom assessment and decision for rhythm control.
An integrated, structured approach to AF care, as applied suc-
cessfully to other domains of medicine [322–324], will facilitate
consistent, guideline-adherent AF management for all patients
[325] (Figure 6), with the potential to improve outcomes [42, 326,
327]. Such approaches are consistent with the Innovative Care
for Chronic Conditions Framework proposal put forward by the
World Health Organization [328]. Review by an AF service, or at
least referral to a cardiologist, will usually be required after the
initial assessment to fully evaluate the effect of AF on cardiovas-
cular health [329]. There may also be reasons for early or urgent
referral (Table 9). Integrated care of all patients with newly diag-
nosed AF should help to overcome the current shortcomings of
AF management, such as underuse of anticoagulation, access to
rate and rhythm control therapy, and inconsistent approaches to
cardiovascular risk reduction. Integrated AF care requires the
cooperation of primary care physicians, cardiologists, cardiac sur-
geons, AF specialists, stroke specialists, allied health practitioners,
and patients, encompassing lifestyle interventions, treatment of
underlying cardiovascular diseases, and AF-specific therapy
(Figure 7).
8.1 Evidence supporting integrated atrial
fibrillation care
Several structured approaches to AF care have been developed.
Some evidence underpins their use, while more research is
needed into the best way of delivering integrated AF care.
Figure 5: Acute and chronic management of atrial fibrillation patients, desired cardiovascular outcomes, and patient benefits. Adapted from the report on the 4th
AFNET/EHRA consensus conference [76].
Recommendations for patients with kidney disease and atrial
fibrillation

















Integrated AF management in an RCT increased the use of
evidence-based care, and reduced by approximately one-third
the composite outcome of cardiovascular hospitalization
and cardiovascular death over a mean follow-up of 22 months
(14.3% vs. 20.8%, HR 0.65; 95% CI 0.45–0.93; P = 0.017) compared
with usual care in a large tertiary care centre [330]. Integrated AF
management appeared cost-effective in that study [331].
However, an Australian RCT showed only a marginal effect on
unplanned admissions and death using integrated AF care limited
to the initial care period, possibly emphasizing the need for sus-
tained integration of AF care [332]. Two observational studies of
integrated AF care found fewer hospitalizations [333, 334], one
study showed fewer cases of stroke [333], and a further non-
randomized study identified a trend for a lower rate of the com-
posite outcome of death, cardiovascular hospitalization, and AF-
related emergency visits [335]. More research is needed, and
integrated AF care is likely to require different designs in different
healthcare settings.
8.2 Components of integrated atrial fibrillation care
8.2.1 Patient involvement. Patients should have a central role
in the care process. As treatment of AF requires patients to
change their lifestyles and adhere to chronic therapy, at times
without an immediately tangible benefit, they need to under-
stand their responsibilities in the care process. Physicians and
healthcare professionals are responsible for providing access to
evidence-based therapy, but adherence to therapy is ultimately
the responsibility of informed and autonomous patients, best
described as ‘shared accountability’ [336]. Hence, information
and the education of patients, and often of their partners and rel-
atives, is indispensable to encourage a self-management role and
to empower patients to participate in shared decision-making
[326, 328], and to support understanding of the disease and the
suggested treatments [337].
8.2.2 Multidisciplinary atrial fibrillation teams. Delegation
of tasks from specialists to general physicians and from physi-
cians to allied health professionals is a fundamental concept of
Figure 6: Achieving optimal management of atrial fibrillation patients.
Table 9: Clinical signs calling for urgent involvement of a
specialized atrial fibrillation servicea
aAnticoagulation should be initiated early in all suitable patients and
will not routinely require specialist input.
Figure 7: Fundamentals of integrated care in atrial fibrillation patients.
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integrated care models. A multidisciplinary AF team approach
includes an efficient mix of interpersonal and communication
skills, education, and expertise in AF management, as well as the
use of dedicated technology. This approach underlines the
importance of redesigning daily practice in a way that encour-
ages non-specialists and allied professionals to have an important
role in educating patients and co-ordinating care, while the spe-
cialist remains medically responsible. Cultural and regional differ-
ences will determine the composition of AF teams.
8.2.3 Role of non-specialists. Some non-specialist health care
professionals, e.g. physicians in primary care have extensive
expertise in stroke prevention and initial management of AF
patients. Others may seek training to acquire such knowledge.
Other components of AF management (e.g. assessment of con-
comitant cardiovascular conditions, antiarrhythmic drug therapy,
or interventional treatment) often require specialist input.
Integrated AF care structures should support treatment initiation
by non-specialists where appropriate, and provide ready access
to specialist knowledge to optimize AF care.
8.2.4 Technology use to support atrial fibrillation care.
Technology, such as decision support software, has the potential
to enhance the implementation of evidence-based care and
improve outcomes, when used to enhance expert advice [338].
Electronic tools can also ensure coherent communication within
the AF team. With a view to support the wider use of such tech-
nology, this Task Force is providing digital decision tools, in the
form of freely accessible smartphone apps, to AF healthcare pro-
fessionals and to AF patients.
8.3 Diagnostic workup of atrial fibrillation patients
AF is often found in patients with other, at times undiagnosed,
cardiovascular conditions. Thus, all AF patients will benefit from
a comprehensive cardiovascular assessment [339].
8.3.1 Recommended evaluation in all atrial fibrillation
patients. A complete medical history should be taken and all
patients should undergo clinical evaluation that includes thor-
ough assessment for concomitant conditions, establishing the AF
pattern, estimation of stroke risk and AF-related symptoms, and
assessment of arrhythmia-related complications such as
thrombo-embolism or LV dysfunction. A 12-lead ECG is recom-
mended to establish a suspected diagnosis of AF, to determine
rate in AF, and to screen for conduction defects, ischaemia, and
signs of structural heart disease. Initial blood tests should evalu-
ate thyroid and kidney function, as well as serum electrolytes and
full blood count. Transthoracic echocardiography is recom-
mended in all AF patients to guide treatment decisions.
Transthoracic echocardiography should be used to identify struc-
tural disease (e.g. valvular disease) and assess LV size
and function (systolic and diastolic), atrial size, and right heart
function [339, 340]. Although biomarkers such as natriuretic pep-
tides are elevated in AF patients, there is insufficient data to sug-
gest that blood-based parameters are independent markers for
AF [341–343].
8.3.2 Additional investigations in selected patients with
atrial fibrillation. Ambulatory ECG monitoring in AF patients
can assess the adequacy of rate control, relate symptoms with AF
recurrences, and detect focal induction of bouts of paroxysmal AF.
Transoesophageal echocardiography (TOE) is useful to further
assess valvular heart disease and to exclude intracardiac thrombi,
especially in the LAA, to facilitate early cardioversion or catheter
ablation [344]. Patients with symptoms or signs of myocardial
ischaemia should undergo coronary angiography or stress testing
as appropriate. In patients with AF and signs of cerebral ischaemia
or stroke, computed tomography (CT) or magnetic resonance
Recommendations for an integrated approach to care
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imaging (MRI) of the brain is recommended to detect stroke and
support decisions regarding acute management and long-term
anticoagulation. Delayed-enhancement MRI of the left atrium
using gadolinium contrast [345–347], T1 mapping using cardiac
MRI [347], and intracardiac echo [348] may help to guide treatment
decisions in AF, but require external validation in multicentre
studies.
8.4 Structured follow-up
Most AF patients need regular follow-up to ensure continued
optimal management. Follow-up may be undertaken in primary
care, by specially trained nurses, by cardiologists, or by AF spe-
cialists [325, 330]. A specialist should co-ordinate care and
follow-up. Follow-up should ensure implementation of the man-
agement plan, continued engagement of the patient, and therapy
adaptation where needed.
8.5 Defining goals of atrial fibrillation management
AF management comprises therapies with prognostic impact
(anticoagulation and treatment of cardiovascular conditions) and
therapies predominantly providing symptomatic benefit (rate
control and rhythm control, Table 10). Therapies with prognostic
benefit need careful explanation to patients when their benefits
are not directly felt. Rhythm control therapy can be successful if
symptoms are controlled, even when AF recurs. Explaining the
expected benefits to each patient at the start of AF management
will prevent unfounded expectations and has the potential to
optimize quality of life.
9. STROKE PREVENTION THERAPY IN ATRIAL
FIBRILLATION PATIENTS
OAC therapy can prevent the majority of ischaemic strokes in
AF patients and can prolong life [38, 39, 42, 194, 201, 329, 350–
352]. It is superior to no treatment or aspirin in patients with dif-
ferent profiles for stroke risk [353, 354]. The net clinical benefit is
almost universal, with the exception of patients at very low
stroke risk, and OAC should therefore be used in most patients
with AF (Figure 8). Despite this evidence, underuse or premature
termination of OAC therapy is still common. Bleeding events,
both severe and nuisance bleeds, a perceived ‘high risk of bleed-
ing’ on anticoagulation, and the efforts required to monitor and
dose-adjust VKA therapy are among the most common reasons
for withholding or ending OAC [352, 355–359]. However, the
considerable stroke risk without OAC often exceeds the bleeding
risk on OAC, even in the elderly, in patients with cognitive dys-
function, or in patients with frequent falls or frailty [360, 361].
The bleeding risk on aspirin is not different to the bleeding risk
on VKA [362] or NOAC therapy [354, 363], while VKA and
NOACs, but not aspirin, effectively prevent strokes in AF patients
[38, 354, 362, 363].
Table 10: Goal-based follow-up
b.p.m. = beats per minute; mEHRA symptoms scale = modified European Heart Rhythm Association symptoms scale; GP = general practitioner; INR = interna-
tional normalized ratio; LV = left ventricular; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.
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9.1 Prediction of stroke and bleeding risk
9.1.1 Clinical risk scores for stroke and systemic embo-
lism. Simple, clinically applicable stroke risk-stratification
schemes in AF patients were developed in the late 1990s in small
cohort studies, and have later been refined and validated
in larger populations [364–368]. The introduction of the
CHA2DS2-VASc score (Table 11) has simplified the initial deci-
sion for OAC in AF patients. Since its first incorporation in the
ESC guidelines in 2010 [369], it has been widely used [370]. We
recommend estimating stroke risk in AF patients based on the
CHA2DS2-VASc score [368]. In general, patients without clinical
stroke risk factors do not need antithrombotic therapy, while
patients with stroke risk factors (i.e. CHA2DS2-VASc score of 1 or
more for men, and 2 or more for women) are likely to benefit
from OAC.
Other, less established risk factors for stroke include unstable
international normalized ratio (INR) and low time in therapeutic
range (TTR) in patients treated with VKAs; previous bleed or
anaemia; alcohol excess and other markers for decreased therapy
adherence; CKD; elevated high-sensitivity troponin; and elevated
N-terminal pro-B-type natriuretic peptide.
9.1.2 Anticoagulation in patients with a CHA2DS2-VASc
score of 1 in men and 2 in women. Controlled trials studying
OAC in AF patients have been enriched for patients at high risk
of stroke [38, 39, 42, 194, 201, 329, 351, 352], and hence there is
strong evidence that patients with a CHA2DS2-VASc risk score of
2 or more in men, and 3 or more in women, benefit from OAC.
Fortunately, we now have a growing evidence base regarding
stroke risk in patients with one clinical risk factor (i.e. a CHA2DS2-
VASc score of 1 for men, and 2 for women), although this relies
largely on observed stroke rates in patients not receiving OAC. In
many of these patients, anticoagulation seems to provide a clini-
cal benefit [371–375]. The rates of stroke and thrombo-embolism
vary considerably in patients with CHA2DS2-VASc scores of 1 or
2 due to differences in outcomes, populations, and anticoagula-
tion status (Web Table 1) [371, 376, 377, 1041]. We therefore
commissioned an analysis of stroke risk in men and women with
one additional stroke risk factor to inform these guidelines (Web
Table 1, last line). OAC should be considered for men with a
CHA2DS2-VASc score of 1 and women with a score of 2, balanc-
ing the expected stroke reduction, bleeding risk, and patient pref-
erence. Importantly, age (65 years and older) conveys a relatively
high and continuously increasing stroke risk that also potentiates
Figure 8: Stroke prevention in atrial fibrillation.













other risk factors (such as heart failure and sex). Hence, an indi-
vidualized weighing of risk, as well as patient preferences, should
inform the decision to anticoagulate patients with only one
CHA2DS2-VASc risk factor, apart from female sex. Female sex
does not appear to increase stroke risk in the absence of other
stroke risk factors (Web Table 1) [378, 379].
Measurement of cardiac troponin (high-sensitivity troponin T or
I) and N-terminal pro-B-type natriuretic peptide may provide addi-
tional prognostic information in selected AF patients [380–382].
Biomarker-based risk scores may, in the future, prove helpful to bet-
ter stratify patients (e.g. those at a truly low risk of stroke) [75, 382].
9.1.3 Clinical risk scores for bleeding. Several bleeding risk
scores have been developed, mainly in patients on VKAs. These
include HAS-BLED [hypertension, abnormal renal/liver function
(1 point each), stroke, bleeding history or predisposition, labile
INR, elderly (>65 years), drugs/alcohol concomitantly (1 point
each)], ORBIT (Outcomes Registry for Better Informed Treatment
of Atrial Fibrillation), and more recently, the ABC (age, bio-
markers, clinical history) bleeding score, which also makes use of
selected biomarkers [383–385]. Stroke and bleeding risk factors
overlap (compare Tables 11 and 12). For example, older age is
one of the most important predictors of both ischaemic stroke
and bleeding in AF patients [386, 387]. A high bleeding risk score
should generally not result in withholding OAC. Rather, bleeding
risk factors should be identified and treatable factors corrected
(see section 9.5). Table 12 provides details of modifiable bleeding
risk factors.
9.2 Stroke prevention
9.2.1 Vitamin K antagonists. Warfarin and other VKAs were
the first anticoagulants used in AF patients. VKA therapy reduces
the risk of stroke by two-thirds and mortality by one-quarter
compared with control (aspirin or no therapy) [38]. VKAs have
been used in many patients throughout the world with good
outcomes [394–396], and this is reflected in the warfarin arms of
the NOAC trials (see section 9.2.2.). The use of VKAs is limited by
the narrow therapeutic interval, necessitating frequent monitor-
ing and dose adjustments, but VKAs, when delivered with
adequate time in therapeutic range (TTR), are effective for stroke
prevention in AF patients. Clinical parameters can help to iden-
tify patients who are likely to achieve a decent TTR on VKA ther-
apy [397]. These have been summarized in the SAMe-TT2R2
score. Patients who fare well on this score, when treated with a
VKA, have on average a higher TTR than patients who do not
fare well on the score [398, 399]. VKAs are currently the only
treatment with established safety in AF patients with rheumatic
mitral valve disease and/or a mechanical heart valve prosthesis
[400].
9.2.2 Non-vitamin K antagonist oral anticoagulants.
NOACs, including the direct thrombin inhibitor dabigatran and
the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban,
are suitable alternatives to VKAs for stroke prevention in AF
(Table 13). Their use in clinical practice is increasing rapidly
[401]. All NOACs have a predictable effect (onset and offset)
without need for regular anticoagulation monitoring. The phase
III trials have been conducted with carefully selected doses of
the NOACs, including clear rules for dose reduction that should
be followed in clinical practice (Table 13).
9.2.2.1 Apixaban. In the ARISTOTLE (Apixaban for Reduction in
Stroke and Other Thrombo-embolic Events in Atrial Fibrillation)
trial [319], apixaban 5 mg twice daily reduced stroke or systemic
embolism by 21% compared with warfarin, combined with a
31% reduction in major bleeding and an 11% reduction in all-
cause mortality (all statistically significant). Rates of haemorrhagic
stroke and intracranial haemorrhage, but not of ischaemic stroke,
were lower on apixaban. Rates of gastrointestinal bleeding were
similar between the two treatment arms [402].
Apixaban is the only NOAC that has been compared with
aspirin in AF patients; apixaban significantly reduced stroke or
systemic embolism by 55% compared with aspirin, with no or
only a small difference in rates of major bleeding or intracranial
haemorrhage [354, 403].
9.2.2.2 Dabigatran. In the RE-LY (Randomized Evaluation of Long-
Term Anticoagulation Therapy) study [318, 404], dabigatran 150
mg twice daily reduced stroke and systemic embolism by 35%
compared with warfarin without a significant difference in major
bleeding events. Dabigatran 110 mg twice daily was non-inferior
to warfarin for prevention of stroke and systemic embolism, with
20% fewer major bleeding events. Both dabigatran doses signifi-
cantly reduced haemorrhagic stroke and intracranial haemor-
rhage. Dabigatran 150 mg twice daily significantly reduced
ischaemic stroke by 24% and vascular mortality by 12%, while
gastrointestinal bleeding was significantly increased by 50%.
There was a non-significant numerical increase in the rate of
myocardial infarction with both dabigatran doses [318, 404],
which has not been replicated in large post-authorization analy-
ses [396]. These observational data have also replicated the bene-
fit of dabigatran over VKA found in the RE-LY trial in patients
who were mainly treated with the higher dabigatran dose (150
mg twice daily) [396].
Recommendations for prediction of stroke and bleeding risk
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure,
hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled), Vascular
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9.2.2.3 Edoxaban. In the ENGAGE AF-TIMI 48 (Effective
Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis in Myocardial Infarction 48) trial [321],
edoxaban 60 mg once daily and edoxaban 30 mg once daily
(with dose reductions in certain patients, Table 13), were com-
pared with adjusted-dose warfarin [405]. Edoxaban 60 mg once
daily was non-inferior to warfarin (Table 13). In an on-treatment
analysis, edoxaban 60 mg once daily significantly reduced stroke
or systemic embolism by 21% and significantly reduced major
bleeding events by 20% compared with warfarin, while edoxaban
30 mg once daily was non-inferior to warfarin for prevention of
stroke and systemic embolism but significantly reduced major
bleeding events by 53%. Cardiovascular death was reduced in
patients randomized to edoxaban 60 mg once daily or edoxaban
30 mg once daily compared with warfarin. Only the higher dose
regimen has been approved for stroke prevention in AF.
9.2.2.4 Rivaroxaban. In the ROCKET-AF (Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation) trial [320], patients were randomized to rivaroxaban
20 mg once daily or VKA, with a dose adjustment to 15 mg daily
for those with estimated CrCl 30–49 mL/min by the Cockroft–
Gault formula (Table 13). Rivaroxaban was non-inferior to war-
farin for the prevention of stroke and systemic embolism in the
intent-to-treat analysis, while the per-protocol on-treatment
analysis achieved statistical superiority with a 21% reduction in
stroke or systemic embolism compared with warfarin.
Rivaroxaban did not reduce the rates of mortality, ischaemic
stroke, or major bleeding events compared to VKA. There was an
increase in gastrointestinal bleeding events, but a significant
reduction in haemorrhagic stroke and intracranial haemorrhage
with rivaroxaban compared with warfarin. Comparable event
rates have been reported in post-authorization analyses, which
are part of the post-approval risk management process
[406, 407].
Table 11: Clinical risk factors for stroke, transient ischaemic
attack, and systemic embolism in the CHA2DS2-VASc score
CHA2DS2-VASc = Congestive Heart failure, hypertension, Age >_75
(doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and
Sex (female).
Table 12: Modifiable and non-modifiable risk factors for
bleeding in anticoagulated patients based on bleeding risk
scores
ABC = age, biomarkers, clinical history; ATRIA = AnTicoagulation and
Risk factors In Atrial fibrillation; CKD = chronic kidney disease; CrCl =
creatinine clearance; HAS-BLED = hypertension, abnormal renal/liver
function (1 point each), stroke, bleeding history or predisposition, labile
INR, elderly (>65 years), drugs/alcohol concomitantly (1 point each);
HEMORR2HAGES = hepatic or renal disease, ethanol abuse, malig-
nancy, older (age >75), reduced platelet count or function, rebleeding
risk (prior bleed; 2 points), hypertension (uncontrolled), anaemia,
genetic factors (CYP 2C9 polymorphisms), excessive fall risk (including
neuropsychiatric disease), and stroke; INR = international normalized
ratio; ORBIT = Outcomes Registry for Better Informed Treatment of
Atrial Fibrillation; TTR = time in therapeutic range; VKA = vitamin K
antagonist.
aDerived from the HAS-BLED score [384].
bDerived from the HEMORR2HAGES score [383].
cDerived from the ATRIA score [385].
dDerived from the ORBIT score [388].
eDerived from the ABC bleeding score [387].













Table 13: Characteristics of approved non-vitamin K antagonist oral anticoagulants compared
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9.2.3 Non-vitamin K antagonist oral anticoagulants or
vitamin K antagonists. Both VKAs and NOACs are effective for
the prevention of stroke in AF. A meta-analysis [39] based on the
high-dose treatment groups of the pivotal studies of warfarin vs.
NOACs included 42 411 patients receiving a NOAC and 29 272
receiving warfarin. NOACs in these dosages significantly reduced
stroke or systemic embolic events by 19% compared with warfarin
(RR 0.81; 95% CI 0.73–0.91; P < 0.0001), mainly driven by a reduc-
tion in haemorrhagic stroke (RR 0.49; 95% CI 0.38–0.64;
P < 0.0001). Mortality was 10% lower in patients randomized to
NOAC therapy (RR 0.90; 95% CI 0.85–0.95; P = 0.0003) and intra-
cranial haemorrhage was halved (RR 0.48; 95% CI 0.39–0.59;
P < 0.0001), while gastrointestinal bleeding events were more fre-
quent (RR 1.25; 95% CI 1.01–1.55; P = 0.04) [39]. The stroke reduc-
tion with NOACs was consistent in all evaluated subgroups, while
there was a suggestion of greater relative reduction in bleeding
with NOACs at centres with poor INR control (interaction
P = 0.022). Notably, the substantial reduction in intracranial hae-
morrhage by NOACs compared with warfarin seems unrelated to
the quality of INR control [408, 409].
9.2.4 Oral anticoagulation in atrial fibrillation patients
with chronic kidney disease. CKD is associated with stroke
and bleeding in large data sets [410, 411]. Anticoagulation can be
safely used in AF patients with moderate or moderate-to-severe
CKD [glomerular filtration rate (GFR) >_15 mL/min]: the SPAF
(Stroke Prevention in Atrial Fibrillation) III trial randomized 805/
1936 participants with stage 3 CKD (estimated GFR <59 mL/min/
1.73 m2), and reported good outcomes on warfarin (INR 2–3)
[412]. This finding is supported by a large Swedish database, in
which stroke risk was lower in CKD patients with AF treated with
warfarin (adjusted HR 0.76; 95% CI 0.72–0.80) [413], while bleed-
ing was also slightly increased, especially during therapy initiation
[414]. In a meta-analysis of the major NOAC trials, patients with
mild or moderate CKD suffered fewer strokes, systemic emboli,
or major bleeding events on NOACs than on warfarin [415].
Kidney function should be regularly monitored in AF patients on
OACs to allow dose adaptation for those on NOACs (Table 14)
and to refine risk estimation [416].
9.2.5 Oral anticoagulation in atrial fibrillation patients
on dialysis. Approximately one in eight dialysis patients suffer
from AF, with an incidence rate of 2.7/100 patient-years [417]. AF
is associated with increased mortality in patients on dialysis [417].
There are no randomized trials assessing OAC in haemodialysis
patients [418], and no controlled trials of NOACs in patients with
severe CKD (CrCl <25–30 mL/min) [318–321]. Warfarin use was
associated either with a neutral or increased risk of stroke in
database analyses of patients on dialysis [419–421], including a
population-based analysis in Canada (adjusted HR for stroke
1.14; 95% CI 0.78–1.67, adjusted HR for bleeding 1.44; 95% CI
1.13–1.85) [422]. In contrast, data from Denmark suggest a bene-
fit of OAC in patients on renal replacement therapy [423]. Hence,
controlled studies of anticoagulants (both VKAs and NOACs) in
AF patients on dialysis are needed [424].
9.2.6 Patients with atrial fibrillation requiring kidney
transplantation. There are no randomized trials assessing OAC
in patients after kidney transplantation. The prescription of
NOAC therapy should be guided by the estimated GFR of the
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transplanted kidney. Potential pharmacokinetic interactions of
OAC with immunosuppressive agents should be considered.
9.2.7 Antiplatelet therapy as an alternative to oral
anticoagulants. The evidence supporting antiplatelet mono-
therapy for stroke prevention in AF is very limited [38, 428–430].
VKA therapy prevents stroke, systemic embolism, myocardial
infarction, and vascular death better than single or dual antipla-
telet therapy with aspirin and clopidogrel (annual risk of 5.6%
for aspirin and clopidogrel vs. 3.9% with VKA therapy) [431].
Even greater benefits were seen in VKA-treated patients with a
high TTR [432]. Antiplatelet therapy increases bleeding risk,
especially dual antiplatelet therapy (2.0% vs. 1.3% with antiplate-
let monotherapy; P < 0.001) [433], with bleeding rates that are
similar to those on OAC [354, 362, 431, 434]. Thus, antiplatelet
therapy cannot be recommended for stroke prevention in AF
patients.
9.3 Left atrial appendage occlusion and exclusion
9.3.1 Left atrial appendage occlusion devices.
Interventional LAA occlusion [446–449], and limited experience
with percutaneous LAA ligation, has mainly been reported in
observational studies and registries. Only one device
(WatchmanVR ) has been compared with VKA therapy in random-
ized trials [PROTECT AF (Watchman Left Atrial Appendage
System for Embolic Protection in Patients With AF trial), see Web
Table 2; and PREVAIL (Prospective Randomized Evaluation of the
Watchman LAA Closure Device In Patients with AF Versus Long
Term Warfarin Therapy trial)] [449–451]. In these data sets,
LAA occlusion was non-inferior to VKA treatment for the preven-
tion of stroke in AF patients with moderate stroke risk, with a
possibility of lower bleeding rates in the patients who continued
follow-up [452, 453]. These data were confirmed in a patient-
level meta-analysis of the two trials and their associated registries
[453]. LAA occlusion may also reduce stroke risk in patients with
Recommendations for stroke prevention in patients with atrial fibrillation
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74,
and Sex (female); INR = international normalized ratio; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; TTR = time in thera-
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contraindications to OAC [454, 455]. The implantation procedure
can cause serious complications [446, 456–458], with high event
rates reported in analyses from insurance databases and system-
atic reviews, possibly identifying a certain degree of reporting
bias [446, 456]. A large recent European registry reported a high
rate of implantation success (98%), with an acceptable
procedure-related complication rate of 4% at 30 days [459]. Most
patients who historically would be considered unsuitable for OAC
therapy seem to do relatively well on contemporarily managed
OAC [396, 407, 460]. Adequately powered controlled trials are
urgently needed to inform the best use of these devices, including
LAA occluders in patients who are truly unsuitable for OAC or in
patients who suffer a stroke on OAC, randomized comparisons of
LAA occluders with NOACs, and assessment of the minimal antipla-
telet therapy acceptable after LAA occlusion.
9.3.2 Surgical left atrial appendage occlusion or exclu-
sion. Surgical LAA occlusion or exclusion concomitant to cardiac
surgery has been performed for many decades and with various
techniques. Multiple observational studies indicate the feasibility
and safety of surgical LAA occlusion/exclusion, but only limited
controlled trial data are available [461–464]. Residual LAA flow or
incomplete LAA exclusion can increase stroke risk [465]. In most
studies, LAA occlusion/exclusion was performed during other
open heart surgery, and more recently in combination with surgi-
cal ablation of AF [463] or as a stand-alone thoracoscopic proce-
dure. One randomized trial evaluating the role of concomitant AF
surgery and LAA occlusion reported in 2015, without a clear
benefit of LAA exclusion for stroke prevention in the subgroup
undergoing AF surgery [466]. A large randomized trial is currently
underway [467].
9.4 Secondary stroke prevention
The most important risk factors for stroke in patients with AF are
advanced age and previous cardioembolic stroke or TIA [382],
emphasizing the need for OAC in these patients. The highest risk
of recurrent stroke is in the early phase after a first stroke or TIA
[469, 470].
9.4.1 Treatment of acute ischaemic stroke. Systemic throm-
bolysis with recombinant tissue plasminogen activator (rtPA) is
an effective and approved medical treatment for acute ischaemic
stroke in patients presenting within 4.5 h of symptom onset
[471]. Systemic thrombolysis is contraindicated in patients on
therapeutic OAC [472, 473]. Recombinant tissue plasminogen
activator can be given in patients treated with a VKA if the INR is
below 1.7 [474], or in dabigatran-treated patients with a normal
activated partial thromboplastin time and last intake of drug >48
h previously (based on expert consensus) [472]. Whether specific
NOAC antidotes [475] could be used followed by systemic
thrombolysis needs to be investigated. Thrombectomy can be
performed in anticoagulated patients with distal occlusion of the
internal carotid artery or middle cerebral artery in a 6 h window
[476].
9.4.2 Initiation of anticoagulation after transient ischae-
mic attack or ischaemic stroke. Data on the optimal use of
anticoagulants (heparin, low-molecular-weight heparin, heparin-
oid, VKA, NOAC) in the first days after a stroke are scarce.
Parenteral anticoagulants seem to be associated with a non-
significant reduction in recurrent ischaemic stroke when adminis-
tered 7–14 days after the acute stroke [odds ratio (OR) 0.68; 95%
CI 0.44–1.06), with a significant increase in symptomatic intracra-
nial bleeding (OR 2.89; 95% CI 1.19–7.01), and a similar rate of
death or disability at final follow-up [477]. It seems likely that the
bleeding risk on parenteral anticoagulation exceeds the stroke
prevention benefit in the first days after a large stroke, whereas
patients with a TIA or a small stroke may benefit from early
(immediate) initiation or continuation of anticoagulation.
Therefore, we propose to initiate anticoagulation in AF patients
between 1 and 12 days after an ischaemic stroke, depending on
stroke severity (Figure 9) [478]. We suggest repeat brain imaging
to determine the optimal initiation of anticoagulation in patients
with a large stroke at risk for haemorrhagic transformation. Long-
term OAC with a VKA [363, 479–481] or NOAC [482] conveys
benefits in AF patients who survived a stroke. NOACs seem to
convey slightly better outcomes, mainly driven by fewer intracra-
nial haemorrhages and haemorrhagic strokes (OR 0.44; 95% CI
0.32–0.62) [482]. Detailed data for edoxaban have not yet been
published [321]. If a patient suffers a stroke or TIA whilst taking
an anticoagulant, switching to another anticoagulant should be
considered.
9.4.3 Initiation of anticoagulation after intracranial hae-
morrhage. No prospective studies have investigated the benefit
or risk of the initiation of OAC after intracranial haemorrhage
[483], and patients with a history of intracranial bleeding were
Recommendations for occlusion or exclusion of the left atrial
appendage
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excluded from the randomized trials comparing NOACs with
VKAs. The available evidence indicates that anticoagulation in
patients with AF can be reinitiated after 4–8 weeks, especially
when the cause of bleeding or the relevant risk factor (e.g.
uncontrolled hypertension, see Table 12) has been treated, and
that such treatment leads to fewer recurrent (ischaemic) strokes
and lower mortality [460, 484]. If anticoagulation is resumed, it
seems reasonable to consider anticoagulants with a low bleeding
risk [39]. Figure 10 depicts a consensus opinion on the initiation or
resumption of OAC after an intracranial haemorrhage. We recom-
mend a multidisciplinary decision with input from stroke physi-
cians/neurologists, cardiologists, neuroradiologists, and neuro-
surgeons.
9.5 Strategies to minimize bleeding on
anticoagulant therapy
In a meta-analysis of 47 studies, the overall incidence of major
bleeding with VKAs was 2.1 (range 0.9–3.4) per 100 patient-years
in controlled trials and 2.0 (range 0.2–7.6) per 100 patient-years
for observational data sets [488]. Minimizing treatable bleeding
risk factors (see Table 12) seems paramount to reduce the bleed-
ing rate on anticoagulants.
9.5.1 Uncontrolled hypertension. Uncontrolled hypertension
increases the risk of bleeding on OAC [53]. Hence, keeping sys-
tolic blood pressure well controlled is of particular relevance in
anticoagulated patients with AF. Treatment according to current
guidelines is recommended in patients with known hypertension
[489].
9.5.2 Previous bleeding event. History of bleeding events and
the presence of anaemia are important parts of the assessment of
all patients receiving OAC. The majority of bleeding events are
gastrointestinal. Compared with warfarin, the risk of gastrointesti-
nal bleeds was increased for dabigatran 150 mg twice daily [396,
490], rivaroxaban 20 mg once daily [491], and edoxaban 60 mg
once daily [321]. The risk of gastrointestinal bleeds was compara-
ble to warfarin on dabigatran 110 mg twice daily [490] and on
apixaban 5 mg twice daily [319]. Recent observational analyses
Figure 9: Initiation or continuation of anticoagulation in atrial fibrillation patients after a stroke or transient ischaemic attack. This approach is based on consensus
rather than prospective data.
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do not replicate these findings, suggesting a smaller effect [396,
492, 493]. In patients in whom the source of bleeding has been
identified and corrected, OAC can be reinitiated. This also
appears true for patients who have had an intracranial haemor-
rhage, once modifiable bleeding risk factors (e.g. uncontrolled
hypertension) have been corrected [460, 484].
9.5.3 Labile international normalized ratio and adequate
non-vitamin K antagonist oral anticoagulant dosing. TTR
on VKA therapy is an important predictor of major haemorrhage
[432, 441, 494]. Therefore, we recommend targeting the INR
between 2.0 and 3.0 in patients on VKAs, maintaining a high TTR
(e.g. >_70% [494]), and to consider switching to a NOAC when a
high TTR cannot be sustained [444]. NOAC dosing should follow
the dose-reduction criteria evaluated in the clinical trials, consid-
ering renal function, age, and weight. Patient information and
empowerment, best delivered through integrated AF manage-
ment, seem paramount to achieve this goal.
9.5.4 Alcohol abuse. Alcohol excess is a risk factor for bleeding
in anticoagulated patients [384], mediated by poor adherence,
liver disease, variceal bleeding, and risk of major trauma. Severe
alcohol abuse and binge drinking habits should be corrected in
patients eligible for OAC.
9.5.5 Falls and dementia. Falls and dementia are associated
with increased mortality in AF patients [495], without evidence
that these conditions markedly increase the risk of intracranial
haemorrhage [495, 496]. Hence, anticoagulation should only be
withheld from patients with severe uncontrolled falls (e.g. epi-
lepsy or advanced multisystem atrophy with backwards falls), or
in selected patients with dementia where compliance and adher-
ence cannot be ensured by a caregiver.
9.5.6 Genetic testing. In addition to food and drug interac-
tions, multiple genetic variations affect the metabolism of VKAs
[497]. The systematic use of genetic information for adjustment
of VKA dosage has been evaluated in several controlled clinical
studies [498–500]. Genetic testing has little effect on TTR or
bleeding risk on warfarin, and is not recommended for clinical
use at present [501].
9.5.7 Bridging periods off oral anticoagulation. Most cardi-
ovascular interventions (e.g. percutaneous coronary intervention
or pacemaker implantation) can be performed safely on contin-
ued OAC. When interruption of OAC is required, bridging does
not seem to be beneficial, except in patients with mechanical
heart valves: In a randomized trial of 1884 patients with AF, inter-
ruption of anticoagulation was non-inferior to heparin bridging
for the outcome of arterial thrombo-embolism (incidence of
0.4% and 0.3%, respectively) and resulted in a lower risk of major
bleeding (1.3% and 3.2%, respectively) [502]. OAC interruptions
should be minimized to prevent stroke.
9.6 Management of bleeding events in
anticoagulated patients with atrial fibrillation
9.6.1 Management of minor, moderate, and severe bleed-
ing. General assessment of an anticoagulated patient with AF
experiencing a bleeding event should include the assessment of
bleeding site, onset, and severity of the bleeding, the time-point
of last intake of OAC and other antithrombotic drugs, and other
factors influencing bleeding risk such as CKD, alcohol abuse, and
concurrent medications. Laboratory tests should include haemo-
globin, haematocrit, platelet count, renal function, and, for VKA
patients, prothrombin time, activated partial thromboplastin
time, and INR. Coagulation tests do not provide much informa-
tion in patients on NOACs, except for activated partial thrombo-
plastin time in the case of dabigatran. More specific coagulation
tests do exist, including diluted thrombin time (HEMOCLOT) for
dabigatran and calibrated quantitative anti-factor Xa assays for
factor Xa inhibitors [503]. However, these tests are not always
Recommendations for secondary stroke prevention
AF = atrial fibrillation; INR = international normalized ratio; LMWH =
low molecular weight heparin; NOAC = non-vitamin K antagonist oral
anticoagulant; OAC = oral anticoagulation; TIA = transient ischaemic

















readily available and are often unnecessary for bleeding manage-
ment [504].
We propose a simple scheme to manage bleeding events in
patients on OAC (Figure 11). Minor bleeding events should be
treated with supportive measures such as mechanical compres-
sion or minor surgery to achieve haemostasis. In patients receiv-
ing VKAs, the next dose of VKA can be postponed. NOACs have
a short plasma half-life of approximately 12 h, and improved
haemostasis is expected within 12–24 h after a delayed or omit-
ted dose. Treatment of moderate bleeding events may require
blood transfusions and fluid replacement. Specific diagnostic
and treatment interventions directed against the cause of the
bleeding (e.g. gastroscopy) should be performed promptly. If
the intake of NOAC was recent (<2–4 h), charcoal administra-
tion and/or gastric lavage will reduce further exposure.
Dialysis clears dabigatran but is less effective for the other
NOACs.
Immediate reversal of the antithrombotic effect is indicated
in severe or life-threatening bleeding events. An agreed institu-
tional procedure for the management of life-threatening bleeds
should be documented and accessible at all times to ensure
adequate initial management. For VKAs, administration of fresh
frozen plasma restores coagulation more rapidly than vitamin
K, and prothrombin complex concentrates achieve even faster
blood coagulation [505]. Registry data suggest that the combi-
nation of plasma and prothrombin complex concentrates is
associated with the lowest case fatality following intracranial
haemorrhage on VKA treatment with an INR >_1.3 [506]. In a
multicentre randomized trial of 188 patients, four-factor pro-
thrombin complex concentrates achieved more rapid INR
reversal and effective haemostasis than plasma in patients
undergoing urgent surgical or invasive procedures [507].
Administration of prothrombin complex concentrates may also
be considered for severe bleeding on NOAC treatment if spe-
cific antidotes are not available.
Several antidotes to NOACs are under development.
Idarucizumab (approved in 2015 by the US Food and Drug
Administration and the European Medicines Agency) is a clini-
cally available humanized antibody fragment that binds dabiga-
tran and rapidly and dose-dependently reverses its effects
Figure 10: Initiation or resumption of anticoagulation in atrial fibrillation patients after an intracranial bleed. This approach is based on consensus opinion and retro-
spective data. In all patients, evaluation by a multidisciplinary panel is required before treatment (stroke physician/neurologist, cardiologist, neuroradiologist, and
neurosurgeon).
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without over-correction or thrombin generation [475].
Andexanet alpha, a modified recombinant human factor Xa that
lacks enzymatic activity, reverses the anticoagulant activity of fac-
tor Xa antagonists in healthy subjects within minutes after
administration and for the duration of infusion, with a transient
increase in markers of coagulation activity of uncertain clinical
relevance [508]. Another agent under development is ciraparan-
tag (PER977), an antidote designed to reverse both direct throm-
bin and factor Xa inhibitors as well as the indirect inhibitor
enoxaparin [509]. The clinical usefulness of these specific anti-
dotes needs further evaluation.
9.6.2 Oral anticoagulation in atrial fibrillation patients at
risk of or having a bleeding event. While anticoagulation
therapy should be paused to control active bleeding, absolute
contraindications to long-term OAC after a bleeding episode
are rare. When nuisance bleeds are the reason to stop OAC, a
change from one anticoagulant to another seems reasonable.
Many causes or triggers of major bleeding events can be
treated and/or eliminated, including uncontrolled hyperten-
sion, gastrointestinal ulcers, and intracranial aneurysms.
Reinitiation of anticoagulation after a bleeding event is often
clinically justified [460, 510]. Difficult decisions, including the
discontinuation and recommencement of OAC, should be
taken by a multidisciplinary team, balancing the estimated risk
of recurrent stroke and bleeding, and considering the bleeding
risk of different stroke prevention therapies. LAA exclusion or
occlusion might be an alternative in selected patients.
9.7 Combination therapy with oral anticoagulants
and antiplatelets
Approximately 15% of AF patients in contemporary trials [513]
and registries [514–516] have a history of myocardial infarction.
Between 5–15% of AF patients will require stenting at some point
Figure 11: Management of active bleeding in patients receiving anticoagulation. Institutions should have an agreed procedure in place.













in their lives. This scenario requires careful consideration of
antithrombotic therapy, balancing bleeding risk, stroke risk, and
risk of acute coronary syndromes (ACS) [516]. Co-prescription of
OAC with antiplatelet therapy, in particular triple therapy,
increases the absolute risk of major haemorrhage [445, 517, 518].
A recent meta-analysis involving 30 866 patients with a recent
ACS evaluated the effects of adding NOAC therapy to single
(4135 patients) or dual (26 731 patients) antiplatelet therapy
[519]. The addition of a NOAC increased the bleeding risk by 79–
134%, while reducing recurrent ischaemic events only marginally
in patients without AF. OAC monotherapy, and not combination
therapy with antiplatelets, is recommended in AF patients with
stable CAD but without an ACS and/or coronary intervention in
the previous 12 months. In patients treated for ACS, and in those
receiving a coronary stent, short-term triple combination therapy
of OAC, clopidogrel, and aspirin seems warranted (Figure 12).
9.7.1 Antithrombotic therapy after acute coronary syn-
dromes and percutaneous coronary intervention in
patients requiring oral anticoagulation. The optimal combi-
nation antithrombotic therapy or duration of combination ther-
apy for AF patients undergoing percutaneous coronary
intervention is not known, but the continued bleeding risk sug-
gests a short duration. Expert consensus [520], reviewed and
reconsidered by this Task Force, suggests the following principles:
AF patients at risk for stroke, patients with mechanical valves,
and patients with recent or recurrent deep vein thrombosis or
pulmonary embolism should continue OAC during and after
stenting. In general, a short period of triple therapy (OAC, aspirin,
clopidogrel) is recommended, followed by a period of dual ther-
apy (OAC plus a single antiplatelet) (Figure 13). When a NOAC is
used, the consensus recommendation is that the lowest dose
effective for stroke prevention in AF should be considered. Dose
reduction beyond the approved dosing tested in phase III trials
(see Table 13) is not currently recommended, and awaits assess-
ment in ongoing controlled trials. The combination of aspirin,
clopidogrel, and low-dose rivaroxaban (2.5 mg twice daily) is not
recommended for stroke prevention in AF [521].
The use of prasugrel or ticagrelor as part of triple therapy
should be avoided unless there is a clear need for these agents
(e.g. stent thrombosis on aspirin plus clopidogrel), given the lack
of evidence and the greater risk of major bleeding compared
with clopidogrel [522, 523]. Ongoing trials will inform about such
combination therapies in the future.
The omission of aspirin while maintaining clopidogrel and
OAC has been evaluated in the WOEST (What is the Optimal
antiplatElet and anticoagulant therapy in patients with oral anti-
coagulation and coronary StenTing) trial, in which 573 anticoagu-
lated patients undergoing percutaneous coronary intervention
(70% with AF) were randomized to either dual therapy with OAC
and clopidogrel (75 mg once daily) or to triple therapy with
OAC, clopidogrel, and aspirin [524]. Bleeding was lower in the
dual vs. triple therapy arm, driven by fewer minor bleeding
events. The rates of myocardial infarction, stroke, target vessel
revascularization, and stent thrombosis did not differ (albeit with
low event numbers), but all-cause mortality was lower in the
dual therapy group at 1 year (2.5% vs. triple therapy 6.4%).
Although the trial was too small to assess ischaemic outcomes,
dual therapy with OAC and clopidogrel may emerge in the future
as an alternative to triple therapy in patients with AF and ACS
and/or coronary intervention [525].
10. RATE CONTROL THERAPY IN ATRIAL
FIBRILLATION
Rate control is an integral part of the management of AF patients,
and is often sufficient to improve AF-related symptoms.
Compared with stroke prevention and rhythm control, very little
robust evidence exists to inform the best type and intensity of
rate control treatment, with the majority of data derived from
short-term crossover trials and observational studies [41, 526–
528]. Pharmacological rate control can be achieved for acute or
long-term rate control with beta-blockers, digoxin, the calcium
channel blockers diltiazem and verapamil, or combination ther-
apy (Table 15). A number of antiarrhythmic drugs also have rate-
limiting properties (amiodarone, dronedarone, sotalol, and to
some extent propafenone), but they should only be used in
patients needing rhythm control therapy (see Chapter 11).
Recommendations for management of bleeding
AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoa-
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Recommendations for combination therapy with oral anticoagulants and antiplatelets




Figure 12: Antithrombotic therapy after an acute coronary syndrome in atrial fibrillation patients requiring anticoagulation.













10.1 Acute rate control
In the setting of acute new-onset AF, patients are often in need of
heart rate control. Physicians should evaluate underlying causes of
elevated heart rate, such as infection, endocrine imbalance, anae-
mia, and pulmonary embolism. For acute rate control, beta-
blockers and diltiazem/verapamil are preferred over digoxin
because of their rapid onset of action and effectiveness at high
sympathetic tone [528–532]. The choice of drug (Table 15) and tar-
get heart rate will depend on patient characteristics, symptoms,
LVEF and haemodynamics, but a lenient initial approach to heart
rate seems acceptable. Combination therapy may be required
(Figure 14). In patients with HFrEF, beta-blockers, digitalis (digoxin
or digitoxin), or their combination should be used [218, 533], as
diltiazem and verapamil can have negative inotropic effects in
patients with LVEF <40% [222, 534, 535]. In critically ill patients and
those with severely impaired LV systolic function, intravenous
amiodarone can be used where excess heart rate is leading to hae-
modynamic instability [536–538]. Urgent cardioversion should be
considered in unstable patients (see section 11.1).
10.2 Long-term pharmacological rate control
10.2.1 Beta-blockers. Beta-adrenoreceptor blocker monother-
apy is often the first-line rate-controlling agent [539], largely
based on observations of better acute heart rate control than
digoxin. Interestingly, the prognostic benefit of beta-blockers
seen in HFrEF patients with sinus rhythm is lost in those with AF.
In an individual patient-level meta-analysis of RCTs, beta-
blockers did not reduce all-cause mortality compared to placebo
in those with AF at baseline (HR 0.97; 95% CI 0.83–1.14;
P = 0.73), whereas there was a clear benefit in patients with sinus
rhythm (HR 0.73; 95% CI 0.67–0.80; P < 0.001) [23]. The analysis,
which included 3066 participants with HFrEF and AF, showed
consistency across all subgroups and outcomes, with no hetero-
geneity between the 10 RCTs included (I [2] = 0%). Despite this
lack of prognostic benefit in HFrEF, this Task Force still considers
beta-blockers as a useful first-line rate control agent across all AF
patients, based on the potential for symptomatic and functional
improvement as a result of rate control, the lack of harm from
published studies, and the good tolerability profile across all ages
in sinus rhythm and in AF [23, 540].
10.2.2 Non-dihydropyridine calcium channel blockers.
Verapamil or diltiazem provide reasonable rate control in AF
patients [541]. They should be avoided in patients with HFrEF
because of their negative inotropic effects [222, 534, 535].
Verapamil or diltiazem can improve arrhythmia-related symp-
toms [526], in comparison with beta-blockers, which reduced
exercise capacity and increased B-type natriuretic peptide in one
small trial of low-risk patients with preserved LVEF [542].
10.2.3 Digitalis. Cardiac glycosides such as digoxin and digi-
toxin have been in use for over two centuries, although prescrip-
tions have been declining steadily over the past 15 years [543]. In
the randomized Digitalis Investigation Group (DIG) trial, digoxin
had no effect on mortality compared to placebo in HFrEF
patients in sinus rhythm (RR 0.99; 95% CI 0.91–1.07), but reduced
hospital admissions (RR 0.72; 95% CI 0.66–0.79) [544, 545]. There
have been no head-to-head RCTs of digoxin in AF patients [546].
Figure 13: Antithrombotic therapy after elective percutaneous intervention in atrial fibrillation patients requiring anticoagulation.
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Observational studies have associated digoxin use with excess
mortality in AF patients [547–549], but this association is likely
due to selection and prescription biases rather than harm caused
by digoxin [550–553], particularly as digoxin is commonly pre-
scribed to sicker patients [225]. In a crossover mechanistic trial of
47 patients with HFrEF and AF, there were no differences in heart
rate, blood pressure, walking distance, or LVEF between carvedi-
lol and digoxin, although beta-blockers did result in higher B-
type natriuretic peptide levels, combination carvedilol/digoxin
improved LVEF, and digoxin withdrawal reduced LVEF [554].
Comparisons with other rate control therapies are based on
small, short-duration studies that identify no or marginal
differences in exercise capacity, quality of life, or LVEF compared
to digoxin [526, 554–558]. Lower doses of digoxin (<_250 mg once
daily), corresponding to serum digoxin levels of 0.5–0.9 ng/mL,
may be associated with better prognosis [225].
10.2.4 Amiodarone. Amiodarone can be useful for rate control
as a last resort. The wide array of extracardiac adverse effects
associated with amiodarone renders it a reserve agent in patients
whose heart rate cannot be controlled with combination therapy
(e.g. beta-blocker or verapamil/diltiazem combined with
digoxin).
Table 15: Rate control therapy in atrial fibrillation
AF = atrial fibrillation; CKD = chronic kidney disease; i.v. = intravenous; LV = left ventricular; LVEF = left ventricular ejection fraction.
aA number of other beta-blockers are also available, but are not recommended as specific rate control therapy in AF. These include atenolol (25–100 mg once
daily with a short biological half-life), propranolol [non-selective, 1 mg over 1 min and repeat up to 3 mg at 2-min intervals (acute) or 10–40 mg three times
daily (long-term)], or labetalol [non-selective, 1–2 mg/min (acute)].
bIf ongoing requirement for amiodarone, follow with 900 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula.













In summary, there is equipoise for the use of different rate
control agents in AF. The choice of beta-blocker, diltiazem/vera-
pamil, digoxin, or combination therapy should be made on an
individual basis, after consideration of patient characteristics and
patient preference. All available therapies have the potential for
adverse effects and patients should initially be treated with a low
dose and uptitrated to achieve symptom improvement. In prac-
tice, achieving a heart rate <110 b.p.m. will often require combi-
nation therapy (Figure 15). The benefit of different rate control
strategies on symptoms, quality of life, and other intermediate
outcomes is under investigation [559].
10.3 Heart rate targets in atrial fibrillation
The optimal heart rate target in AF patients is unclear. The RACE
(Rate Control Efficacy in Permanent Atrial Fibrillation) II study
randomized 614 patients with permanent AF to either a target
heart rate <80 b.p.m. at rest and <110 b.p.m. during moderate
exercise, or to a lenient heart rate target of <110 b.p.m. There
was no difference in a composite of clinical events (14.9% in the
strict rate control group, 12.9% in the lenient group) [560], NYHA
class, or hospitalizations [560, 561]. Similar results were found in
a pooled analysis of the AFFIRM (Atrial Fibrillation Follow-up
Investigation of Rhythm Management) and RACE trials (1091
participants), albeit with smaller heart rate differences and with-
out randomization [562]. It is worthwhile to note that many
‘adequately rate-controlled’ patients (resting heart rate 60–100
b.p.m.) are severely symptomatic, calling for additional manage-
ment [194]. Nonetheless, lenient rate control is an acceptable ini-
tial approach, regardless of heart failure status, unless symptoms
call for stricter rate control.
10.4 Atrioventricular node ablation and pacing
Ablation of the atrioventricular node/His bundle and implanta-
tion of a VVI pacemaker can control ventricular rate when
medications fail to control rate and symptoms. It is a relatively
simple procedure with a low complication rate and low long-
term mortality risk [563, 564], especially when the pacemaker is
implanted a few weeks before the AV nodal ablation and the
initial pacing rate after ablation is set at 70–90 b.p.m [565, 566].
The procedure does not worsen LV function [567] and may
even improve LVEF in selected patients [568–570]. In selected
HFrEF patients treated with biventricular pacing (cardiac
resynchronization therapy), AF can terminate [571], although
such a ‘rhythm control’ effect of cardiac resynchronization ther-
apy is likely to be small and clearly needs confirmation [572].
AV nodal ablation renders patients pacemaker-dependent for
Figure 14: Acute heart rate control in patients with atrial fibrillation.
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the rest of their lives, limiting AV nodal ablation and pacing to
patients whose symptoms cannot be managed by rate-
controlling medication or by reasonable rhythm control inter-
ventions (see AF Heart Team, section 11.6). The choice of pac-
ing therapy (right ventricular or biventricular pacing with or
without an implantable defibrillator) will depend on individual
patient characteristics, including LVEF [573, 574].
11. RHYTHM CONTROL THERAPY IN ATRIAL
FIBRILLATION
Restoring and maintaining sinus rhythm is an integral part of AF
management. Antiarrhythmic drugs approximately double the
rate of sinus rhythm compared with placebo [580–584]. Catheter
ablation or combination therapy is often effective when antiar-
rhythmic drugs fail [226, 585–587]. Although many clinicians
believe that maintaining sinus rhythm can improve outcomes
in AF patients [588], all trials that have compared rhythm control
and rate control to rate control alone (with appropriate
anticoagulation) have resulted in neutral outcomes [41, 578, 579,
582, 589–593]. Whether modern rhythm control management
involving catheter ablation, combination therapy, and early ther-
apy leads to a reduction in major cardiovascular events is cur-
rently under investigation, e.g. in the EAST – AFNET 4 (Early
treatment of Atrial fibrillation for Stroke prevention Trial) [40]
and CABANA (Catheter Ablation vs. Anti-arrhythmic Drug
Therapy for Atrial Fibrillation Trial) [594] trials. For now, rhythm
control therapy is indicated to improve symptoms in AF patients
who remain symptomatic on adequate rate control therapy.
11.1 Acute restoration of sinus rhythm
11.1.1 Antiarrhythmic drugs for acute restoration of sinus
rhythm (‘pharmacological cardioversion’). Antiarrhythmic
drugs can restore sinus rhythm in patients with AF (pharmaco-
logical cardioversion) as shown in small controlled trials, meta-
analyses [41, 584, 595, 596], and in a few larger controlled trials
[597–605]. Outside of Europe, dofetilide is available and can con-
vert recent-onset AF [606]. Pharmacological cardioversion
restores sinus rhythm in approximately 50% of patients with
recent-onset AF (Table 16) [607–609]. In the short-term, electrical
cardioversion restores sinus rhythm quicker and more effectively
than pharmacological cardioversion and is associated with
shorter hospitalization [609–613]. Pharmacological cardioversion,
conversely, does not require sedation or fasting (Figure 16).
Flecainide and propafenone are effective for pharmacological
cardioversion [595, 602–605, 614, 615], but their use is restricted
to patients without structural heart disease. Ibutilide is an alter-
native where available, but carries a risk of torsades de pointes
[615]. Vernakalant [602–605] can be given to patients with mild
heart failure (NYHA Class I or II), including those with ischaemic
heart disease, provided they do not present with hypotension or
severe aortic stenosis [616–618]. Amiodarone can be used in
patients with heart failure and in patients with ischaemic heart
disease (although patients with severe heart failure were
excluded from most of the AF cardioversion trials) [596].
Amiodarone also slows heart rate by 10–12 b.p.m. after 8–12 h
when given intravenously [596]. Both amiodarone and flecainide
appear more effective than sotalol in restoring sinus rhythm
[600, 601, 619].
Figure 15: Long-term heart rate control in patients with atrial fibrillation.













11.1.2 ‘Pill in the pocket’ cardioversion performed by
patients. In selected patients with infrequent symptomatic epi-
sodes of paroxysmal AF, a single bolus of oral flecainide (200–
300 mg) or propafenone (450–600 mg) can be self-administered
by the patient at home (‘pill in the pocket’ therapy) to restore
sinus rhythm, after safety has been established in the hospital set-
ting [620]. This approach seems marginally less effective than
hospital-based cardioversion [621], but is practical and provides
control and reassurance to selected patients.
11.1.3 Electrical cardioversion. Synchronized direct current
electrical cardioversion quickly and effectively converts AF to
sinus rhythm, and is the method of choice in severely haemody-
namically compromised patients with new-onset AF (Figure 16)
[626–628]. Electrical cardioversion can be performed safely in
sedated patients treated with intravenous midazolam and/or
propofol. Continuous monitoring of blood pressure and oximetry
during the procedure is important [629]. Skin burns may occa-
sionally be observed. Intravenous atropine or isoproterenol, or
temporary transcutaneous pacing, should be available to mitigate
post-cardioversion bradycardia. Biphasic defibrillators are more
effective than monophasic waveforms, and have become the
industry standard [626, 628]. Anterior–posterior electrode posi-
tions generate a stronger shock field in the left atrium than ante-
rolaterally positioned electrodes, and restore sinus rhythm more
effectively [626, 627, 630].
Pre-treatment with amiodarone (requiring a few weeks of ther-
apy) [631, 632], sotalol [631], ibutilide [633], or vernakalant [634]
can improve the efficacy of electrical cardioversion, and similar
effects are likely for flecainide [584] and propafenone [635]. Beta-
blockers [636], verapamil, diltiazem [637–639], and digoxin [640,
641] do not reliably terminate AF or facilitate electrical cardiover-
sion. When antiarrhythmic drug therapy is planned to maintain
sinus rhythm after cardioversion, it seems prudent to start ther-
apy 1–3 days before cardioversion (amiodarone: a few weeks) to
promote pharmacological conversion and to achieve effective
drug levels [584, 601].
11.1.4 Anticoagulation in patients undergoing cardio-
version. Cardioversion carries an inherent risk of stroke in non-
anticoagulated patients [642], which is reduced substantially by
the administration of anticoagulation [643]. Immediate initiation
of anticoagulation is important in all patients scheduled for cardi-
oversion [644–646]. Patients who have been in AF for longer than
48 h should start OAC at least 3 weeks before cardioversion and
continue it for 4 weeks afterwards (in patients without a need for
long-term anticoagulation). OAC should be continued indefi-
nitely in patients at risk of stroke. This practice has never been
evaluated in controlled trials, but seemed safe in a large observa-
tional data set from Finland [647]. When early cardioversion is
desired, TOE can exclude the majority of left atrial thrombi,
allowing immediate cardioversion [648, 649]. Ongoing studies
will inform about the safety and efficacy of newly initiated anti-
coagulation using NOACs in patients scheduled for
cardioversion.
11.2 Long-term antiarrhythmic drug therapy
The aim of antiarrhythmic drug therapy is improvement in
AF-related symptoms [41, 580]. Hence, the decision to initiate
long-term antiarrhythmic drug therapy needs to balance symptom
burden, possible adverse drug reactions, and patient preferences.
The principles of antiarrhythmic drug therapy outlined in the 2010
ESC AF guidelines [369] are still relevant and should be observed:
1. Treatment is aimed at reducing AF-related symptoms;
2. Efficacy of antiarrhythmic drugs to maintain sinus rhythm is modest;
3. Clinically successful antiarrhythmic drug therapy may reduce rather
than eliminate the recurrence of AF;
4. If one antiarrhythmic drug ‘fails’, a clinically acceptable response may
be achieved with another agent;
Recommendations for rate control
AF = atrial fibrillation; b.p.m. = beats per minute; LVEF = left ventricular
ejection fraction.
Digitoxin is a suitable alternative to digoxin, where available. In patients
with heart failure with reduced ejection fraction (LVEF <40%), recom-
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5. Drug-induced pro-arrhythmia or extracardiac side-effects are
frequent;
6. Safety rather than efficacy considerations should primarily guide the
choice of antiarrhythmic drug.
Antiarrhythmic drug therapy approximately doubles sinus rhythm
maintenance compared with no therapy [580]. There is no appre-
ciable effect on mortality or cardiovascular complications, but
rhythm control therapy can slightly increase the risk of hospitaliza-
tions (often for AF) [41, 578, 579, 582, 589–593]. To reduce the risk
of side-effects [201, 580], a shorter duration of antiarrhythmic drug
therapy seems desirable. As an example, short-term treatment (4
weeks) with flecainide for 4 weeks after cardioversion of AF was
well-tolerated and prevented most (80%) AF recurrences when
compared with long-term treatment [584]. Short-term antiarrhyth-
mic drug therapy is also used to avoid early AF recurrences after
catheter ablation [650], and may be reasonable in patients deemed
at increased risk of antiarrhythmic drug side-effects or in those
with a low perceived risk of recurrent AF.
In addition to antiarrhythmic drug therapy and catheter ablation
(see section 11.3), management of concomitant cardiovascular con-
ditions can reduce symptom burden in AF and facilitate the mainte-
nance of sinus rhythm [203, 204, 296, 312]. This includes weight
reduction, blood pressure control, heart failure treatment, increasing
cardiorespiratory fitness, and other measures (see Chapter 7).
11.2.1 Selection of antiarrhythmic drugs for long-term
therapy: safety first! Usually, the safety of antiarrhythmic drug
therapy determines the initial choice of antiarrhythmic drugs
(Figure 17). The following major antiarrhythmic drugs are avail-
able to prevent AF:
11.2.1.1 Amiodarone. Amiodarone is an effective multichannel
blocker, reduces ventricular rate, and is safe in patients with heart
failure [582, 651]. Torsades de pointes pro-arrhythmia can occur,
and QT interval and TU waves should be monitored on therapy
(see Table 17) [652]. Amiodarone often causes extracardiac side-
effects, especially on long-term therapy [653, 654], rendering it a
second-line treatment in patients who are suitable for other anti-
arrhythmic drugs. Amiodarone appears less suitable to episodic
short-term therapy (unless after catheter ablation) [655], probably
because of its long biological half-life.
11.2.1.2 Dronedarone. Dronedarone maintains sinus rhythm,
reduces ventricular rate, and prevents cardiovascular hospital-
izations (mostly due to AF) and cardiovascular death in patients
with paroxysmal or persistent AF or flutter who had at least
one relevant cardiovascular comorbidity [583, 588, 656].
Dronedarone increases mortality in patients with recently
decompensated heart failure (with or without AF) [657], and in
patients with permanent AF in whom sinus rhythm is not
restored [658]. Dronedarone moderately increases serum creati-
nine, reflecting a reduction in creatinine excretion rather than a
decline in kidney function [659].
11.2.1.3 Flecainide and propafenone. Flecainide and propafenone
are effective in preventing recurrent AF [581, 584, 620]. They
should only be used in patients without significant ischaemic
heart disease or heart failure to avoid the risk of life-threatening
ventricular arrhythmias [660]. High ventricular rates resulting
from the conversion of AF into atrial flutter with 1:1 conduction
by flecainide or propafenone can be prevented by pre-
administering a beta-blocker, verapamil, or diltiazem.
Table 16: Antiarrhythmic drugs for pharmacological cardioversion
ACS = acute coronary syndromes; AV = atrioventricular; IHD = ischaemic heart disease; i.v. = intravenous; LVH = left ventricular hypertrophy; NYHA = New
York Heart Association; SBP = systolic blood pressure.
aUse a large peripheral vessel and change to oral amiodarone within 24 h of i.v. (central line) administration.
bIbutilide is only available in selected European countries.













11.2.1.4 Quinidine and disopyramide. Quinidine and disopyramide
have been associated with an increase in all-cause mortality (OR
2.39; 95% CI 1.03–5.59; number needed to harm 109; 95% CI 34–
4985) at 1-year follow-up [580, 661], likely due to ventricular
arrhythmias (torsades de pointes) [580, 661]. Although this pro-
arrhythmic effect is more common at higher doses, they are less
commonly used for rhythm control in AF. Disopyramide may be
useful in ‘vagally mediated’ AF (e.g. AF occurring in athletes and/
or during sleep [76]), and has been shown to reduce LV outflow
gradient and improve symptoms in patients with hypertrophic
cardiomyopathy [662–664].
11.2.1.5 Sotalol. Sotalol has a relevant risk of torsades de pointes
[1% in the Prevention of Atrial Fibrillation After Cardioversion
(PAFAC) trial [118]]. Its d-enantiomer is associated with increased
mortality compared to placebo in patients with LV dysfunction
after a myocardial infarction [665], probably due to ventricular
arrhythmias (OR 2.47; 95% CI 1.2–5.05; number needed to harm
166; 95% CI 61–1159) [580, 665]. On the other hand, d,l-sotalol
has been used in AF patients without safety signals in two con-
trolled trials [581, 601].
11.2.1.6 Dofetilide. Dofetilide is another potassium channel blocker
that is mainly available outside of Europe. Dofetilide restores and
maintains sinus rhythm in heart failure patients [666], and occa-
sionally in patients refractory to other antiarrhythmic drugs [667].
Overall, it seems prudent to limit the use of quinidine, disopyr-
amide, dofetilide, and sotalol to specific situations. Furthermore,
combinations of QT-prolonging antiarrhythmic drugs should
generally be avoided for rhythm control in AF (Table 17).
11.2.2 The twelve-lead electrocardiogram as a tool to
identify patients at risk of pro-arrhythmia. Identifying
patients at risk of pro-arrhythmia can help to mitigate the pro-
arrhythmic risk of antiarrhythmic drugs [668]. In addition to the
clinical characteristics mentioned above, monitoring PR, QT, and
QRS durations during initiation of antiarrhythmic drug therapy
can identify patients at higher risk of drug-induced pro-arrhyth-
mia on longer-term treatment [669–671]. In addition, the pres-
ence of ‘abnormal TU waves’ is a sign of imminent torsades de
pointes [652]. Periodic ECG analysis for pro-arrhythmia signs has
been used successfully in recent antiarrhythmic drug trials
[118, 584, 672]. Specifically, ECG monitoring was used systemati-
cally on days 1–3 in patients receiving flecainide, propafenone,
or sotalol to identify those at risk of pro-arrhythmia
[118, 584, 601]. Based on this evaluated practice, we suggest to
record an ECG in all patients before initiation of antiarrhythmic
drugs. Scheduled ECGs during the initiation period seem reason-
able (Table 17).
11.2.3 New antiarrhythmic drugs. Several compounds that
inhibit the ultrarapid potassium current (IKur) and other inhibitors
of atypical ion channels are in clinical development [673–675].
They are not available for clinical use at present. The antianginal
Figure 16: Rhythm control management of recent onset atrial fibrillation.
e42 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
compound ranolazine inhibits potassium and sodium currents
and increases glucose metabolism at the expense of free fatty
acid metabolism, thereby enhancing the efficient use of oxygen
[676, 677]. Ranolazine was safe in patients with non–ST-segment
elevation myocardial infarction and unstable angina evaluated in
the MERLIN (Metabolic Efficiency With Ranolazine for Less
Ischemia in Non ST-Elevation Acute Coronary Syndrome) trial
[678]. In a post hoc analysis of continuous ECG recordings
obtained during the first 7 days after randomization, patients
assigned to ranolazine had a trend towards fewer episodes of AF
than those on placebo [75 (2.4%) vs. 55 (1.7%) patients; P = 0.08]
[679]. In the HARMONY (A Study to Evaluate the Effect of
Ranolazine and Dronedarone When Given Alone and in
Combination in Patients With Paroxysmal Atrial Fibrillation) trial,
the highest tested dose of a combination of ranolazine (750 mg
twice daily) and dronedarone (225 mg twice daily) slightly
reduced AF burden in 134 subjects with paroxysmal AF and
dual-chamber pacemakers [680]. Small, open-label studies sug-
gest that ranolazine might enhance the antiarrhythmic effect of
amiodarone for cardioversion [681–683], whereas the results
from a controlled trial of ranolazine and the ranolazine–drone-
darone combination to prevent AHRE in pacemaker patients
were ambiguous [684]. At present, there is insufficient evidence
to recommend ranolazine as an antiarrhythmic drug, alone or in
combination with other antiarrhythmic drugs. Of note, the ‘funny
channel blocker’ ivabradine, which is used for angina and heart
failure, increases the risk of AF [685].
11.2.4 Antiarrhythmic effects of non-antiarrhythmic
drugs. ACE inhibitors or ARBs appear to prevent new-onset AF in
patients with LV dysfunction and in hypertensive patients with LV
hypertrophy [219, 236, 237, 239, 246, 250, 686]. Neprilysin
inhibition needs to be studied further, but does not seem to
enhance this effect [224]. A Danish cohort study also suggested that
initial treatment of uncomplicated hypertension with ACE inhibitors
or ARBs reduces incident AF compared with other hypertensive
agents [245]. ARB therapy did not reduce the AF burden in patients
with AF without structural heart disease [241]. Thus, ACE inhibitors
or ARBs are unlikely to have a relevant direct antiarrhythmic effect.
However, it might be justified to consider adding ACE inhibitors or
ARB therapy to antiarrhythmic drugs to reduce AF recurrences after
cardioversion [248, 249, 687].
Compared with placebo, beta-blockers are associated with a
reduced risk of new-onset AF in patients with HFrEF and sinus
rhythm [23]. Beta-blockers have also been reported to reduce
symptomatic AF recurrences [580, 636, 688], but this finding may
be driven by the beneficial effect of rate control, which will ren-
der AF more often asymptomatic.
Peri-operative statin therapy appeared to reduce the risk of
post-operative AF in a number of small RCTs; [689, 690] however,
an adequately powered placebo-controlled trial has shown no
effect of peri-operative rosuvastatin therapy on post-operative AF
[691]. Statin treatment does not prevent AF in other settings [692,
693]. Similarly, polyunsaturated fatty acids failed to show convinc-
ing benefit [241, 694–698]. The role of aldosterone antagonists in
the management of AF has not been extensively investigated in
humans. Although preliminary evidence from trials of eplerenone
is encouraging for primary prevention [243], at present there is no
robust evidence to make any recommendation for the use of
aldosterone antagonists for secondary prevention of AF [699–701].
11.3 Catheter ablation
Since the initial description of triggers in the pulmonary veins
that initiate paroxysmal AF [108], catheter ablation of AF has
Figure 17: Initiation of long-term rhythm control therapy in symptomatic patients with atrial fibrillation.













developed from a specialized, experimental procedure into a
common treatment to prevent recurrent AF [587, 715]. This is pri-
marily achieved through isolation of the pulmonary veins, prob-
ably requiring complete isolation for full effectiveness [716], and
additional ablation in the posterior left atrial wall. AF ablation,
when performed in experienced centres by adequately trained
teams, is more effective than antiarrhythmic drug therapy in
maintaining sinus rhythm, and the complication rate, though not
negligible, is similar to the complication rate for antiarrhythmic
drugs [585, 717].
11.3.1 Indications. Catheter ablation of AF is effective in restor-
ing and maintaining sinus rhythm in patients with symptomatic
paroxysmal, persistent, and probably long-standing persistent AF,
in general as second-line treatment after failure of or intolerance
to antiarrhythmic drug therapy. In such patients, catheter abla-
tion is more effective than antiarrhythmic drug therapy [185, 586,
713, 717–720]. As first-line treatment for paroxysmal AF,
randomized trials showed only modestly improved rhythm out-
come with catheter ablation compared to antiarrhythmic drug
therapy [585, 721–723]. Complication rates were similar, when
ablation was performed in expert centres, justifying catheter
ablation as first-line therapy in selected patients with paroxysmal
AF who ask for interventional therapy. Fewer data are available
reporting the effectiveness and safety of catheter ablation in
patients with persistent or long-standing persistent AF, but all
point to lower recurrence rates after catheter ablation compared
to antiarrhythmic drug therapy with or without cardioversion
(Web Figure 2) [185, 717, 723–726, 1039]. In patients who experi-
ence symptomatic recurrences of AF despite antiarrhythmic drug
therapy, all RCTs showed better sinus rhythm maintenance with
catheter ablation than on antiarrhythmic drugs [586, 713, 727,
728]. There is no current indication for catheter ablation to pre-
vent cardiovascular outcomes (or desired withdrawal of anticoa-
gulation), or to reduce hospitalization [40, 594].
11.3.2 Techniques and technologies. Complete pulmonary
vein isolation (PVI) on an atrial level is the best documented tar-
get for catheter ablation [716, 729–731], achievable by point-by-
point radiofrequency ablation, linear lesions encircling the
Table 17: Oral antiarrhythmic drugs used for maintaining sinus rhythm after cardioversion
AF = atrial fibrillation; AV = atrioventricular; b.p.m. = beats per minute; CrCl = creatinine clearance; CYP2D6 = cytochrome P450 2D6; CYP3A4 = cytochrome
P450 3A4; ECG = electrocardiogram; IHD = ischaemic heart disease; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York Heart
Association; SAN = sino-atrial node; VKA = vitamin K antagonist.
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pulmonary veins, or cryoballoon ablation, with similar outcomes
[732–734]. Complete isolation of the pulmonary veins has better
rhythm outcomes than incomplete isolation [716]. PVI was ini-
tially tested in patients with paroxysmal AF, but appears to be
non-inferior to more extensive ablation in persistent AF as well
[729, 735]. More extensive ablations have been used in patients
with persistent AF, but there are insufficient data to guide the use
of these at present [117, 718, 719, 735–737]. Extended ablation
procedures (beyond PVI) consistently require longer procedures
and more ionizing radiation, potentially creating risk for patients.
Left atrial macro re-entrant tachycardia is relatively uncommon
after PVI (5%). It also seems rare after cryoballoon ablation
[734], but may occur in up to 25% of patients after left atrial sub-
strate modification ablation, often due to incomplete ablation
lines. Thus, for patients with persistent AF, ablation of complex
fractionated electrograms, ablation of rotors, or routine deploy-
ment of linear lesions or other additional ablations does not
seem justified in the first procedure [735, 738, 739]. However,
additional ablation on top of complete PVI [716] may be consid-
ered in patients with recurrent AF after the initial ablation proce-
dure [719, 740, 741]. In patients with documented right atrial
isthmus-dependent flutter undergoing AF ablation, right atrial
isthmus ablation is recommended. Adenosine testing to identify
patients in need of additional ablation remains controversial after
evaluation in several reports [739, 742–744]. Ablation of so-called
‘rotors’, guided by body surface mapping or endocardial map-
ping, is under evaluation and cannot be recommended for rou-
tine clinical use at present.
11.3.3 Outcome and complications. 11.3.3.1 Outcome of
catheter ablation for atrial fibrillation. The rhythm outcome after
catheter ablation of AF is difficult to predict in individual patients
[173, 227, 713, 728]. Most patients require more than one proce-
dure to achieve symptom control [713, 726, 728]. In general, bet-
ter rhythm outcome and lower procedure-related complications
can be expected in younger patients with a short history of AF
and frequent, short AF episodes in the absence of significant
structural heart disease [745]. Catheter ablation is more effective
than antiarrhythmic drug therapy in maintaining sinus rhythm
(Web Figure 2) [746, 1039]. Sinus rhythm without severely symp-
tomatic recurrences of AF is found in up to 70% of patients with
paroxysmal AF, and around 50% in persistent AF [713, 728, 735].
Very late recurrence of AF after years of sinus rhythm is not
uncommon and may reflect disease progression, with important
implications for continuation of AF therapies [728]. Multiple vari-
ables have been identified as risk factors for recurrence after
catheter ablation of AF, but their predictive power is weak. The
Recommendations for rhythm control therapy (continued)
ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; CHA2DS2-VASc = Congestive Heart failure, hypertension,
Age >_75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); ECG = electrocardiogram; LV = left ventricular; LVH = left ventric-
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decision for catheter ablation, thus, should be based on a shared
decision-making process [747] (see Chapter 8), following thor-
ough explanation of the potential benefits and risks, and of the
alternatives such as antiarrhythmic drugs or acceptance of the
current symptoms without rhythm control therapy [175].
11.3.3.2 Complications of catheter ablation for atrial fibrillation.
There is a clear need to systematically capture complications in
clinical practice to improve the quality of AF ablation procedures
[175]. The median length of hospital stay in AF patients under-
going their first ablation as part of the EURObservational
Research Programme (EORP) was 3 days (interquartile range 2–4
days), based on data from 1391 patients from hospitals perform-
ing at least 50 ablations per year. Five to seven per cent of
patients will suffer severe complications after catheter ablation of
AF, and 2–3% will experience life-threatening but usually man-
ageable complications [727, 748–750]. Intraprocedural death has
been reported, but is rare (<0.2%) [751]. The most important
severe complications are stroke/TIA (<1%), cardiac tamponade
(1–2%), pulmonary vein stenosis, and severe oesophageal injury
leading to atrio-oesophageal fistula weeks after ablation
(Table 18). ‘Silent strokes’ (i.e. white matter lesions detectable by
brain MRI) have been observed in around 10% of patients treated
with radiofrequency and cryoballoon ablation [752]. The clinical
relevance of this observation is unclear [749]. Post-procedural
complications include stroke, with the highest risk within the first
week [753], late pericardial tamponade several days after catheter
ablation [751], and oesophageal fistulas, which usually become
apparent 7–30 days after ablation. Timely detection of atrio-
oesophageal fistulas can be life-saving and should be based on
the typical triad of infection without a clear focus, retrosternal
pain, and stroke or TIA [748].
11.3.4 Anticoagulation: before, during, and after abla-
tion. Patients anticoagulated with VKAs should continue therapy
during ablation (with an INR of 2–3) [760]. Anticoagulation with
NOACs is an alternative to warfarin [478, 761–765]. There is no
safety signal from observational cohorts treated with uninter-
rupted NOAC therapy undergoing catheter ablation in experi-
enced centres [761, 763, 766, 767]. The first controlled trial
comparing continuous NOAC and VKA therapy in AF ablation
patients, enrolling around 200 patients, has recently been
published [768], as well as several observational data sets
[761, 769, 770]. Ongoing studies compare uninterrupted VKA with
NOAC therapy in AF patients undergoing ablation [e.g. AXAFA –
AFNET 5 (Anticoagulation using the direct factor Xa inhibitor apix-
aban during Atrial Fibrillation catheter Ablation: Comparison to
vitamin K antagonist therapy; NCT02227550) and RE-CIRCUIT
(Randomized Evaluation of dabigatran etexilate Compared to
warfarin in pulmonaRy vein ablation: assessment of different peri-
proCedUral anticoagulation sTrategies; NCT02348723)]. During
ablation, heparin should be given to maintain an activated clot-
ting time >300 s. Anticoagulation should be maintained for at
least 8 weeks after ablation for all patients. The true incidence of
thrombo-embolic events after catheter ablation has never been
systematically studied and the expected stroke risk has been
adopted from non-ablation AF cohorts. Although observational
studies suggest a relatively low stroke rate in the first few years
after catheter ablation of AF [737, 771–776], the long-term risk of
recurrent AF and the safety profile of anticoagulation in ablated
patients need to be considered. In the absence of controlled trial
data, OAC after catheter ablation should follow general anticoagu-
lation recommendations, regardless of the presumed rhythm
outcome.
11.3.5 Ablation of atrial fibrillation in heart failure
patients. Catheter ablation, compared with amiodarone ther-
apy, significantly reduces recurrent AF in AF patients with HFrEF
[777]. Selected patients with HFrEF and AF can achieve recovery
of LV systolic function after catheter ablation (probably reflecting
tachycardiomyopathy). Several smaller trials suggest improved LV
function after catheter ablation in HFrEF patients [185, 226–228,
778, 779] and reduced hospitalizations [720, 777], especially in
patients without a previous myocardial infarction [780]. Larger
trials are warranted to confirm these findings. Catheter ablation
can be demanding in these patients. Thus, indications for cathe-
ter ablation in HFrEF patients should be carefully balanced, and
the procedures performed in experienced centres.
11.3.6 Follow-up after catheter ablation. Patients and
physicians involved in the follow-up after catheter ablation
should know the signs and symptoms of late complications to
allow swift referral for treatment (Table 18). Patients should also
be aware that symptomatic and asymptomatic AF recurrences
are frequent after catheter ablation [119, 781, 782]. In line with
the primary goal of rhythm control therapy, asymptomatic epi-
sodes should generally not trigger further rhythm control therapy
in routine care. Patients should be seen at least once by a rhythm




TIA = transient ischaemic attack.
aOesophageal fistula should be suspected in patients presenting with
the triad of unspecific signs of infection, chest pain, and stroke or TIA in
the first weeks after an ablation procedure. It requires immediate
therapy.
b<10% for cryoablation or radiofrequency ablation, >20% for phased
radiofrequency ablation.













specialist in the first 12 months after ablation. Further rhythm
control options should be considered in patients with sympto-
matic recurrences, including discussion in a Heart Team
(Figure 17, Figure 19).
11.4 Atrial fibrillation surgery
11.4.1 Concomitant atrial fibrillation surgery. The Cox
maze procedure was first performed 30 years ago as a ‘cut-and-
sew’ technique, including isolation of the posterior left atrium, a
connection to the posterior mitral annulus, a cavotricuspid con-
nection, a cavocaval connection, and exclusion of the LAA
(Figure 18) [783]. Thereby, the Cox maze procedure creates an
electrical labyrinth (maze) of passages through which the sinoa-
trial node impulse finds a route to the atrioventricular node while
preventing fibrillatory conduction. The Cox maze procedure and
other, often simpler, forms of AF surgery have mainly been used
in patients undergoing other open heart surgical procedures
[461, 466, 784–798]. In a systematic review commissioned for
these guidelines, performing concomitant AF surgery resulted in
increased freedom from AF, atrial flutter, and atrial tachycardia
compared to no concomitant AF surgery (RR 1.94; 95% CI 1.51–
2.49; n = 554 from seven RCTs) (Web Figure 3) [1040]. Patients
undergoing the Cox maze procedure required pacemaker
implantation more often (RR 1.69; 95% CI 1.12–2.54; n = 1631
from 17 RCTs), without a detectable difference in other outcomes
or complications. These findings are underpinned by an analysis
of the Society of Thoracic Surgeons database comprising 67 389
patients in AF undergoing open heart surgery: mortality or major
morbidity was not affected by concomitant AF surgery (adjusted
OR 1.00; 95% CI 0.83–1.20), but pacemaker implantation was
more frequent (adjusted OR 1.26; 95% CI 1.07–1.49) [799].
Predictors of AF recurrence after surgery include left atrial dilata-
tion, older age, >10-year history of AF, and non-paroxysmal AF
[800–804]. Regarding AF type, surgical PVI seems effective in par-
oxysmal AF [805]. Biatrial lesion patterns may be more effective
in persistent and long-standing persistent AF [797, 803, 806]. The
suggested management of patients with AF-related symptoms
undergoing cardiac surgery is displayed in Figure 19, with an
important contribution of the AF Heart Team to advise and
inform patient choice.
11.4.2 Stand-alone rhythm control surgery. Current tech-
nology (e.g. bipolar radiofrequency or cryothermy) renders the
Cox maze procedure easier, and more reproducible and feasible,
via a mini-thoracotomy [786, 807, 808]. Thoracoscopic PVI with
bipolar radiofrequency prevents recurrence of paroxysmal AF
(69–91% freedom from arrhythmias at 1 year, see Figure 18B for
lesion set) [468, 809, 810], and seems effective in patients refrac-
tory to catheter ablation [811]. The average length of hospital
stay for thoracoscopic ablation varies from 3.6 to 6.0 days [468,
812, 813]. The FAST (Atrial Fibrillation Catheter Ablation vs.
Surgical Ablation Treatment) trial [468], and another smaller trial
[814], suggested that thoracoscopic AF surgery could be more
Figure 18: A: Surgical lesion sets for the biatrial Cox maze procedure. Surgeon’s view showing left atrial lesions (left panel) and right atrial lesions (middle and right
panel). B: Left atrial lesions in a thoracoscopic minimally invasive surgical procedure (dashed lines), including left atrial appendage exclusion (double line).
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effective than catheter ablation for the maintenance of sinus
rhythm [468, 814], while also causing more complications
(Table 19) [815]. To improve results [468, 816–818], more exten-
sive lesion sets have been performed, including connecting lines
between the PVI (“box lesion”) and lines towards the mitral annu-
lus [812, 819–822]. To improve the generation of transmural
lesions [716], endo-epicardial ablation strategies have recently
been proposed [812, 823–825]. Although preliminary experience
with hybrid simultaneous ablation shows promise, procedural
time and rates of bleeding complications are higher [812, 823].
11.5 Choice of rhythm control following treatment
failure
There is insufficient evidence to underpin clear recommenda-
tions on how to treat patients with recurrent AF after catheter
ablation. Early recurrences of AF or atrial tachycardias after
ablation (occurring within 8 weeks) may be treated with cardio-
version. Many of the published series of patients undergoing AF
ablation included those who failed antiarrhythmic drug therapy.
Thus, considering ablation therapy in patients who have sympto-
matic recurrences on antiarrhythmic drug therapy is often rea-
sonable. Alternatively, trialling another antiarrhythmic drug can
be considered. Combining an antiarrhythmic drug with ablation
(‘hybrid therapy’, see Chapter 12) should be considered based on
the different and possibly synergistic effects of these drugs with
AF ablation, possibly benefitting patients in whom either treat-
ment alone was previously ineffective. Rate control without
rhythm control, surgical ablation, or repeat catheter ablation
should be considered as well (Figure 20). Patient preferences and
local access to therapy are important considerations to inform
the therapy choice in patients who are in need of further rhythm
control therapy after an initial therapy failure.
11.6 The Atrial Fibrillation Heart Team
In view of the complexity of the different treatment options in
patients with failed rhythm control therapy who still require or
demand further rhythm control therapy, this Task Force proposes
that decisions involving AF surgery or extensive AF ablation
should be based on advice from an AF Heart Team. This will also
apply to reversal to a rate control strategy in patients with severe
(EHRA III or IV) AF symptoms. An AF Heart Team should consist
of a cardiologist with expertise in antiarrhythmic drug therapy,
an interventional electrophysiologist, and a cardiac surgeon with
expertise in appropriate patient selection, techniques, and tech-
nologies for interventional or surgical AF ablation (Figure 20).
Such AF Heart Teams—and a collaborative infrastructure support-
ing a continued interaction between physicians delivering contin-
ued care, AF cardiologists, interventional electrophysiologists,
and AF surgeons—should be established to provide optimal
Figure 19: Surgical rhythm control in patients with atrial fibrillation undergoing cardiac surgery.
Table 19: Complications of thoracoscopic atrial fibrillation
surgery
[468,815,822,826]
aThe rate of asymptomatic cerebral embolism is unknown.













advice, and ultimately to improve rhythm outcomes for patients
in need of advanced and complex rhythm control interventions.
12. HYBRID RHYTHM CONTROL THERAPY
AF has many different drivers, which are only partially targeted by
antiarrhythmic drugs or catheter ablation [96]. Hence, combination or
‘hybrid’ rhythm control therapy seems reasonable, although there is
little evidence from controlled trials supporting its use.
12.1 Combining antiarrhythmic drugs and catheter
ablation
Antiarrhythmic drug therapy is commonly given for 8–12 weeks
after ablation to reduce early recurrences of AF after catheter
ablation, supported by a recent controlled trial where amiodar-
one halved early AF recurrences compared with placebo [650].
Prospective studies have not been done, but a meta-analysis of
the available (weak) evidence suggests slightly better prevention
of recurrent AF in patients treated with antiarrhythmic drugs after
catheter ablation [713]. Many patients are treated with antiar-
rhythmic drug therapy after catheter ablation (most often amio-
darone or flecainide) [587], and this seems a reasonable option in
patients with recurrent AF after ablation. It seems common sense
to consider antiarrhythmic drug therapy in patients who are in
need of further rhythm control therapy after catheter ablation,
but controlled trials to confirm this are desirable.
Combining cavotricuspid isthmus ablation and antiarrhythmic
drugs may lead to improved rhythm control without the need
for left atrial ablation in patients who develop ‘drug-induced
atrial flutter’ on therapy with flecainide, propafenone, or amio-
darone [834–836], although recurrent AF is a concern in the
long-term [837, 838].
12.2 Combining antiarrhythmic drugs and
pacemakers
In selected patients with sick sinus syndrome and fast ventricular
response during AF paroxysms requiring rate control therapy, the
addition of a pacemaker not only optimizes rate control but may
also help to control rhythm [711, 712]. Moreover, when antiar-
rhythmic drug treatment leads to sinus node dysfunction and
bradycardia, pacing may permit uptitration of the antiarrhythmic
drug dose. Such strategies have never been prospectively investi-
gated and the existing populations studied are highly selected
[839, 840]. Some patients with AF-induced bradycardia may ben-
efit from catheter ablation of AF, obviating the need for antiar-
rhythmic drugs and pacemaker implantation [829, 830].
13. SPECIFIC SITUATIONS
13.1 Frail and ‘elderly’ patients
Many AF patients present at older age (e.g. >75 or >80 years).
There are no studies suggesting that cardiovascular risk reduction
is less effective in these ‘elderly’ AF patients than in younger
patients. Rather, age is one of the strongest predictors/risk factors
for ischaemic stroke in AF [382]. Good data are available to sup-
port the use of anticoagulants in older patients from BAFTA
(Birmingham Atrial Fibrillation Treatment of the Aged Study)
Figure 20: Choice of rhythm control therapy following treatment failure.
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[362], the NOAC trials [39], and from analyses in elderly
Americans (Medicare) [396]. Elderly AF patients are at higher risk
of stroke and, thus, are more likely to benefit from OAC than
younger patients [841], and yet OAC is still underutilized in the
elderly [220, 842]. Although the evidence base is smaller for other
treatment options in AF, the available data support the use of
available rate and rhythm control interventions, including pace-
makers and catheter ablation, without justification to discrimi-
nate by age group. Individual patients at older age may present
with multiple comorbidities including dementia, a tendency to
falls, CKD, anaemia, hypertension, diabetes, and cognitive dys-
function. Such conditions may limit quality of life more than AF-
related symptoms. Impairment of renal and hepatic function and
multiple simultaneous medications make drug interactions and
adverse drug reactions more likely. Integrated AF management
and careful adaptation of drug dosing seem reasonable to reduce
the complications of AF therapy in such patients [843].
13.2 Inherited cardiomyopathies, channelopathies,
and accessory pathways
Several inherited cardiac conditions are associated with early-
onset AF (Table 20). Treatment of the underlying cardiac condi-
tion is an important contribution to AF management in these
young patients (see also ESC guidelines on sudden cardiac death
[844] and hypertrophic cardiomyopathy [845]).
13.2.1 Wolff–Parkinson–White syndrome. Patients with pre-
excitation and AF are at risk of rapid conduction across the
accessory pathway, resulting in a fast ventricular rate, possible
ventricular fibrillation, and sudden death. In AF patients with evi-
dence of an antegrade accessory pathway, catheter ablation of
the pathway is recommended [869, 870]. This procedure is safe
and effective and may be considered as a prophylactic treatment
Recommendations for catheter ablation of atrial fibrillation and atrial fibrillation surgery

















strategy [871, 872]. In AF patients surviving a sudden death event
with evidence of an accessory pathway, urgent catheter ablation
of the pathway is recommended [869]. A documented short pre-
excited RR interval (<250 ms) during spontaneous or induced AF
is one of the risk markers for sudden death in Wolff–Parkinson–
White syndrome (WPW) syndrome, in addition to a history of
symptomatic tachycardia, the presence of multiple accessory
pathways, and Ebstein’s anomaly. Intravenous procainamide,
propafenone, or ajmaline can be used to acutely slow ventricular
rate [873, 874], whereas digoxin, verapamil, and diltiazem are
contraindicated [875]. Intravenous amiodarone should be used
with caution, as there are case reports of accelerated ventricular
rhythms and ventricular fibrillation in patients with pre-excited
AF receiving intravenous amiodarone infusion [876].
13.2.2 Hypertrophic cardiomyopathy. AF is the most com-
mon arrhythmia in patients with hypertrophic cardiomyopathy,
affecting approximately one-quarter of this population [877].
Observational data highlight a high stroke risk in hypertrophic car-
diomyopathy patients with AF, confirming the need for OAC [878].
While there is more experience with VKAs, there are no data to
suggest that NOACs cannot be used in these patients [845]. Studies
of rate or rhythm control medications in patients with hypertro-
phic cardiomyopathy are relatively scarce. Beta-blockers and diltia-
zem or verapamil seem reasonable treatment options for rate
control in these patients. In the absence of significant LV outflow
tract obstruction, digoxin can be used alone or in combination
with beta-blockers [845]. Amiodarone seems a safe antiarrhythmic
drug in AF patients with hypertrophic cardiomyopathy [879], and
expert opinion suggests that disopyramide may be beneficial in
those with outflow tract obstruction. AF ablation is effective to
suppress symptomatic AF recurrences [880–884]. Surgical treat-
ment of AF may be appropriate in patients with hypertrophic car-
diomyopathy undergoing surgery (e.g. for LV outflow tract
obstruction or mitral valve surgery), but experience is limited.
13.2.3 Channelopathies and arrhythmogenic right ven-
tricular cardiomyopathy. Many channelopathies and inher-
ited cardiomyopathies are associated with AF. AF prevalence
ranges from 5–20% in patients with long QT syndrome or
Brugada syndrome, and is up to 70% in short QT syndrome
(Table 20) [853, 856–858]. Penetrance of disease phenotype
including AF is variable [61, 852, 885, 886]. Both shortening as
well as prolongation of the atrial action potential have been
demonstrated as likely mechanisms underlying AF in these dis-
eases. It seems reasonable to consider antiarrhythmic drugs that
reverse the suspected channel defect in AF patients with inher-
ited cardiomyopathies (e.g. a sodium channel blocker in LQT3
[852], or quinidine in Brugada syndrome [887]). More impor-
tantly, new-onset AF in young, otherwise healthy individuals
should trigger a careful search for such inherited conditions,
including clinical history, family history, ECG phenotype, and
echocardiography and/or other cardiac imaging.
Monogenic defects only account for 3–5% of all patients with
AF, even in younger populations [846, 848, 888–890]. Furthermore,
there is no clear link between detected mutations and specific out-
comes or therapeutic needs. For these reasons, genetic testing is
not recommended in the general AF population [77]. Other guide-
lines have described the indications for genetic testing in patients
with inherited arrhythmogenic diseases [844, 891].
Table 20: Inherited cardiomyopathies, channelopathies, and pathways associated with atrial fibrillation
AF = atrial fibrillation; VT = ventricular tachycardia.
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13.3 Sports and atrial fibrillation
Physical activity improves cardiovascular health, which translates
into a lower risk of AF [898]. Therefore, physical activity is a cor-
nerstone of preventing AF. Intensive sports practice, especially
endurance sports (>1500 h of endurance sports practice) [899],
increases the risk of AF later in life [900–902], probably mediated
by altered autonomic tone, volume load during exercise, atrial
hypertrophy, and dilatation [903, 904]. This results in a U-shaped
relationship of physical activity and incident AF [214, 898, 902,
905, 906]. Detraining can reduce AF in models [904] and reduces
ventricular arrhythmias in athletes [907], but the role of detrain-
ing for AF in human athletes is unknown. The management of
athletes with AF is similar to general AF management, but
requires a few special considerations. Clinical risk factors will
determine the need for anticoagulation. Sports with direct bodily
contact or prone to trauma should be avoided in patients on
OAC. Beta-blockers are not well tolerated and at times prohib-
ited, and digoxin, verapamil, and diltiazem are often not potent
enough to slow heart rate during exertional AF. Catheter ablation
for AF probably has similar outcomes in athletes as in non-ath-
letes [908, 909], but further data are needed. Pill-in-the-pocket
therapy has been used as well [620]. After ingestion of flecainide
or propafenone as pill-in-the-pocket, patients should refrain
from sports as long as AF persists and until two half-lives of the
antiarrhythmic drug have elapsed. Prophylactic ablation of the
flutter circuit may be considered in athletes treated with sodium
channel blockers [910].
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AF in pregnant women is rare and is usually associated with
pre-existing heart disease. AF is associated with increased
complications for the mother and foetus [911, 912]. Better treat-
ment of congenital heart diseases will probably increase the inci-
dence of AF during pregnancy in the future [913]. Pregnant
women with AF should be managed as high-risk pregnancies
in close collaboration with cardiologists, obstetricians, and
neonatologists.
13.4.1 Rate control. Owing to a lack of specific data, beta-
blockers, verapamil, diltiazem, and digoxin all carry a US Food
and Drug Administration pregnancy safety category of C (bene-
fits may outweigh risk), except for atenolol (category D: positive
evidence of risk). Their use should be at the lowest dose and for
the shortest time required. None of the agents are teratogenic,
but they readily cross the placenta [914]. Beta-blockers are com-
monly used in pregnant women with cardiovascular conditions
(e.g. for management of gestational hypertension and pre-
eclampsia), but may be associated with intrauterine
growth retardation [915], and hence growth scans after 20
weeks’ gestation are recommended. Digoxin is considered safe
for maternal and foetal arrhythmias [916]. There are insufficient
data to comment on verapamil or diltiazem, hence rate control
using beta-blockers and/or digoxin is recommended [917]. With
regards to breastfeeding, all rate control agents are present in
breast milk, although levels of beta-blockers, digoxin, and vera-
pamil are too low to be considered harmful. Diltiazem will be
present at high levels and should be considered second-line
treatment [918].
13.4.2 Rhythm control. Rhythm control therapy in pregnant
patients with AF has only been reported in case studies.
Amiodarone is associated with severe adverse foetal side-effects
and should only be considered for emergency situations [919].
Flecainide and sotalol can both be used for conversion of foetal
arrhythmias without major adverse effects [920], and thus are
likely to be safe to treat maternal symptomatic AF. Electrical car-
dioversion can be effective for restoration of sinus rhythm when
tachyarrhythmia is causing haemodynamic instability, with low
rates of adverse outcomes for both mother and foetus [921].
However, in view of the risk of foetal distress, electrical cardio-
version should only be carried out where facilities are available
for foetal monitoring and emergency caesarean section. As with
other emergencies during pregnancy, patients should receive
100% oxygen, intravenous access should be established early,
and the mother should be positioned in the left lateral position
to improve venous return [922].
13.4.3 Anticoagulation. VKAs should be avoided in the first
trimester because of teratogenic effects, and in the 2–4 weeks
preceding delivery to avoid foetal bleeding. Low-molecular-
weight heparins are a safe substitute, as they do not cross the
placenta [923]. In the third trimester, frequent laboratory checks
for adequate anticoagulation (e.g. every 10–14 days) and corre-
sponding dose adjustments are advised, given that in some
women high doses of both VKA and heparin may be needed to
maintain adequate anticoagulation. Pregnant patients with AF
and mechanical prosthetic valves who elect to stop VKA
treatment in consultation with their specialist team between 6–
12 weeks of gestation, should receive continuous, dose-adjusted
unfractionated heparin or dose-adjusted subcutaneous low-
molecular-weight heparin. As only limited data are available
about teratogenesis for NOACs, these drugs should be avoided
during pregnancy.
13.5 Post-operative atrial fibrillation
AF is common after cardiac surgery (occurring in 15–45%
of patients) [924–926], and is associated with increased length of
hospital stay and higher rates of complications and mortality
[927]. Post-operative AF is also not uncommon after other major
surgery, especially in elderly patients. The treatment of post-
operative AF is mainly based on studies of patients undergoing
cardiac surgery, with much less evidence in the non-cardiac sur-
gery setting.
13.5.1 Prevention of post-operative atrial fibrillation.
Beta-blockers reduce post-operative AF and supraventricular
tachycardias, albeit with high heterogeneity and moderate risk of
bias in a systematic review of published studies. The most com-
monly studied drug was propranolol, with AF in 16.3% of the
treatment group vs. 31.7% in the control group [925]. In the
majority of these studies, beta-blockers were administered post-
operatively, a regimen supported in a recent meta-analysis [928].
Amiodarone reduced the incidence of post-operative AF
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compared to beta-blocker therapy in several meta-analyses, also
reducing hospital stay [925, 929–931].
Despite initial reports from meta-analyses [689, 932, 933], pre-
operative treatment with statins did not prevent post-operative
AF in a prospective controlled trial [934]. Other therapies have
also been studied in small, hypothesis-generating trials, but have
not demonstrated clear beneficial effects. These include magne-
sium [925, 935, 936], n-3 polyunsaturated fatty acids [937–945],
colchicine [946], corticosteroids [947, 948], and posterior pericar-
dectomy [949]. Post-operative overdrive biatrial pacing has not
gained widespread use despite some suggestion of prophylactic
effects [925, 950].
13.5.2 Anticoagulation. Post-operative AF is associated with
an increased early stroke risk, increased morbidity, and 30-day
mortality [927, 951, 952]. In the long-term, patients with an epi-
sode of post-operative AF have a two-fold increase in cardiovas-
cular mortality, and a substantially increased risk of future AF and
ischaemic stroke, compared with patients that remain in sinus
rhythm after surgery [952–958]. OAC at discharge has been asso-
ciated with a reduced long-term mortality in patients with post,-
operative AF [959], without evidence from controlled trials. Good
quality data are needed to determine whether long-term antico-
agulation can prevent strokes in patients with post-operative AF
at high stroke risk [368, 386], and to assess whether short epi-
sodes of post-operative AF (e.g. <48 h) carry a similar risk as lon-
ger episodes [960]. The indication and timing of OAC in post-
operative AF patients should take into consideration the risk of
post-operative bleeding.
13.5.3 Rhythm control therapy in post-operative atrial
fibrillation. In haemodynamically unstable patients, cardiover-
sion and consideration of antiarrhythmic drugs is recom-
mended. Amiodarone or vernakalant have been efficient in
converting post-operative AF to sinus rhythm [603, 950, 961]. A
recent medium-sized trial randomizing patients with post-
operative AF to either rhythm control therapy with amiodarone
or to rate control did not find a difference in hospital admissions
during a 60-day follow-up [962], underpinning that the aim of
rhythm control therapy should be to improve AF-related symp-
toms in post-operative AF. In asymptomatic patients and in
those with acceptable symptoms, rate control or deferred cardi-
oversion preceded by anticoagulation is a reasonable approach.
13.6 Atrial arrhythmias in grown-up patients with
congenital heart disease
Atrial arrhythmias (AF, atrial flutter, atrial tachycardias) often occur
late after surgical repair of congenital heart defects, occurring in
15–40% of grown-up patients with congenital heart disease
(GUCH). They are associated with heart failure, syncope, thrombo-
embolic events, and sudden death [963–967]. The pathophysiologi-
cal substrate is complex, associated with hypertrophy, fibrosis,
hypoxaemia, chronic haemodynamic overload, and surgical scars
and patches. Additionally, related primary anomalies in the con-
duction pathways can lead to re-entrant atrial and ventricular
tachycardia, heart block, and sinus node dysfunction [963]. Macro
re-entrant atrial tachycardia or atypical atrial flutter may be seen
after nearly any surgical procedure involving atriotomy or atrial
patches.
13.6.1 General management of atrial arrhythmias in
grown-up patients with congenital heart disease. The con-
ventional stroke risk factors should be used to inform decisions on
long-term anticoagulation in GUCH patients with AF. In addition,
anticoagulation should be considered in GUCH patients with atrial
arrhythmias when they present with intracardiac repair, cyanosis,
Fontan palliation, or systemic right ventricle [968]. Beta-blockers,
verapamil, diltiazem, and digitalis can be used. Care should be
taken to avoid bradycardia and hypotension.
Sodium channel blockers suppress approximately half of atrial
arrhythmias in Fontan patients [969]. Amiodarone is more effec-
tive, but long-term treatment with an antiarrhythmic drug carries
a high risk of extracardiac side-effects in this relatively young
population. Intracardiac thrombi are common in GUCH patients
undergoing cardioversion for AF, but also in patients with atrial
tachycardias or atrial flutter [970]. Therefore, both a TOE and
anticoagulation for a few weeks before the planned cardioversion
should be considered [964]. Radiofrequency ablation may be a
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good option for symptomatic GUCH patients with atrial arrhyth-
mias, especially in those with atrial flutter and other macro re-
entrant tachycardias. Interventions should be performed in
adequately qualified centres by specialized teams.
13.6.2 Atrial tachyarrhythmias and atrial septal defects.
Atrial flutter and fibrillation occur in 14–22% of adults with unoper-
ated atrial septal defects, especially in older patients [971], and can
lead to heart failure [972]. Early repair can reduce but not eliminate
the risk of AF [973]. Biatrial volume overload [974], pulmonary
hypertension [975], and possibly the arrhythmogenic effect of atrial
patches can contribute to these arrhythmias [976]. Anticoagulation
should be decided upon based on stroke risk factors. In patients
with a history of paroxysmal or persistent AF, AF surgery could be
considered at the time of surgical closure, or catheter ablation at
the time of interventional atrial septal defect closure. Catheter abla-
tion of late atrial arrhythmias has been shown to be effective in
small cohorts of patients after surgical atrial septal defect [977].
13.6.3 Atrial tachyarrhythmias after Fontan operation.
Atrial arrhythmias occur in up to 40% of patients with a Fontan cir-
culation, and can manifest as atrial flutter, primary atrial tachycar-
dia, AF, and accelerated junctional rhythm or junctional
tachycardia [978] with or without sinoatrial node dysfunction [979].
Patients with atriopulmonary anastomoses (possibly due to higher
atrial volume and pressure load) and those with early post-
operative atrial arrhythmias are more likely to develop long-term
atrial arrhythmias [980]. Atrial arrhythmias can also be the first
manifestation of obstruction of the atriopulmonary anastomosis, a
complication that must be identified. Right atrial thrombus forma-
tion is common in Fontan patients with atrial arrhythmias and
requires oral anticoagulation [981]. Operative conversion to total
cavopulmonary artery connection with concomitant arrhythmia
surgery can, in some patients, improve heart failure symptoms and
reduce recurrent arrhythmias [969, 982], with low recurrence rates
of clinically apparent atrial arrhythmias in the first few years after
repeat surgery [983–985]. Catheter ablation of atrial arrhythmia in
Fontan patients has been successful in selected patients [986].
13.6.4 Atrial tachyarrhythmias after tetralogy of Fallot
correction. After repair of tetralogy of Fallot, approximately
one-third of patients develop atrial arrhythmias, including intra-
atrial re-entrant tachycardia, focal atrial tachycardia, and AF
[987]. Circuits involving the cavotricuspid isthmus and areas of
presumed surgical right atrial scarring have been described as
responsible for atrial arrhythmias.
13.7 Management of atrial flutter
The goals for the management of atrial flutter are similar to those
for AF [992]. Based on the available evidence, the stroke risk in
patients with atrial flutter is not much different from that in AF
[827]. Furthermore, many patients diagnosed with atrial flutter
develop AF [993–995]. Thus, anticoagulation should be used in
patients with atrial flutter similar to that in patients with AF. Rate
control in atrial flutter is achieved with the same medications as in
AF, but is often more difficult to achieve. Flecainide, propafenone,
dofetilide, and intravenous ibutilide are useful for cardioversion of
atrial flutter. They should be combined with a rate-controlling
agent to avoid 1:1 conduction of slowing flutter waves to the ven-
tricles. Ibutilide is more effective for conversion of atrial flutter than
AF, whereas vernakalant is less effective in converting typical atrial
flutter [996, 997]. Electrical cardioversion of atrial flutter can be per-
formed using lower energies (50–100 J) than for AF [998, 999].
Atrial overdrive pacing through pacemaker leads or endocardial or
transoesophageal catheters can convert atrial flutter to sinus
rhythm [1000, 1001]. Anticoagulation and TOE around cardiover-
sion or overdrive pacing should be used similar to that in AF.
Recommendations in patients with grown-up congenital heart disease
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Ablation of the cavotricuspid isthmus for isthmus-dependent
right atrial flutter (either the common counter-clockwise atrial flut-
ter or the less-common clockwise atrial flutter) restores and main-
tains sinus rhythm with a success rate of 90–95% [1002]. It may
also reduce AF recurrences in selected patients [1003, 1004], and
help to prevent hospitalizations [1004, 1005]. Isthmus ablation is
comparably safe and more effective than antiarrhythmic drug
therapy, and is recommended for recurrent atrial flutter [585–587,
713]. Catheter ablation of left atrial macro re-entrant tachycardia is
more complex, with lower success rates and higher recurrence
rates [1006, 1007].
14. PATIENT INVOLVEMENT, EDUCATION, AND
SELF-MANAGEMENT
14.1 Patient-centred care
Autonomous, informed patients are better placed to adhere to
long-term therapy, and it is very likely that long-term manage-
ment of chronic conditions such as AF will benefit from informed
patients who are aware of their own responsibilities in the dis-
ease management process [328]. Shared decision-making [747]
and patient-centred organization of care can help to ensure
adherence to management and empower patients, and respect
individual patient preferences, needs, and values (see section 8.2)
[326, 1008, 1009]. Patients in an active role tend to have better
health outcomes and care experiences, and engagement itself
can be considered as an intermediate outcome [1010].
14.2 Integrated patient education
Education is a prerequisite for informed, involved patients and
patient-centred care. However, lack of AF-related knowledge in
patients is common, even in those who have received verbal and
written information [32, 1011, 1012], indicating the need to further
develop structured patient education. Several patient information
tools have been developed, largely focusing on oral anticoagula-
tion [1013–1016]. This task force has developed a dedicated app
for AF patients to support patient information and education.
Understanding patients’ perceptions and attitudes towards AF and
its management can improve AF management and related out-
comes [1017]. This includes tailored patient education focusing on
the disease, symptom recognition, therapy, modifiable risk factors
for AF, and self-management activities [1018, 1019].
14.3 Self-management and shared decision-making
Self-management is primarily focused on tasks to manage the con-
dition, such as adhering to a therapeutic regimen or modifying
behaviour (e.g. resulting in smoking cessation or weight loss)
[1020]. It requires understanding of the treatment modalities and
goals [350]. Within a multidisciplinary team, allied health professio-
nals can guide this interactive process in which communication,
trust, and reciprocal respect foster patient engagement [1021].
Shared decision-making should be considered as a routine part of
the decision-making process [747], supported by decision aids
where applicable [1022]. Models of care that integrate education,
engagement, and shared decision making are now available [1023],
and may be of particular value in the management of AF.
15. GAPS IN EVIDENCE
There are some areas of AF management that are supported by
excellent evidence from multiple, adequately powered randomized
trials (e.g. oral anticoagulation). Other areas, such as rhythm control
therapy, integrated AF management, and lifestyle modifications are
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clearly developing the required evidence, while areas such as rate
control are in dire need of better studies to underpin future guide-
lines. Here, we identify areas in need of further research.
15.1 Major health modifiers causing atrial fibrillation
Atrial fibrillation has different causes in different patients. More
research is needed into the major causes (and electrophysiologi-
cal mechanisms) of AF in different patient groups [176, 1024].
Such research should consider the major comorbidities associ-
ated with AF, and characterize the response to AF therapy in
patients with different, pathophysiologically distinct types of AF.
15.2 How much atrial fibrillation constitutes a
mandate for therapy?
Technological advances allow screening for an irregular pulse
using patient-operated ECG devices, smartphones, and a variety
of other technologies. These may be very useful to detect silent,
undiagnosed AF [157]. Adequately powered studies evaluating
the diagnostic accuracy of such technologies, the diagnostic yield
in different populations, the shortest duration and pattern of
atrial arrhythmias conveying a stroke risk, and the effect of ECG
screening on outcomes are needed.
15.3 Atrial high-rate episodes (AHRE) and need for
anticoagulation
All of the information on the benefit of OAC has been generated
in patients with AF diagnosed by ECG. Technological advances
allow ready detection of AHRE in patients with implanted devices
and an atrial lead. Such patients are at increased stroke risk, but
it is unclear whether they benefit from OAC. Controlled trials
evaluating OAC in AHRE patients are ongoing and will provide
evidence on the best antithrombotic therapy in these patients.
15.4 Stroke risk in specific populations
Several specific AF groups should be studied to better characterize
their risk for AF, stroke, and other AF-related complications (e.g.
patients with one stroke risk factor, and non-Caucasian patients).
Confounding factors (e.g. different therapy of concomitant cardio-
vascular diseases) may help to explain the variability in the
reported rates of incident AF, prevalent AF, and AF complications.
This also applies to the effect of gender in AF patients [47].
15.5 Anticoagulation in patients with severe
chronic kidney disease
The use of NOACs has not been tested in patients with creatinine
clearance <30 mL/min, and there is very little evidence on the
effects of OAC in patients on haemodialysis or on other forms of
renal replacement therapy. Studies evaluating OAC in patients
with severe CKD are needed to inform the best management in
this patient group at high risk for stroke and bleeding.
15.6 Left atrial appendage occlusion for stroke
prevention
The most common justification for LAA occlusion devices in clini-
cal practice is a perceived high bleeding risk and, less often,
contraindications for OAC [459]. Unfortunately, LAA occluders
have not been tested in such populations. Furthermore, LAA
occluders have not been compared with NOAC therapy in
patients at risk for bleeding, or with thoracoscopic LAA clipping.
There is a clear need to conduct adequately designed and pow-
ered trials to define the clinical role of LAA occluders compared
with NOAC therapy in patients with relative or absolute contrain-
dications for anticoagulation, and/or in those suffering from an
ischaemic stroke on anticoagulant therapy.
15.7 Anticoagulation in atrial fibrillation patients
after a bleeding or stroke event
At least 2% of anticoagulated patients with AF will experience a
serious bleeding event per year. Observational data suggest that
OAC can be reinitiated even after an intracerebral bleeding event
[460, 484]. Controlled studies evaluating different anticoagulation
and stroke prevention interventions are urgently needed to pro-
vide evidence on the best management of patients who have suf-
fered a bleeding event that would usually lead to withholding
OAC. Some studies (e.g. APACHE-AF [Apixaban versus Antiplate-
let drugs or no antithrombotic drugs after anticoagulation-
associated intraCerebral HaEmorrhage in patients with Atrial
Fibrillation] [1025]) are ongoing, but adequately powered trials
are needed. Similarly, prospectively collected data are needed on
the stroke prevention and bleeding risk following (re-)initiation
of OAC after stroke or intracranial bleeding.
15.8 Anticoagulation and optimal timing of
non-acute cardioversion
Based on retrospective data, previous recommendations on the
safe time-window in which a cardioversion can be performed in
new-onset AF used <_48 h as the ‘gold standard’ for non-
protected cardioversion. However, new evidence has emerged
that initiating pre-cardioversion anticoagulation in patients with
AF episodes of <24 h or even <12 h would provide even better
safety [642, 647, 1026–1028]. Further research is needed to estab-
lish a clear safety margin in this clinical situation.
15.9 Competing causes of stroke or transient
ischaemic attack in atrial fibrillation patients
Prospective RCTs have demonstrated the superiority of carotid
endarterectomy compared to stenting in patients with sympto-
matic high-degree stenosis of the internal carotid artery [1029]. As
endartectomy minimizes the need for combination therapy with
OAC and antiplatelets [1030], this approach has appeal in patients
with AF to reduce bleeding risk. However, few of these studies
included patients with AF. In a large observational study, the com-
posite of in-hospital mortality, post-procedural stroke, and cardiac
complications was higher in AF patients undergoing carotid stent-
ing (457/7668; 6.0%) compared with endarterectomy (4438/51
320; 8.6%; P < 0.0001) [1031]. Despite adjustment for baseline risk,
this may just reflect the type of patients referred for each proce-
dure, and further randomized studies are needed to confirm the
optimal treatment strategy in AF patients with carotid disease.
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15.10 Anticoagulation in patients with biological
heart valves (including transcatheter aortic valve
implantation) and specific forms of valvular heart
disease
The optimal antithrombotic therapy in the first months after bio-
logical valve replacement (including after catheter-based valve
replacement) is not known. VKAs remain the mainstay during the
initial post-operative period; NOACs probably deliver the same
protection. In patients without AF, many centres use platelet inhibi-
tors only. NOACs appear to be equally effective as VKAs in patients
with moderate aortic stenosis, based on a subanalysis from the
ROCKET-AF trial [1032], as well as the Loire Valley AF project
[1033]. Further data would be helpful to confirm these observations
[1034]. The safety and efficacy of NOACs in patients with rheumatic
mitral valve disease has not been evaluated and should be studied.
15.11 Anticoagulation after ‘successful’ catheter
ablation
In view of the long-term recurrence rates of AF, this Task Force
recommends that OAC is continued in AF patients after ‘success-
ful’ catheter ablation. Nonetheless, observational data suggest
that the stroke risk may be lower after catheter ablation of AF
compared with other AF patients. The ongoing EAST – AFNET 4
trial will inform, in a more general way, whether rhythm control
therapy can reduce stroke rates in anticoagulated AF patients. In
addition, there seems to be a place for a controlled trial evaluat-
ing the termination of OAC therapy at an interval after ‘successful’
catheter ablation.
15.12 Comparison of rate control agents
Although the use of rate control therapy is very common in AF
patients, robust data comparing rate control therapies are scant,
with the majority of studies being small uncontrolled trials over
short periods of follow-up. Some studies are ongoing [e.g. RATE-
AF (Rate Control Therapy Evaluation in Permanent Atrial
Fibrillation) [559]] and will investigate the potential benefits of dif-
ferent rate-controlling agents, characteristics, or biomarkers that
can help to personalize the use of rate control, and the adverse
event profile of specific drugs in defined groups of patients.
15.13 Catheter ablation in persistent and long-
standing persistent atrial fibrillation
While a few recent randomized studies support the use of catheter
or surgical ablation in patients with persistent AF and long-standing
persistent AF [1042], there is a clear need for more data evaluating
this intervention in adequately powered randomized trials.
15.14 Optimal technique for repeat catheter ablation
PVI emerges as the most important target for catheter ablation of
AF. Although a plethora of different additional ablation techni-
ques have been published, their added value is questionable in
patients undergoing a first catheter ablation, including those with
persistent AF [735, 1042]. Many patients are in need of multiple
catheter ablation procedures, and such interventions often follow
local or operator-specific protocols without clear evidence to
support the choice of ablation target or intervention. There is a
clear clinical need to define the best approach in patients who
are in need of a second ablation procedure.
15.15 Combination therapy for maintenance of
sinus rhythm
In the follow-up after initially successful catheter ablation, even
when done in experienced centres, many patients will experience
symptomatic recurrences of AF. These patients are often man-
aged with antiarrhythmic drugs. There is a surprising paucity of
data evaluating different rhythm control interventions in patients
with recurrent AF after catheter ablation. Such studies seem rea-
sonable and feasible.
15.16 Can rhythm control therapy convey a
prognostic benefit in atrial fibrillation patients?
The progress in rhythm control therapy (catheter ablation, new
antiarrhythmic drugs) and observational long-term analyses sug-
gest that rhythm control therapy may have a prognostic benefit
in anticoagulated AF patients. Ongoing trials such as CABANA
and EAST – AFNET 4 will provide initial answers to this important
question, but more data are needed, including trials of surgical
ablation techniques.
15.17 Thoracoscopic ‘stand-alone’ atrial fibrillation
surgery
Minimally invasive epicardial ablation surgery for the treatment of
stand-alone AF was reported a decade ago [1035]. The procedure
has since evolved towards a totally thoracoscopic procedure [1036],
and lesion sets were extended to a complete left atrial maze [822].
Randomized trials using a standardized procedure are urgently
needed to clearly define the benefits and risks of thoracoscopic AF
ablation, and to further support decisions of the AF Heart Team.
15.18 Surgical exclusion of the left atrial appendage
Exclusion of the LAA has been performed by cardiothoracic sur-
geons for decades, but prospective randomized studies compar-
ing the rate of ischaemic stroke with or without left appendage
exclusion are presently lacking. The LAAOS (Left Atrial
Appendage Occlusion Study) III is currently randomizing cardiac
surgery patients with AF to undergo concomitant occlusion or no
occlusion of the appendage [467]. More data are also needed to
confirm the safety and efficacy of thoracoscopic exclusion, fol-
lowing early positive observational data [1037].
15.19 Concomitant atrial fibrillation surgery
Adequately powered randomized trials are needed, employing
systematic follow-up with uniform lesion sets and energy sources,
to evaluate the benefits and risks of concomitant AF surgery in
symptomatic AF patients. An RCT on non-uniform lesion sets
with long-term follow-up is due to publish shortly [1038]. Such
trials will assist the AF Heart Team to decide on optimal therapy
for individual patients, including the full repertoire of medical
and surgical options for the treatment of AF.
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ACE = angiotensin-converting enzyme; AF = atrial fibrillation; AHRE = atrial high rate episodes; ARB = angiotensin receptor blocker; CHA2DS2-VASc =
Congestive Heart failure, hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); ECG = electrocardio-
gram; EHRA = European Heart Rhythm Association; ICD = implantable cardioverter defibrillator; INR = international normalized ratio; LV = left ventricular;
LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation;
TIA = transient ischaemic attack; TOE = transoesophageal echocardiography; TTR = time in therapeutic range; VKA = vitamin K antagonist.














Three additional Web figures and two additional Web tables can
be accessed in the Web addenda to the 2016 ESC AF Guidelines,
available at European Heart Journal online and also via the ESC
Website (www.escardio.org/guidelines).
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Cardiology, Georges H. Mairesse; Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Daniela
Loncar Maticevic; Bulgaria: Bulgarian Society of Cardiology,
Tchavdar Shalganov; Croatia: Croatian Cardiac Society, Bosko
Skoric; Cyprus: Cyprus Society of Cardiology, Loizos
Antoniades; Czech Republic: Czech Society of Cardiology,
Milos Taborsky; Denmark: Danish Society of Cardiology, Steen
Pehrson; Egypt: Egyptian Society of Cardiology, Said Khaled;
Estonia: Estonian Society of Cardiology, Priit Kampus; Finland:
Finnish Cardiac Society, Antti Hedman; The Former Yugoslav
Republic of Macedonia: Macedonian Society of Cardiology,
Lidija Poposka; France: French Society of Cardiology, Jean-Yves
Le Heuzey; Georgia: Georgian Society of Cardiology, Kakhaber
Estadashvili; Germany: German Cardiac Society, Dietmar
B€ansch; Hungary: Hungarian Society of Cardiology, Zoltan
Csanadi; Ireland: Irish Cardiac Society, David Keane; Israel:
Israel Heart Society, Roy Beinart; Italy: Italian Federation of
Cardiology, Francesco Romeo; Kazakhstan: Association of
Cardiologists of Kazakhstan, Kulzida Koshumbayeva; Kosovo:
Kosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan:
Kyrgyz Society of Cardiology, Aibek Mirrakhimov, Latvia:
Latvian Society of Cardiology, Oskars Kalejs; Lebanon: Lebanese
Society of Cardiology, Samer Nasr; Lithuania: Lithuanian
Society of Cardiology, Germanas Marinskis; Luxembourg:
Luxembourg Society of Cardiology, Carlo Dimmer; Malta:
Maltese Cardiac Society, Mark Sammut; Moldova: Moldavian
Society of Cardiology, Aurel Grosu; Morocco: Moroccan
Society of Cardiology, Salima Abdelali; The Netherlands:
Netherlands Society of Cardiology, Martin E. W. Hemels;
Norway: Norwegian Society of Cardiology, Ole-Gunnar
Anfinsen; Poland: Polish Cardiac Society, Beata Sredniawa;
Portugal: Portuguese Society of Cardiology, Pedro Adragao;
Romania: Romanian Society of Cardiology, Gheorghe-Andrei
Dan; Russian Federation: Russian Society of Cardiology,
Evgeny N. Mikhaylov; San Marino: San Marino Society of
Cardiology, Marco Zavatta; Serbia: Cardiology Society of Serbia,
Tatjana Potpara; Slovakia: Slovak Society of Cardiology, Peter
Hlivak Slovenia: Slovenian Society of Cardiology, Igor Zupan;
17. A SHORT SUMMARY OF THE
MANAGEMENT OF ATRIAL FIBRILLATION
PATIENTS
Here, we provide 17 simple rules to guide the diagnosis and manage-
ment of AF patients according to the 2016 ESC Guidelines for the man-
agement of atrial fibrillation developed in cooperation with EACTS.
1. Use ECG screening in at-risk populations for AF, especially stroke
survivors and the elderly.
2. Document AF by ECG before starting treatment.
3. Evaluate all AF patients by clinical evaluation, ECG, and echocar-
diogram for underlying cardiovascular conditions such as hyper-
tension, heart failure, valvular heart disease, and others.
4. Provide tailored information and education to AF patients to
empower them to support AF management.
5. Propose lifestyle changes to all suitable AF patients to make their
management more effective.
6. Treat underlying cardiovascular conditions adequately, e.g. valve
repair or replacement in AF patients with significant valvular heart
disease, treatment of heart failure, or management of hyperten-
sion, among others.
7. Use oral anticoagulation in all AF patients unless they are at low
risk for stroke based on the CHA2DS2VASc score or have true con-
traindications for anticoagulant therapy.
8. Anticoagulate patients with atrial flutter similar to AF. Offer isthmus
ablation to symptomatic flutter patients.
9. Reduce all modifiable bleeding risk factors in all AF patients on oral
anticoagulation, e.g. by treating hypertension, minimizing the
duration and intensity of concomitant antiplatelet and non-
steroidal anti-inflammatory drug therapy, treating anaemia and
eliminating causes for blood loss, maintaining stable INR values in
patients on VKAs, and moderating alcohol intake.
10. Check ventricular rate in all AF patients and use rate control medi-
cations to achieve lenient rate control.
11. Evaluate AF-related symptoms in all AF patients using the modified
EHRA symptoms scale. Whenever patients have AF-related symp-
toms, aim to improve symptoms by adjustment of rate control
therapy and by offering antiarrhythmic drugs, cardioversion, or
catheter or surgical ablation.
12. Select antiarrhythmic drugs based on their safety profile and con-
sider catheter or surgical ablation when antiarrhythmic drugs fail.
13. Do not offer routine genetic testing in AF patients unless there is
suspicion of an inherited cardiac condition.
14. Do not use antiplatelet therapy for stroke prevention in AF.
15. Do not permanently discontinue oral anticoagulation in AF
patients at increased risk of stroke unless such a decision is taken
by a multidisciplinary team.
16. Do not use rhythm control therapy in asymptomatic AF patients,
nor in patients with permanent AF.
17. Do not perform cardioversion or catheter ablation without antico-
agulation, unless an atrial thrombus has been ruled out transoeso-
phageal echocardiogram.
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Spain: Spanish Society of Cardiology, Angel Arenal; Sweden:
Swedish Society of Cardiology, Frieder Braunschweig;
Switzerland: Swiss Society of Cardiology, Dipen Shah; Tunisia:
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Ag
Sana Ouali; Turkey: Turkish Society of Cardiology, Mesut
Demir; Ukraine: Ukrainian Association of Cardiology, Oleg
Sychov; United Kingdom: British Cardiovascular Society, Ed
Duncan.
20. REFERENCES
[1] Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ
et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of
Disease 2010 Study. Circulation 2014;129:837–847.
[2] Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of cur-
rent and future incidence and prevalence of atrial fibrillation in the U.S.
adult population. Am J Cardiol 2013;112:1142–1147.
[3] Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker
BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the
Rotterdam study. Eur Heart J 2006;27:949–953.
[4] Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al.
Lifetime risk for development of atrial fibrillation: the Framingham Heart
Study. Circulation 2004;110:1042–1046.
[5] Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV. Prevalence
of diagnosed atrial fibrillation in adults: national implications for rhythm
management and stroke prevention: the AnTicoagulation and Risk
Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–2375.
[6] Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A et al.
Projections on the number of individuals with atrial fibrillation in the
European Union, from 2000 to 2060. Eur Heart J 2013;34:2746–2751.
[7] Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of
atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213–220.
[8] Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke
risk, and warfarin therapy revisited: a population-based study. Stroke
2013;44:3103–3108.
[9] Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective
national study of the prevalence, incidence, management and outcome
of a large contemporary cohort of patients with incident non-valvular
atrial fibrillation. J Am Heart Assoc 2015;4:e001486.
[10] McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of
patients with atrial fibrillation. Circulation 2012;126:e143–146.
[11] Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile
and burden of an evolving epidemic in the 21st century. Int J Cardiol
2013;167:1807–1824.
[12] Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, progno-
sis, and predisposing conditions for atrial fibrillation: population-based
estimates. Am J Cardiol 1998;82:2N–9N.
[13] Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and man-
agement of atrial fibrillation in developing countries. Int J Cardiol 2013;
167:2412–2420.
[14] Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P et al.
RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and
management of atrial fibrillation in a prospective registry of 15,400 emer-
gency department patients in 46 countries: the RE-LY Atrial Fibrillation
Registry. Circulation 2014;129:1568–1576.
[15] Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O’Neill J et al.
Distribution and risk profile of paroxysmal, persistent, and permanent
atrial fibrillation in routine clinical practice: insight from the real-life
global survey evaluating patients with atrial fibrillation international
registry. Circ Arrhythm Electrophysiol 2012;5:632–639.
[16] Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal
relations of atrial fibrillation and congestive heart failure and their joint
influence on mortality: the Framingham Heart Study. Circulation 2003;
107:2920–2925.
[17] Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ. Detection of
atrial fibrillation after ischemic stroke or transient ischemic attack: a sys-
tematic review and meta-analysis. Stroke 2014;45:520–526.
[18] Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA
et al. CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial
fibrillation. N Engl J Med 2014;370:2478–2486.
[19] Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD et al. 50
year trends in atrial fibrillation prevalence, incidence, risk factors, and
mortality in the Framingham Heart Study: a cohort study. Lancet 2015;
386:154–162.
[20] Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D.
Impact of atrial fibrillation on the risk of death: the Framingham Heart
Study. Circulation 1998;98:946–952.
[21] Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of
the long-term risks associated with atrial fibrillation: 20-year follow-up of
the Renfrew/Paisley study. Am J Med 2002;113:359–364.
[22] Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM,
Edvardsson N. All-cause mortality in 272,186 patients hospitalized with
incident atrial fibrillation 1995-2008: a Swedish nationwide long-term
case-control study. Eur Heart J 2013;34:1061–1067.
[23] Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG et al.
Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta
blockers in patients with heart failure plus atrial fibrillation: an individual-
patient data meta-analysis. Lancet 2014;384:2235–2243.
[24] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk
factor for stroke: the Framingham Study. Stroke 1991;22:983–988.
[25] Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural
history of atrial fibrillation: incidence, risk factors, and prognosis in the
Manitoba Follow-Up Study. Am J Med 1995;98:476–484.
[26] Henriksson KM, Farahmand B, Asberg S, Edvardsson N, Terent A.
Comparison of cardiovascular risk factors and survival in patients with
ischemic or hemorrhagic stroke. Int J Stroke 2012;7:276–281.
[27] Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D et al.
Improved detection of silent atrial fibrillation using 72-hour Holter ECG
in patients with ischemic stroke: a prospective multicenter cohort study.
Stroke 2013;44:3357–3364.
[28] Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE,
Hofman A. Atrial fibrillation and dementia in a population-based study.
The Rotterdam Study. Stroke 1997;28:316–321.
[29] Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C et al.
Atrial fibrillation in stroke-free patients is associated with memory
impairment and hippocampal atrophy. Eur Heart J 2008;29:2125–2132.
[30] Ball J, Carrington MJ, Stewart S. SAFETY investigators. Mild cognitive
impairment in high-risk patients with chronic atrial fibrillation: a forgot-
ten component of clinical management? Heart 2013;99:542–547.
[31] Marzona I, O’Donnell M, Teo K, Gao P, Anderson C, Bosch J. Increased
risk of cognitive and functional decline in patients with atrial fibrillation:
results of the ONTARGET and TRANSCEND studies. CMAJ 2012;184:
E329–336.
[32] Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial
fibrillation: a systematic review. Am J Med 2006;119:448.e1–19.
[33] von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A,
Kirchhof P. Depressed mood amplifies heart-related symptoms in persis-
tent and paroxysmal atrial fibrillation patients: a longitudinal analysis—
data from the German Competence Network on Atrial Fibrillation.
Europace 2015;17:1354–1362.
[34] Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR et al.
Drivers of hospitalization for patients with atrial fibrillation: Results from the
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
(ORBIT-AF). Am Heart J 2014;167:735–742.e2.
[35] Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K.
Management of patients wtih atrial fibrillation by primary care physicians
in Germany: 1-year results of the ATRIUM registry. Clin Cardiol 2014;37:
277–284.
[36] Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an
emerging epidemic: an economic analysis of atrial fibrillation in the UK.
Heart 2004;90:286–292.
[37] Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of
total incremental health care costs in patients with atrial fibrillation in the
United States. Circ Cardiovasc Qual Outcomes 2011;4:313–320.
[38] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to
prevent stroke in patients who have nonvalvular atrial fibrillation. Ann
Intern Med 2007;146:857–867.
[39] Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N,
Ezekowitz MD et al. Comparison of the efficacy and safety of new oral
anticoagulants with warfarin in patients with atrial fibrillation: a meta-
analysis of randomised trials. Lancet 2014;383:955–962.
[40] Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P.
Improving outcomes in patients with atrial fibrillation: rationale and
design of the Early treatment of Atrial fibrillation for Stroke prevention
Trial. Am Heart J 2013;166:442–448.













[41] Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME,
Kong DF et al. Rate- and rhythm-control therapies in patients with atrial
fibrillation: a systematic review. Ann Intern Med 2014;160:760–773.
[42] Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu
L et al. Prognosis and treatment of atrial fibrillation patients by European
cardiologists: one year follow-up of the EURObservational Research
Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot
registry). Eur Heart J 2014;35:3365–3376.
[43] Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M
et al. RE-LY Investigators. Causes of death and influencing factors in
patients with atrial fibrillation: a competing-risk analysis from the
randomized evaluation of long-term anticoagulant therapy study.
Circulation 2013;128:2192–2201.
[44] Senoo K, Lip GY, Lane DA, Buller HR, Kotecha D. Residual risk of stroke
and death in anticoagulated patients according to the type of atrial fibril-
lation: AMADEUS Trial. Stroke 2015;46:2523–2528.
[45] Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA
et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern
Med 2014;174:107–114.
[46] Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M.
Atrial fibrillation as risk factor for cardiovascular disease and death in
women compared with men: systematic review and meta-analysis of
cohort studies. BMJ 2016;532:h7013.
[47] Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE.
Atrial fibrillation in women: epidemiology, pathophysiology, presenta-
tion, and prognosis. Nat Rev Cardiol 2016;13:321–332.
[48] Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM,
Edvardsson N. Gender-related differences in risk of cardiovascular mor-
bidity and all-cause mortality in patients hospitalized with incident atrial
fibrillation without concomitant diseases: A nationwide cohort study of
9519 patients. Int J Cardiol 2014;177:91–99.
[49] Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG.
Gender differences in the risk of ischemic stroke and peripheral embo-
lism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial
fibrillation (ATRIA) study. Circulation 2005;112:1687–1691.
[50] Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski
FE. Meta-analysis of gender differences in residual stroke risk and major
bleeding in patients with nonvalvular atrial fibrillation treated with oral
anticoagulants. Am J Cardiol 2014;113:485–490.
[51] Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM,
Ostojic MC. Gender-related differences in presentation, treatment and
long-term outcome in patients with first-diagnosed atrial fibrillation and
structurally normal heart: the Belgrade atrial fibrillation study. Int J
Cardiol 2012;161:39–44.
[52] Ball J, Carrington MJ, Wood KA, Stewart S. SAFETY Investigators. Women
versus men with chronic atrial fibrillation: insights from the Standard ver-
sus Atrial Fibrillation spEcific managemenT studY (SAFETY). PLoS One
2013;8:e65795.
[53] Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding com-
plications in patients with atrial fibrillation: a systematic review. QJM
2007;100:599–607.
[54] Roten L, Rimoldi SF, Schwick N, Sakata T, Heimgartner C, Fuhrer J et al.
Gender differences in patients referred for atrial fibrillation management
to a tertiary center. Pacing Clin Electrophysiol 2009;32:622–626.
[55] Forleo GB, Tondo C, De Luca L, Dello Russo A, Casella M, De Sanctis V
et al. Gender-related differences in catheter ablation of atrial fibrillation.
Europace 2007;9:613–620.
[56] Henry L, Hunt S, Holmes SD, Martin LM, Ad N. Are there gender differen-
ces in outcomes after the Cox-Maze procedure for atrial fibrillation?
Innovations (Phila) 2013;8:190–198.
[57] Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender
in atrial fibrillation: Ten years later. Gend Med 2010;7:206–217.
[58] Fox CS, Parise H, D’Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ
et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in off-
spring. JAMA 2004;291:2851–2855.
[59] Oyen N, Ranthe MF, Carstensen L, Boyd HA, Olesen MS, Olesen SP et al.
Familial aggregation of lone atrial fibrillation in young persons. J Am Coll
Cardiol 2012;60:917–921.
[60] Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV et al.
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat
Genet 2012;44:670–675.
[61] Olesen MS, Nielsen MW, Haunso S, Svendsen JH. Atrial fibrillation: the
role of common and rare genetic variants. Eur J Hum Genet 2014;22:
297–306.
[62] Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S et al.
METASTROKE Consortium, AFGen Consortium, Benjamin EJ, Milan DJ,
Melander O, Heckbert SR, Ford I, Liu Y et al. Integrating genetic, tran-
scriptional, and functional analyses to identify 5 novel genes for atrial
fibrillation. Circulation 2014;130:1225–1235.
[63] Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H,
Sigurdsson A et al. Variants conferring risk of atrial fibrillation on chromo-
some 4q25. Nature 2007;448:353–357.
[64] Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G et al. Novel
genetic markers associate with atrial fibrillation risk in Europeans and
Japanese. J Am Coll Cardiol 2014;63:1200–1210.
[65] Lemmens R, Buysschaert I, Geelen V, Fernandez-Cadenas I, Montaner J,
Schmidt H et al. International Stroke Genetics Consortium. The associa-
tion of the 4q25 susceptibility variant for atrial fibrillation with stroke is
limited to stroke of cardioembolic etiology. Stroke 2010;41:1850–1857.
[66] Tada H, Shiffman D, Smith JG, Sjogren M, Lubitz SA, Ellinor PT et al.
Twelve-single nucleotide polymorphism genetic risk score identifies indi-
viduals at increased risk for future atrial fibrillation and stroke. Stroke
2014;45:2856–2862.
[67] Wang J, Klysik E, Sood S, Johnson RL, Wehrens XH, Martin JF.
Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-
sided pacemaker specification. Proc Natl Acad Sci U S A 2010;107:9753–
9758.
[68] Franco D, Chinchilla A, Daimi H, Dominguez JN, Aranega A. Modulation
of conductive elements by Pitx2 and their impact on atrial arrhythmo-
genesis. Cardiovasc Res 2011;91:223–231.
[69] Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH et al. PITX2c is
expressed in the adult left atrium, and reducing Pitx2c expression pro-
motes atrial fibrillation inducibility and complex changes in gene expres-
sion. Circ Cardiovasc Genet 2011;4:123–133.
[70] Wang J, Bai Y, Li N, Ye W, Zhang M, Greene SB et al. Pitx2-microRNA
pathway that delimits sinoatrial node development and inhibits predis-
position to atrial fibrillation. Proc Natl Acad Sci U S A 2014;111:
9181–9186.
[71] Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A.
Chromosome 4q25 variants and atrial fibrillation recurrence after cathe-
ter ablation. J Am Coll Cardiol 2010;55:747–753.
[72] Parvez B, Shoemaker MB, Muhammad R, Richardson R, Jiang L, Blair MA
et al. Common genetic polymorphism at 4q25 locus predicts atrial fibril-
lation recurrence after successful cardioversion. Heart Rhythm 2013;10:
849–855.
[73] Benjamin Shoemaker M, Muhammad R, Parvez B, White BW, Streur M,
Song Y et al. Common atrial fibrillation risk alleles at 4q25 predict recur-
rence after catheter-based atrial fibrillation ablation. Heart Rhythm 2013;
10:394–400.
[74] Parvez B, Vaglio J, Rowan S, Muhammad R, Kucera G, Stubblefield T et al.
Symptomatic response to antiarrhythmic drug therapy is modulated by a
common single nucleotide polymorphism in atrial fibrillation. J Am Coll
Cardiol 2012;60:539–545.
[75] Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KA, Katus H et al.
ESC CRT R&D and European Affairs Work Shop on Personalized
Medicine. The continuum of personalized cardiovascular medicine: a
position paper of the European Society of Cardiology. Eur Heart J 2014;
35:3250–3257.
[76] Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A
et al. Personalized management of atrial fibrillation: Proceedings from
the fourth Atrial Fibrillation competence NETwork/European Heart
Rhythm Association consensus conference. Europace 2013;15:
1540–1556.
[77] Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al.
Heart Rhythm Society, European Heart Rhythm Association. HRS/
EHRA expert consensus statement on the state of genetic testing for the
channelopathies and cardiomyopathies: this document was developed as
a partnership between the Heart Rhythm Society (HRS) and the
European Heart Rhythm Association (EHRA). Europace 2011;13:
1077–1109.
[78] Anne W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P et al.
Matrix metalloproteinases and atrial remodeling in patients with mitral
valve disease and atrial fibrillation. Cardiovasc Res 2005;67:655–666.
[79] Chimenti C, Russo MA, Carpi A, Frustaci A. Histological substrate of
human atrial fibrillation. Biomed Pharmacother 2010;64:177–183.
[80] Nguyen BL, Fishbein MC, Chen LS, Chen PS, Masroor S.
Histopathological substrate for chronic atrial fibrillation in humans. Heart
Rhythm 2009;6:454–460.
e64 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[81] Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A.
Histological substrate of atrial biopsies in patients with lone atrial fibril-
lation. Circulation 1997;96:1180–1184.
[82] Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F et al.
Human epicardial adipose tissue induces fibrosis of the atrial myocar-
dium through the secretion of adipo-fibrokines. Eur Heart J 2013;36:
795–805a.
[83] Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C et al.
Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial
fibrillation. Circulation 2002;106:2091–2097.
[84] Schotten U, Ausma J, Stellbrink C, Sabatschus I, Vogel M, Frechen D
et al. Cellular mechanisms of depressed atrial contractility in patients
with chronic atrial fibrillation. Circulation 2001;103:691–698.
[85] Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets
JL. Electropathological substrate of long-standing persistent atrial fibril-
lation in patients with structural heart disease: longitudinal dissociation.
Circ Arrhythm Electrophysiol 2010;3:606–615.
[86] Spach MS, Josephson ME. Initiating reentry: the role of nonuniform ani-
sotropy in small circuits. J Cardiovasc Electrophysiol 1994;5:182–209.
[87] Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of
atrial fibrillation substrate during development and reversal of heart
failure in dogs. Circulation 2002;105:2672–2678.
[88] Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH et al.
Effect of atrial fibrillation on atrial thrombogenesis in humans: impact
of rate and rhythm. J Am Coll Cardiol 2013;61:852–860.
[89] Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in
atrial fibrillation: a clinical review. Eur Heart J 2013;34:1475–1480.
[90] Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A et al. Atrial
extracellular matrix remodeling and the maintenance of atrial fibrilla-
tion. Circulation 2004;109:363–368.
[91] Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M
et al. Decreased plasminogen activator inhibitor and tissue metallopro-
teinase inhibitor expression may promote increased metalloproteinase
activity with increasing duration of human atrial fibrillation. J
Cardiovasc Electrophysiol 2007;18:1076–1082.
[92] Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation.
Cardiovasc Res 2014;102:205–213.
[93] Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S
et al. Amyloid deposition as a cause of atrial remodelling in persistent
valvular atrial fibrillation. Eur Heart J 2004;25:1237–1241.
[94] Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T et al. The G
protein-gated potassium current I(K,ACh) is constitutively active in
patients with chronic atrial fibrillation. Circulation 2005;112:
3697–3706.
[95] Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM,
Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation.
Circ Res 1999;85:428–436.
[96] Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mech-
anisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011;
91:265–325.
[97] Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M et al. Cellular
and molecular mechanisms of atrial arrhythmogenesis in patients with
paroxysmal atrial fibrillation. Circulation 2014;129:145–156.
[98] Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I et al.
Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+
exchanger function underlie delayed afterdepolarizations in patients
with chronic atrial fibrillation. Circulation 2012;125:2059–2070.
[99] Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D,
Mehlhorn U et al. Effects of chronic atrial fibrillation on gap
junction distribution in human and rat atria. J Am Coll Cardiol 2001;38:
883–891.
[100] Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S,
Heimburger M et al. Myocardial cell death in fibrillating and dilated
human right atria. J Am Coll Cardiol 1999;34:1577–1586.
[101] Spach MS, Heidlage JF, Barr RC, Dolber PC. Cell size and communica-
tion: role in structural and electrical development and remodeling of
the heart. Heart Rhythm 2004;1:500–515.
[102] Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE,
Vardas PE. Isolated atrial microvascular dysfunction in patients with
lone recurrent atrial fibrillation. J Am Coll Cardiol 2008;51:2053–2057.
[103] Barretto AC, Mady C, Nussbacher A, Ianni BM, Oliveira SA, Jatene A.
Atrial fibrillation in endomyocardial fibrosis is a marker of worse prog-
nosis. Int J Cardiol 1998;67:19–25.
[104] Levy S. Factors predisposing to the development of atrial fibrillation.
Pacing Clin Electrophysiol 1997;20:2670–2674.
[105] Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic
nervous system in atrial fibrillation: pathophysiology and therapy. Circ
Res 2014;114:1500–1515.
[106] Christ T, Rozmaritsa N, Engel A, Berk E, Knaut M, Metzner K et al.
Arrhythmias, elicited by catecholamines and serotonin, vanish in human
chronic atrial fibrillation. Proc Natl Acad Sci U S A 2014;111:
11193–11198.
[107] Greiser M, Kerfant BG, Williams GS, Voigt N, Harks E, Dibb KM et al.
Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial
myocytes. J Clin Invest 2014;124:4759–4772.
[108] Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G
et al. Spontaneous initiation of atrial fibrillation by ectopic beats origi-
nating in the pulmonary veins. N Engl J Med 1998;339:659–666.
[109] Patterson E, Jackman WM, Beckman KJ, Lazzara R, Lockwood D,
Scherlag BJ et al. Spontaneous pulmonary vein firing in man: relation-
ship to tachycardia-pause early afterdepolarizations and triggered
arrhythmia in canine pulmonary veins in vitro. J Cardiovasc
Electrophysiol 2007;18:1067–1075.
[110] Atienza F, Almendral J, Moreno J, Vaidyanathan R, Talkachou A, Kalifa J
et al. Activation of inward rectifier potassium channels accelerates atrial
fibrillation in humans: evidence for a reentrant mechanism. Circulation
2006;114:2434–2442.
[111] Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreen-
trant sources as a mechanism of atrial fibrillation in the isolated sheep
heart. Circulation 2000;101:194–199.
[112] Sahadevan J, Ryu K, Peltz L, Khrestian CM, Stewart RW, Markowitz AH.
Epicardial mapping of chronic atrial fibrillation in patients: preliminary
observations. Circulation 2004;110:3293–3299.
[113] Sanders P, Nalliah CJ, Dubois R, Takahashi Y, Hocini M, Rotter M et al.
Frequency mapping of the pulmonary veins in paroxysmal versus per-
manent atrial fibrillation. J Cardiovasc Electrophysiol 2006;17:965–972.
[114] Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia
independent of focal discharge. Am Heart J 1959;58:59–70.
[115] Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C et al.
The surgical treatment of atrial fibrillation. II. Intraoperative electrophy-
siologic mapping and description of the electrophysiologic basis of
atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991;101:
406–426.
[116] Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller
JM. Treatment of atrial fibrillation by the ablation of localized sources:
CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without
Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012;60:
628–636.
[117] Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S
et al. Driver domains in persistent atrial fibrillation. Circulation 2014;
130:530–538.
[118] Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T et al.
Prevention of atrial fibrillation after cardioversion: results of the PAFAC
trial. Eur Heart J 2004;25:1385–1394.
[119] Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH,
Carbucicchio C. Perception of atrial fibrillation before and after radio-
frequency catheter ablation: relevance of asymptomatic arrhythmia
recurrence. Circulation 2005;112:307–313.
[120] Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ,
Cappato R et al. Early and comprehensive management of atrial fibrilla-
tion: executive summary of the proceedings from the 2nd AFNET-EHRA
consensus conference ‘research perspectives in AF’. Eur Heart J 2009;30:
2969–2977c.
[121] Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus sympto-
matic atrial fibrillation: A systematic review of age/gender differences
and cardiovascular outcomes. Int J Cardiol 2015;191:172–177.
[122] Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: preva-
lence, prognosis, quality of life, and management. J Interv Card
Electrophysiol 2000;4:369–382.
[123] Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrilla-
tion: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J
2010;31:967–975.
[124] Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M
et al. Risk of ischaemic stroke according to pattern of atrial fibrillation:
analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
Eur Heart J 2015;36:281–287a.
[125] Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G,
Hankey GJ et al. Higher risk of death and stroke in patients with persis-
tent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Eur Heart J 2015;36:288–296.













[126] Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R et al.
Screening versus routine practice in detection of atrial fibrillation in
patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;
335:383.
[127] Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R et al.
Continuous stroke unit electrocardiographic monitoring versus 24-hour
Holter electrocardiography for detection of paroxysmal atrial fibrillation
after stroke. Stroke 2012;43:2689–2694.
[128] Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J et al.
EMBRACE Investigators and Coordinators. Atrial fibrillation in patients
with cryptogenic stroke. N Engl J Med 2014;370:2467–2477.
[129] Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M.
Population screening of 75- and 76-year-old men and women for silent
atrial fibrillation (STROKESTOP). Europace 2013;15:135–140.
[130] Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY. Prevalence of
atrial fibrillation in the general population and in high-risk groups: the
ECHOES study. Europace 2012;14:1553–1559.
[131] Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S et al. A
randomised controlled trial and cost-effectiveness study of systematic
screening (targeted and total population screening) versus routine prac-
tice for the detection of atrial fibrillation in people aged 65 and over.
The SAFE study. Health Technol Assess 2005;9:iii–iv, ix–x, 1–74.
[132] Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg
L et al. Cost-effectiveness of mass screening for untreated atrial fibrilla-
tion using intermittent ECG recording. Europace 2015;17:1023–1029.
[133] Levin LA, Husberg M, Sobocinski PD, Kull VF, Friberg L, Rosenqvist M. A
cost-effectiveness analysis of screening for silent atrial fibrillation after
ischaemic stroke. Europace 2015;17:207–214.
[134] Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify
unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;
110:213–222.
[135] Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening
of atrial fibrillation in a 75-year-old population: implications for stroke
prevention. Circulation 2013;127:930–937.
[136] Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette
A et al. Prospective, multicentre validation of a simple, patient-operated
electrocardiographic system for the detection of arrhythmias and elec-
trocardiographic changes. Europace 2009;11:1362–1368.
[137] Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R et al.
Validation and clinical use of a novel diagnostic device for screening of
atrial fibrillation. Europace 2014;16:1291–1295.
[138] Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J et al.
Comparison of 24-hour Holter monitoring with 14-day novel adhesive
patch electrocardiographic monitoring. Am J Med 2014;127:95.e11–97.
[139] Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J et al.
Feasibility and cost-effectiveness of stroke prevention through com-
munity screening for atrial fibrillation using iPhone ECG in pharmacies.
The SEARCH-AF study. Thromb Haemost 2014;111:1167–1176.
[140] Quinn FR, Gladstone D. Screening for undiagnosed atrial fibrillation in
the community. Curr Opin Cardiol 2014;29:28–35.
[141] Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A
et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of
stroke. N Engl J Med 2012;366:120–129.
[142] Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D
et al. Performance of a new leadless implantable cardiac monitor in
detecting and quantifying atrial fibrillation - results of the XPECT trial.
Circ Arrhythm Electrophysiol 2010;3:141–147.
[143] Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C
et al. ASSERT Investigators. Temporal relationship between subclinical
atrial fibrillation and embolic events. Circulation 2014;129:2094–2099.
[144] Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M et al.
Device-detected atrial fibrillation and risk for stroke: an analysis of
>10,000 patients from the SOS AF project (Stroke preventiOn Strategies
based on Atrial Fibrillation information from implanted devices). Eur
Heart J 2014;35:508–516.
[145] Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L
et al. Device-detected atrial tachyarrhythmias predict adverse outcome
in real-world patients with implantable biventricular defibrillators. J Am
Coll Cardiol 2011;57:167–172.
[146] Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J.
Temporal relationship of atrial tachyarrhythmias, cerebrovascular
events, and systemic emboli based on stored device data: a subgroup
analysis of TRENDS. Heart Rhythm 2011;8:1416–1423.
[147] Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C
et al. The relationship between daily atrial tachyarrhythmia burden
from implantable device diagnostics and stroke risk: the TRENDS study.
Circ Arrhythm Electrophysiol 2009;2:474–480.
[148] Lamas G. How much atrial fibrillation is too much atrial fibrillation? N
Engl J Med 2012;366:178–180.
[149] Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al.
Comprehensive risk reduction in patients with atrial fibrillation: emerg-
ing diagnostic and therapeutic options—a report from the 3rd Atrial
Fibrillation Competence NETwork/European Heart Rhythm Association
consensus conference. Europace 2012;14:8–27.
[150] Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al.
Comprehensive risk reduction in patients with atrial fibrillation:
Emerging diagnostic and therapeutic options. Executive summary of the
report from the 3rd AFNET/EHRA consensus conference. Thromb
Haemost 2011;106:1012–1019.
[151] Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM,
Hachinski V. Diagnosis of atrial fibrillation after stroke and transient
ischaemic attack: a systematic review and meta-analysis. Lancet Neurol
2015;14:377–387.
[152] Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA
et al. Predictors for atrial fibrillation detection after cryptogenic stroke:
Results from CRYSTAL AF. Neurology 2016;86:261–269.
[153] Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL.
Classification of subtype of acute ischemic stroke. Definitions for use in
a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke
Treatment. Stroke 1993;24:35–41.
[154] Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ
et al. Cryptogenic Stroke/ESUS International Working Group. Embolic
strokes of undetermined source: the case for a new clinical construct.
Lancet Neurol 2014;13:429–438.
[155] Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R et al.
Accuracy of diagnosing atrial fibrillation on electrocardiogram by pri-
mary care practitioners and interpretative diagnostic software: analysis
of data from screening for atrial fibrillation in the elderly (SAFE) trial.
BMJ 2007;335:380.
[156] Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk
of recurrent atrial fibrillation as documented by an implantable moni-
toring device: implications for optimal patient care. J Am Coll Cardiol
2004;43:47–52.
[157] Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M.
Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP
Study. Circulation 2015;131:2176–2184.
[158] Bun SS, Latcu DG, Marchlinski F, Saoudi N. Atrial flutter: more than just
one of a kind. Eur Heart J 2015;36:2356–2363.
[159] Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN et al.
Incidence and predictors of atrial flutter in the general population. J Am
Coll Cardiol 2000;36:2242–2246.
[160] Halligan SC, Gersh BJ, Brown RD Jr, Rosales AG, Munger TM, Shen WK
et al. The natural history of lone atrial flutter. Ann Intern Med 2004;140:
265–268.
[161] Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL et al.
Long-term progression and outcomes with aging in patients with lone
atrial fibrillation: a 30-year follow-up study. Circulation 2007;115:
3050–3056.
[162] Gillis AM, Rose MS. Temporal patterns of paroxysmal atrial fibrillation
following DDDR pacemaker implantation. Am J Cardiol 2000;85:
1445–1450.
[163] Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications
of atrial fibrillation poorly reflect its temporal persistence: insights from
1,195 patients continuously monitored with implantable devices. J Am
Coll Cardiol 2014;63:2840–2848.
[164] Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY.
Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial
Fibrillation Project. Int J Cardiol 2013;167:2682–2687.
[165] Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias:
state of the art. Lancet 2012;380:1509–1519.
[166] Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM
et al. Lone atrial fibrillation: does it exist? J Am Coll Cardiol 2014;63:
1715–1723.
[167] Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and patho-
physiology of atrial fibrillation: relationships among clinical features,
epidemiology, and mechanisms. Circ Res 2014;114:1453–1468.
[168] Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF et al. Atrial substrate
properties and outcome of catheter ablation in patients with paroxys-
mal atrial fibrillation associated with diabetes mellitus or impaired fast-
ing glucose. Am J Cardiol 2010;106:1615–1620.
e66 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[169] Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K
et al. The impact of smoking on thromboembolism and mortality in
patients with incident atrial fibrillation: insights from the Danish Diet,
Cancer, and Health study. Chest 2014;145:559–566.
[170] Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA
et al. Alcohol intake and prognosis of atrial fibrillation. Heart 2013;99:
1093–1099.
[171] Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G
et al. Association of left atrial fibrosis detected by delayed-enhancement
magnetic resonance imaging and the risk of stroke in patients with atrial
fibrillation. J Am Coll Cardiol 2011;57:831–838.
[172] Neilan TG, Shah RV, Abbasi SA, Farhad H, Groarke JD, Dodson JA et al.
The incidence, pattern, and prognostic value of left ventricular myocar-
dial scar by late gadolinium enhancement in patients with atrial fibrilla-
tion. J Am Coll Cardiol 2013;62:2205–2214.
[173] Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F
et al. Association of atrial tissue fibrosis identified by delayed enhance-
ment MRI and atrial fibrillation catheter ablation: the DECAAF study.
JAMA 2014;311:498–506.
[174] Bonizzi P, Zeemering S, Karel JM, Di Marco LY, Uldry L, Van Zaen J et al.
Systematic comparison of non-invasive measures for the assessment of
atrial fibrillation complexity: a step forward towards standardization of
atrial fibrillation electrogram analysis. Europace 2014;17:318–325.
[175] Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C,
Boriani G et al. A roadmap to improve the quality of atrial fibrillation
management: proceedings from the fifth Atrial Fibrillation Network/
European Heart Rhythm Association consensus conference. Europace
2016;18:37–50.
[176] Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR
et al. Expert consensus document: Defining the major health modifiers
causing atrial fibrillation: a roadmap to underpin personalized preven-
tion and treatment. Nat Rev Cardiol 2016;13:230–237.
[177] Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM et al.
The impairment of health-related quality of life in patients with inter-
mittent atrial fibrillation: implications for the assessment of investiga-
tional therapy. J Am Coll Cardiol 2000;36:1303–1309.
[178] Sears SF, Serber ER, Alvarez LG, Schwartzman DS, Hoyt RH, Ujhelyi MR.
Understanding atrial symptom reports: objective versus subjective pre-
dictors. Pacing Clin Electrophysiol 2005;28:801–807.
[179] Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life
with type of atrial fibrillation. Rev Esp Cardiol 2010;63:1402–1409.
[180] Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H et al.
RealiseAF investigators. Symptoms, functional status and quality of life
in patients with controlled and uncontrolled atrial fibrillation: data from
the RealiseAF cross-sectional international registry. Heart 2012;98:
195–201.
[181] Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH. Pharmacological
Intervention in Atrial Fibrillation (PIAF) Study investigators. Impact of
rate versus rhythm control on quality of life in patients with persistent
atrial fibrillation. Results from a prospective randomized study. Eur
Heart J 2003;24:1430–1436.
[182] Pepine CJ. Effects of pharmacologic therapy on health-related quality of
life in elderly patients with atrial fibrillation: a systematic review of
randomized and nonrandomized trials. Clin Med Insights Cardiol 2013;
7:1–20.
[183] Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG
et al. RACE Study Group. Effect of rate or rhythm control on quality of life
in persistent atrial fibrillation. Results from the Rate Control Versus
Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004;43:241–247.
[184] Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D
et al. The Australian intervention randomized control of rate in atrial
fibrillation trial (AIRCRAFT). J Am Coll Cardiol 2003;41:1697–1702.
[185] Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley
SL et al. A randomized trial to assess catheter ablation versus rate con-
trol in the management of persistent atrial fibrillation in heart failure. J
Am Coll Cardiol 2013;61:1894–1903.
[186] Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF
et al. Symptoms and functional status of patients with atrial fibrillation:
state of the art and future research opportunities. Circulation 2012;125:
2933–2943.
[187] Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramirez P, Badia X.
Validation of the AF-QoL, a disease-specific quality of life questionnaire
for patients with atrial fibrillation. Europace 2010;12:364–370.
[188] Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR et al.
Development and validation of the Atrial Fibrillation Effect on
QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation.
Circ Arrhythm Electrophysiol 2011;4:15–25.
[189] Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR et al.
Interpreting changes in quality of life in atrial fibrillation: How much
change is meaningful? Am Heart J 2013;166:381–387.e8.
[190] Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the
International Quality of Life Assessment (IQOLA) Project. J Clin
Epidemiol 1998;51:903–912.
[191] Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al.
Development and preliminary testing of the new five-level version of
EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–1736.
[192] Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al.
Outcome parameters for trials in atrial fibrillation: executive summary.
Eur Heart J 2007;28:2803–2817.
[193] Dorian P, Cvitkovic SS, Kerr CR, Crystal E, Gillis AM, Guerra PG et al. A
novel, simple scale for assessing the symptom severity of atrial fibrilla-
tion at the bedside: the CCS-SAF scale. Can J Cardiol 2006;22:383–386.
[194] Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY,
Schilling RJ et al. Management of atrial fibrillation in seven European
countries after the publication of the 2010 ESC Guidelines on atrial
fibrillation: primary results of the PREvention oF thromboemolic
events—European Registry in Atrial Fibrillation (PREFER in AF). Europace
2014;16:6–14.
[195] Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA
et al. Improved outcomes with European Society of Cardiology
guideline-adherent antithrombotic treatment in high-risk patients with
atrial fibrillation: a report from the EORP-AF General Pilot Registry.
Europace 2015;17:1777–1786.
[196] Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ et al.
Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation (ORBIT-AF) Investigators and Patients. Association Between
Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes:
Results From the Outcomes Registry for Better Informed Treatment of
Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 2015;8:
393–402.
[197] Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI,
Rasmussen LH et al. Asymptomatic atrial fibrillation: clinical correlates,
management, and outcomes in the EORP-AF Pilot General Registry. Am
J Med 2015;128:509–518 e2.
[198] Szymanski FM, Filipiak KJ, Karpinski G, Platek AE, Opolski G. Occurrence
of poor sleep quality in atrial fibrillation patients according to the EHRA
score. Acta Cardiol 2014;69:291–296.
[199] Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P. The
European Heart Rhythm Association symptom classification for atrial
fibrillation: validation and improvement through a simple modification.
Europace 2014;16:965–972.
[200] Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P. ATRIUM
investigators. Management of atrial fibrillation by primary care physi-
cians in Germany: baseline results of the ATRIUM registry. Clin Res
Cardiol 2011;100:897–905.
[201] Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P et al.
The Registry of the German Competence NETwork on Atrial Fibrillation:
Patient characteristics and initial management. Europace 2009;11:
423–434.
[202] von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T,
Calvert M et al. Depression in paroxysmal and persistent atrial fibrilla-
tion patients: a cross-sectional comparison of patients enroled in two
large clinical trials. Europace 2014;16:812–819.
[203] Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D
et al. Aggressive risk factor reduction study for atrial fibrillation and
implications for the outcome of ablation: the ARREST-AF cohort study. J
Am Coll Cardiol 2014;64:2222–2231.
[204] Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME
et al. Effect of weight reduction and cardiometabolic risk factor manage-
ment on symptom burden and severity in patients with atrial fibrillation:
a randomized clinical trial. JAMA 2013;310:2050–2060.
[205] Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP
et al. Incidence of and risk factors for atrial fibrillation in older adults.
Circulation 1997;96:2455–2461.
[206] Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC
et al. The spectrum of thyroid disease and risk of new onset atrial fibril-
lation: a large population cohort study. BMJ 2012;345:e7895.
[207] Kim EJ, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ. Relation of
hypothyroidism and incident atrial fibrillation (from the Framingham
Heart Study). Am Heart J 2014;167:123–126.













[208] Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P,
Hillege HL et al. Incidence of atrial fibrillation and relationship with car-
diovascular events, heart failure, and mortality: A community-based
study from the netherlands. J Am Coll Cardiol 2015;66:1000–1007.
[209] Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung func-
tion and risk of atrial fibrillation in the Copenhagen City Heart Study.
Eur Respir J 2003;21:1012–1016.
[210] Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T.
Obstructive sleep apnea, obesity, and the risk of incident atrial fibrilla-
tion. J Am Coll Cardiol 2007;49:565–571.
[211] Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W
et al. Association of chronic kidney disease with atrial fibrillation among
adults in the United States: REasons for Geographic and Racial
Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol
2011;4:26–32.
[212] Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ,
Ambrose M et al. Smoking and incidence of atrial fibrillation: results
from the Atherosclerosis Risk in Communities (ARIC) study. Heart
Rhythm 2011;8:1160–1166.
[213] Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial
fibrillation: a prospective study and dose-response meta-analysis. J Am
Coll Cardiol 2014;64:281–289.
[214] Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM.
Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol
2009;103:1572–1577.
[215] Guha K, McDonagh T. Heart failure epidemiology: European perspec-
tive. Curr Cardiol Rev 2013;9:123–127.
[216] Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart
failure? Europace 2011;13:ii13–17.
[217] Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of
the cost of atrial fibrillation. Value Health 2012;15:240–248.
[218] Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we
do? Eur Heart J 2015;36:3250–3257.
[219] Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL,
McMurray JJ et al. Atrial fibrillation and risk of clinical events in chronic
heart failure with and without left ventricular systolic dysfunction:
results from the Candesartan in Heart failure-Assessment of Reduction
in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;
47:1997–2004.
[220] Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation
and heart failure due to reduced versus preserved ejection fraction: A
systematic review and meta-analysis of death and adverse outcomes.
Int J Cardiol 2016;203:660–666.
[221] Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F,
Neyses L. A meta-analysis of the prognostic significance of atrial fibrilla-
tion in chronic heart failure. Eur J Heart Fail 2009;11:676–683.
[222] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS
et al. The Task Force for the diagnosis and teatment of acute and
chronic heart failure of the European Society of Cardiology (ESC). 2016
ESC Guidelines for the diagnosis and treatment of acute and chronic
heart failure. Eur Heart J;doi:10.1093/eurheartj/ehw128. Published
online ahead of print 20 May 2016.
[223] Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T et al.
European Heart Rhythm Association/Heart Failure Association joint
consensus document on arrhythmias in heart failure, endorsed by the
Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.
Europace 2016;18:12–36.
[224] McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR
et al. PARADIGM-HF Investigators and Committees. Angiotensin-nepri-
lysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:
993–1004.
[225] Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY et al. Safety
and efficacy of digoxin: systematic review and meta-analysis of observa-
tional and controlled trial data. BMJ 2015;351:h4451.
[226] Anselmino M, Matta M, D’Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ
et al. Catheter ablation of atrial fibrillation in patients with left ventricu-
lar systolic dysfunction: a systematic review and meta-analysis. Circ
Arrhythm Electrophysiol 2014;7:1011–1018.
[227] Ganesan AN, Nandal S, Luker J, Pathak RK, Mahajan R, Twomey D et al.
Catheter ablation of atrial fibrillation in patients with concomitant left
ventricular impairment: a systematic review of efficacy and effect on
ejection fraction. Heart Lung Circ 2015;24:270–280.
[228] Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO et al.
PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation
in patients with heart failure. N Engl J Med 2008;359:1778–1785.
[229] Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: patho-
physiology, mechanisms, clinical features and management. Int J
Cardiol 2014;172:40–46.
[230] Kusunose K, Yamada H, Nishio S, Tomita N, Niki T, Yamaguchi K et al.
Clinical utility of single-beat E/e’ obtained by simultaneous recording of
flow and tissue Doppler velocities in atrial fibrillation with preserved
systolic function. JACC Cardiovasc Imaging 2009;2:1147–1156.
[231] Li C, Zhang J, Zhou C, Huang L, Tang H, Rao L. Will simultaneous meas-
urement of E/e’ index facilitate the non-invasive assessment of left ven-
tricular filling pressure in patients with non-valvular atrial fibrillation?
Eur J Echocardiogr 2010;11:296–301.
[232] Senechal M, O’Connor K, Deblois J, Magne J, Dumesnil JG, Pibarot P
et al. A simple Doppler echocardiography method to evaluate pulmo-
nary capillary wedge pressure in patients with atrial fibrillation.
Echocardiography 2008;25:57–63.
[233] Sohn DW, Song JM, Zo JH, Chai IH, Kim HS, Chun HG. Mitral annulus
velocity in the evaluation of left ventricular diastolic function in atrial
fibrillation. J Am Soc Echocardiogr 1999;12:927–931.
[234] Wada Y, Murata K, Tanaka T, Nose Y, Kihara C, Uchida K et al.
Simultaneous Doppler tracing of transmitral inflow and mitral annular
velocity as an estimate of elevated left ventricular filling pressure in
patients with atrial fibrillation. Circ J 2012;76:675–681.
[235] Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L et al. Patient
selection in heart failure with preserved ejection fraction clinical trials. J
Am Coll Cardiol 2015;65:1668–1682.
[236] Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder
RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibi-
tion a meta-analysis. J Am Coll Cardiol 2010;55:2299–2307.
[237] Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S.
Prevention of atrial fibrillation with angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll
Cardiol 2005;45:1832–1839.
[238] Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of
abrogation of the renin-angiotensin system: a systematic review and
meta-analysis. Am J Ther 2008;15:36–43.
[239] Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB,
Maggioni AP et al. CHARM Investigators. Prevention of atrial fibrillation
in patients with symptomatic chronic heart failure by candesartan in the
Candesartan in Heart failure: Assessment of Reduction in Mortality and
morbidity (CHARM) program. Am Heart J 2006;152:86–92.
[240] GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG,
Staszewsky L, Maggioni AP et al. Valsartan for prevention of recurrent
atrial fibrillation. N Engl J Med 2009;360:1606–1617.
[241] Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG et al.
Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
Circ Arrhythm Electrophysiol 2012;5:43–51.
[242] Active I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather
M, Hart RG et al. Irbesartan in patients with atrial fibrillation. N Engl J
Med 2011;364:928–938.
[243] Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H
et al. Eplerenone and atrial fibrillation in mild systolic heart failure:
results from the EMPHASIS-HF (Eplerenone in Mild Patients
Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll
Cardiol 2012;59:1598–1603.
[244] Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C et al. Increased
expression of extracellular signal-regulated kinase and angiotensin-
converting enzyme in human atria during atrial fibrillation. J Am Coll
Cardiol 2000;35:1669–1677.
[245] Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive
treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J
2014;35:1205–1214.
[246] Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al.
Angiotensin II receptor blockade reduces new-onset atrial fibrillation
and subsequent stroke compared to atenolol: the Losartan Intervention
For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol
2005;45:712–719.
[247] Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S et al.
Hypertension and atrial fibrillation: diagnostic approach, prevention
and treatment. Position paper of the Working Group ‘Hypertension
Arrhythmias and Thrombosis’ of the European Society of Hypertension.
J Hypertens 2012;30:239–252.
[248] Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E et al. Use
of irbesartan to maintain sinus rhythm in patients with long-lasting per-
sistent atrial fibrillation: a prospective and randomized study.
Circulation 2002;106:331–336.
e68 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[249] Ueng K-C, Tsai T-P, Yu W-C, Tsai C-F, Lin M-C, Chan K-C et al. Use of
enalapril to facilitate sinus rhythm maintenance after external cardiover-
sion of long-standing persistent atrial fibrillation. Results of a prospec-
tive and controlled study. Eur Heart J 2003;24:2090–2098.
[250] Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition
of renin-angiotensin system prevents new-onset atrial fibrillation. Am
Heart J 2006;152:217–222.
[251] Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect
of candesartan and various inflammatory markers on maintenance of
sinus rhythm after electrical cardioversion for atrial fibrillation. Am J
Cardiol 2007;99:1544–1548.
[252] Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju
PM. Prevalence of atrial fibrillation in elderly subjects (the
Cardiovascular Health Study). Am J Cardiol 1994;74:236–241.
[253] Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G,
Baumgartner H et al. Joint Task Force on the Management of Valvular
Heart Disease of the European Society of Cardiology (ESC), European
Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the
management of valvular heart disease (version 2012). Eur Heart J 2012;
33:2451–2496.
[254] Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton
RA et al. 2014 AHA/ACC guideline for the management of patients with
valvular heart disease: executive summary: a report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol 2014;63:2438–2488.
[255] Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW
et al. Atrial fibrillation management: a prospective survey in ESC mem-
ber countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J
2005;26:2422–2434.
[256] Moretti M, Fabris E, Morosin M, Merlo M, Barbati G, Pinamonti B et al.
Prognostic significance of atrial fibrillation and severity of symptoms of
heart failure in patients with low gradient aortic stenosis and preserved
left ventricular ejection fraction. Am J Cardiol 2014;114:1722–1728.
[257] Ngaage DL, Schaff HV, Mullany CJ, Barnes S, Dearani JA, Daly RC et al.
Influence of preoperative atrial fibrillation on late results of mitral
repair: is concomitant ablation justified? Ann Thorac Surg 2007;84:
434–442; discussion 442–433.
[258] Ngaage DL, Schaff HV, Barnes SA, Sundt TM III, Mullany CJ, Dearani JA
et al. Prognostic implications of preoperative atrial fibrillation in patients
undergoing aortic valve replacement: is there an argument for concom-
itant arrhythmia surgery? Ann Thorac Surg 2006;82:1392–1399.
[259] Eguchi K, Ohtaki E, Matsumura T, Tanaka K, Tohbaru T, Iguchi N et al.
Pre-operative atrial fibrillation as the key determinant of outcome of
mitral valve repair for degenerative mitral regurgitation. Eur Heart J
2005;26:1866–1872.
[260] Lim E, Barlow CW, Hosseinpour AR, Wisbey C, Wilson K, Pidgeon W
et al. Influence of atrial fibrillation on outcome following mitral valve
repair. Circulation 2001;104:I59–63.
[261] Maan A, Heist EK, Passeri J, Inglessis I, Baker J, Ptaszek L et al. Impact of
atrial fibrillation on outcomes in patients who underwent transcatheter
aortic valve replacement. Am J Cardiol 2015;115:220–226.
[262] Barbash IM, Minha S, Ben-Dor I, Dvir D, Torguson R, Aly M et al.
Predictors and clinical implications of atrial fibrillation in patients with
severe aortic stenosis undergoing transcatheter aortic valve implanta-
tion. Catheter Cardiovasc Interv 2015;85:468–477.
[263] Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting
dilemmas. Stroke 1988;19:937–941.
[264] Messika-Zeitoun D, Bellamy M, Avierinos JF, Breen J, Eusemann C, Rossi
A et al. Left atrial remodelling in mitral regurgitation—methodologic
approach, physiological determinants, and outcome implications: a pro-
spective quantitative Doppler-echocardiographic and electron beam-
computed tomographic study. Eur Heart J 2007;28:1773–1781.
[265] Calvo N, Bisbal F, Guiu E, Ramos P, Nadal M, Tolosana JM et al. Impact
of atrial fibrillation-induced tachycardiomyopathy in patients under-
going pulmonary vein isolation. Int J Cardiol 2013;168:4093–4097.
[266] Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N, Rosenqvist M.
Prospective study of left ventricular function after radiofrequency abla-
tion of atrioventricular junction in patients with atrial fibrillation. Br
Heart J 1995;74:261–267.
[267] Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE et al.
Evidence of atrial functional mitral regurgitation due to atrial fibrillation:
reversal with arrhythmia control. J Am Coll Cardiol 2011;58:1474–1481.
[268] Kihara T, Gillinov AM, Takasaki K, Fukuda S, Song JM, Shiota M. Mitral
regurgitation associated with mitral annular dilation in patients with
lone atrial fibrillation: an echocardiographic study. Echocardiography
2009;26:885–889.
[269] Zhou X, Otsuji Y, Yoshifuku S, Yuasa T, Zhang H, Takasaki K et al. Impact
of atrial fibrillation on tricuspid and mitral annular dilatation and valvu-
lar regurgitation. Circ J 2002;66:913–916.
[270] Ring L, Dutka DP, Wells FC, Fynn SP, Shapiro LM, Rana BS. Mechanisms
of atrial mitral regurgitation: insights using 3D transoesophageal echo.
Eur Heart J Cardiovasc Imaging 2014;15:500–508.
[271] Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G,
Baumgartner H et al. ESC Committee for Practice Guidelines (CPG),
Joint Task Force on the Management of Valvular Heart Disease of the
European Society of Cardiology (ESC), European Association for Cardio-
Thoracic Surgery (EACTS). Guidelines on the management of valvular
heart disease (version 2012): the Joint Task Force on the Management
of Valvular Heart Disease of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery (EACTS). Eur
J Cardiothorac Surg 2012;42:S1–44.
[272] Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C.
The definition of valvular and non-valvular atrial fibrillation: results of a
physicians’ survey. Europace 2014;16:1720–1725.
[273] Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in car-
diac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:
755–759.
[274] Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in
Rheumatic Heart Disease. Br Med J 1964;1:1209–1212.
[275] De Caterina R, Camm AJ. What is ‘valvular’ atrial fibrillation? A reap-
praisal. Eur Heart J 2014;35:3328–3335.
[276] Goldstone AB, Patrick WL, Cohen JE, Aribeana CN, Popat R, Woo YJ.
Early surgical intervention or watchful waiting for the management of
asymptomatic mitral regurgitation: a systematic review and meta-analy-
sis. Ann Cardiothorac Surg 2015;4:220–229.
[277] Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus
and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012;
60:1421–1428.
[278] Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A et al. Risks
of cardiovascular events and effects of routine blood pressure lowering
among patients with type 2 diabetes and atrial fibrillation: results of the
ADVANCE study. Eur Heart J 2009;30:1128–1135.
[279] Rizzo MR, Sasso FC, Marfella R, Siniscalchi M, Paolisso P, Carbonara O
et al. Autonomic dysfunction is associated with brief episodes of atrial
fibrillation in type 2 diabetes. J Diabetes Complications 2015;29:88–92.
[280] Olson TM, Terzic A. Human K(ATP) channelopathies: diseases of meta-
bolic homeostasis. Pflugers Arch 2010;460:295–306.
[281] Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA
et al. C-reactive protein elevation in patients with atrial arrhythmias:
inflammatory mechanisms and persistence of atrial fibrillation.
Circulation 2001;104:2886–2891.
[282] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease.
Nat Rev Immunol 2011;11:98–107.
[283] Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibril-
lation and diabetes. J Cardiovasc Electrophysiol 2015;26:223–225.
[284] Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J et al.
Impact of intensive glycemic control on the incidence of atrial fibrilla-
tion and associated cardiovascular outcomes in patients with type 2 dia-
betes mellitus (from the Action to Control Cardiovascular Risk in
Diabetes Study). Am J Cardiol 2014;114:1217–1222.
[285] Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH.
Duration of Diabetes Mellitus and Risk of Thromboembolism and
Bleeding in Atrial Fibrillation: Nationwide Cohort Study. Stroke 2015;46:
2168–2174.
[286] Chang S-H, Wu L-S, Chiou M-J, Liu J-R, Yu K-H, Kuo C-F et al.
Association of metformin with lower atrial fibrillation risk among
patients with type 2 diabetes mellitus: a population-based dynamic
cohort and in vitro studies. Cardiovasc Diabetol 2014;13:123.
[287] Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associ-
ated diabetic retinopathy on stroke and severe bleeding risk in diabetic
patients with atrial fibrillation: the Loire valley atrial fibrillation project.
Chest 2015;147:1103–1110.
[288] Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY.
Physical activity, obesity, weight change, and risk of atrial fibrillation:
the Atherosclerosis Risk in Communities study. Circ Arrhythm
Electrophysiol 2014;7:620–625.
[289] Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ.
Long-term cardiovascular consequences of obesity: 20-year follow-up













of more than 15 000 middle-aged men and women (the Renfrew-
Paisley study). Eur Heart J 2006;27:96–106.
[290] Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg
JS. Atrial fibrillation and obesity—results of a meta-analysis. Am Heart J
2008;155:310–315.
[291] Wang TJ, Parise H, Levy D, D’Agostino RB Sr, Wolf PA, Vasan RS. Obesity
and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471–2477.
[292] Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB.
Body mass index and adverse events in patients with incident atrial
fibrillation. Am J Med 2013;126:640.e649–617.
[293] Karason K, Molgaard H, Wikstrand J, Sjostrom L. Heart rate variability
in obesity and the effect of weight loss. Am J Cardiol 1999;83:
1242–1247.
[294] Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL. Effect of obe-
sity and overweight on left ventricular diastolic function: a community-
based study in an elderly cohort. J Am Coll Cardiol 2011;57:1368–1374.
[295] Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-
reactive protein levels in overweight and obese adults. JAMA 1999;282:
2131–2135.
[296] Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong
CX et al. Long-Term Effect of Goal-Directed Weight Management in an
Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am
Coll Cardiol 2015;65:2159–2169.
[297] Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan
R et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence
in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J
Am Coll Cardiol 2015;66:985–996.
[298] Cha YM, Friedman PA, Asirvatham SJ, Shen WK, Munger TM, Rea RF
et al. Catheter ablation for atrial fibrillation in patients with obesity.
Circulation 2008;117:2583–2590.
[299] Jongnarangsin K, Chugh A, Good E, Mukerji S, Dey S, Crawford T et al.
Body mass index, obstructive sleep apnea, and outcomes of catheter abla-
tion of atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:668–672.
[300] Guijian L, Jinchuan Y, Rongzeng D, Jun Q, Jun W, Wenqing Z. Impact of
body mass index on atrial fibrillation recurrence: a meta-analysis of
observational studies. Pacing Clin Electrophysiol 2013;36:748–756.
[301] Zhuang J, Lu Y, Tang K, Peng W, Xu Y. Influence of body mass index on
recurrence and quality of life in atrial fibrillation patients after catheter abla-
tion: a meta-analysis and systematic review. Clin Cardiol 2013;36:269–275.
[302] Ector J, Dragusin O, Adriaenssens B, Huybrechts W, Willems R, Ector H.
Obesity is a major determinant of radiation dose in patients undergoing
pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 2007;
50:234–242.
[303] Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M
et al. Relation of morbid obesity and female gender to risk of procedural
complications in patients undergoing atrial fibrillation ablation. Am J
Cardiol 2013;111:368–373.
[304] Vizzardi E, Sciatti E, Bonadei I, D’Aloia A, Curnis A, Metra M. Obstructive
sleep apnoea-hypopnoea and arrhythmias: new updates. J Cardiovasc
Med (Hagerstown) 2014, doi 10.2459/JCM.0000000000000043.
[305] Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation; 2012 update.
Curr Cardiol Rev 2012;8:265–272.
[306] Lin YK, Lai MS, Chen YC, Cheng CC, Huang JH, Chen SA et al. Hypoxia
and reoxygenation modulate the arrhythmogenic activity of the pulmo-
nary vein and atrium. Clin Sci (Lond) 2012;122:121–132.
[307] Linz D. Atrial fibrillation in obstructive sleep apnea: atrial arrhythmo-
genic substrate of a different sort. Am J Cardiol 2012;110:1071.
[308] Patel D, Mohanty P, Di Biase L, Shaheen M, Lewis WR, Quan K et al.
Safety and efficacy of pulmonary vein antral isolation in patients with
obstructive sleep apnea: the impact of continuous positive airway pres-
sure. Circ Arrhythm Electrophysiol 2010;3:445–451.
[309] Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K et al. Treatment
of obstructive sleep apnea reduces the risk of atrial fibrillation recur-
rence after catheter ablation. J Am Coll Cardiol 2013;62:300–305.
[310] Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y et al.
Concomitant obstructive sleep apnea increases the recurrence of atrial
fibrillation following radiofrequency catheter ablation of atrial fibrilla-
tion: clinical impact of continuous positive airway pressure therapy.
Heart Rhythm 2013;10:331–337.
[311] Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP et al.
Effect of sleep apnea and continuous positive airway pressure on cardiac
structure and recurrence of atrial fibrillation. J Am Heart Assoc 2013;2:
e000421.
[312] Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y et al. Efficacy of catheter abla-
tion of atrial fibrillation in patients with obstructive sleep apnoea with
and without continuous positive airway pressure treatment: a meta-
analysis of observational studies. Europace 2014;16:1309–1314.
[313] Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP,
Erdmann E et al. Adaptive Servo-Ventilation for Central Sleep Apnea in
Systolic Heart Failure. N Engl J Med 2015;373:1095–1105.
[314] Bitter T, Nolker G, Vogt J, Prinz C, Horstkotte D, Oldenburg O.
Predictors of recurrence in patients undergoing cryoballoon ablation
for treatment of atrial fibrillation: the independent role of sleep-
disordered breathing. J Cardiovasc Electrophysiol 2012;23:18–25.
[315] Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of
obstructive sleep apnea as predictor of atrial fibrillation recurrence after
catheter ablation. Am J Cardiol 2011;108:47–51.
[316] Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke
prevention in atrial fibrillation patients with chronic kidney disease. Can
J Cardiol 2013;29:S71–78.
[317] Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P,
Valdes M et al. Renal impairment in a "real-life" cohort of anticoagulated
patients with atrial fibrillation (implications for thromboembolism and
bleeding). Am J Cardiol 2013;111:1159–1164.
[318] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A
et al. RE-LY Steering Committee and Investigators. Dabigatran versus war-
farin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.
[319] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M
et al. ARISTOTLE Committees and Investigators. Apixaban versus war-
farin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.
[320] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al.
ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular
atrial fibrillation. N Engl J Med 2011;365:883–891.
[321] Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL
et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl
J Med 2013;369:2093–2104.
[322] Page K, Marwick TH, Lee R, Grenfell R, Abhayaratna WP, Aggarwal A
et al. A systematic approach to chronic heart failure care: a consensus
statement. Med J Aust 2014;201:146–150.
[323] Stock S, Pitcavage JM, Simic D, Altin S, Graf C, Feng W. Chronic care model
strategies in the United States and Germany deliver patient-centered, high-
quality diabetes care. Health Aff (Millwood) 2014;33:1540–1548.
[324] Lundstrom H, Siersma V, Nielsen AB, Brodersen J, Reventlow S,
Andersen PK. The effectiveness of structured personal care of type 2 dia-
betes on recurrent outcomes: a 19 year follow-up of the study Diabetes
Care in General Practice (DCGP). Diabetologia 2014;57:1119–1123.
[325] Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ et al. A
proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert
programmes as a way to structure daily practice. Eur Heart J 2013;34:
2725–2730.
[326] Wagner EH, Austin BT, Von Korff M. Organizing care for patients with
chronic illness. Milbank Q 1996;74:511–544.
[327] Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A et al.
Euro Heart Survey Investigators. Guideline-adherent antithrombotic
treatment is associated with improved outcomes compared with under-
treatment in high-risk patients with atrial fibrillation. The Euro Heart
Survey on Atrial Fibrillation. Am Heart J 2007;153:1006–1012.
[328] Nuno R, Coleman K, Bengoa R, Sauto R. Integrated care for chronic con-
ditions: the contribution of the ICCC Framework. Health Policy 2012;
105:55–64.
[329] Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A et al.
Impact of the type of centre on management of AF patients: surprising
evidence for differences in antithrombotic therapy decisions. Thromb
Haemost 2011;105:1010–1023.
[330] Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R et al.
Nurse-led care vs. usual care for patients with atrial fibrillation: results of
a randomized trial of integrated chronic care vs. routine clinical care in
ambulatory patients with atrial fibrillation. Eur Heart J 2012;33:
2692–2699.
[331] Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H. Cost-effective-
ness of a specialized atrial fibrillation clinic vs. usual care in patients
with atrial fibrillation. Europace 2013;15:1128–1135.
[332] Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C et al.
Standard versus atrial fibrillation-specific management strategy (SAFETY)
to reduce recurrent admission and prolong survival: pragmatic, multi-
centre, randomised controlled trial. Lancet 2015;385:775–784.
[333] Tran HN, Tafreshi J, Hernandez EA, Pai SM, Torres VI, Pai RG. A multidis-
ciplinary atrial fibrillation clinic. Curr Cardiol Rev 2013;9:55–62.
[334] Conti A, Canuti E, Mariannini Y, Viviani G, Poggioni C, Boni V et al.
Clinical management of atrial fibrillation: early interventions,
e70 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
observation, and structured follow-up reduce hospitalizations. Am J
Emerg Med 2012;30:1962–1969.
[335] Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S et al.
An Integrated Management Approach to Atrial Fibrillation. J Am Heart
Assoc 2016;5:e002950.
[336] Peterson ED, Ho PM, Barton M, Beam C, Burgess LH, Casey DE Jr. et al.
ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician-Patient Shared
Accountability in Performance Measures: A Report of the American
College of Cardiology/American Heart Association Task Force on
Performance Measures. Circulation 2014;130:1984–1994.
[337] Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills
MT et al. Cardiac tachyarrhythmias and patient values and preferences
for their management: the European Heart Rhythm Association (EHRA)
consensus document endorsed by the Heart Rhythm Society (HRS), Asia
Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana
de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2015;
17:1747–1769.
[338] Hendriks JM, de Wit R, Vrijhoef HJ, Tieleman RG, Crijns HJ. An inte-
grated chronic care program for patients with atrial fibrillation: study
protocol and methodology for an ongoing prospective randomised
controlled trial. Int J Nurs Stud 2010;47:1310–1316.
[339] Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M et al. EACVI/
EHRA Expert Consensus Document on the role of multi-modality imag-
ing for the evaluation of patients with atrial fibrillation. Eur Heart J
Cardiovasc Imaging 2016;17:355–383.
[340] Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al.
Recommendations for cardiac chamber quantification by echocardiog-
raphy in adults: an update from the american society of echocardiogra-
phy and the European association of cardiovascular imaging. Eur Heart J
Cardiovasc Imaging 2015;16:233–271.
[341] Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley
RR et al. High-sensitivity cardiac troponin T and the risk of incident
atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.
Am Heart J 2015;169:31–38.
[342] Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju
P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation.
Circulation 2003;108:3006–3010.
[343] Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C,
Gottdiener JS. N-terminal pro-B-type natriuretic peptide is a major pre-
dictor of the development of atrial fibrillation: the Cardiovascular
Health Study. Circulation 2009;120:1768–1774.
[344] Bartel T, Erbel R. Acute Trial Investigators. Transoesophageal echocar-
diography for immediate and safe cardioversion in patients with atrial
fibrillation. Eur Heart J 2001;22:2041–2044.
[345] Mahnkopf C, Mitlacher M, Brachmann J. [Relevance of magnetic reso-
nance imaging for catheter ablation of atrial fibrillation].
Herzschrittmacherther Elektrophysiol 2014;25:252–257.
[346] Haemers P, Claus P, Willems R. The use of cardiac magnetic resonance
imaging in the diagnostic workup and treatment of atrial fibrillation.
Cardiol Res Pract 2012;2012:658937.
[347] Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL et al. Diffuse
ventricular fibrosis in atrial fibrillation: noninvasive evaluation and rela-
tionships with aging and systolic dysfunction. J Am Coll Cardiol 2012;60:
2402–2408.
[348] Lewalter T, Ibrahim R, Albers B, Camm AJ. An update and current expert
opinions on percutaneous left atrial appendage occlusion for stroke
prevention in atrial fibrillation. Europace 2013;15:652–656.
[349] Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al.
Outcome parameters for trials in atrial fibrillation: executive summary:
Recommendations from a consensus conference organized by the
German Atrial Fibrillation Competence NETwork (AFNET) and the
European Heart Rhythm Association (EHRA). Eur Heart J 2007;28:
2803–2817.
[350] Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P,
Charles C et al. Values and preferences in oral anticoagulation in
patients with atrial fibrillation, physicians’ and patients’ perspectives:
protocol for a two-phase study. BMC Health Serv Res 2008;8:221.
[351] Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J et al.
Contemporary management of atrial fibrillation: what can clinical regis-
tries tell us about stroke prevention and current therapeutic
approaches? J Am Heart Assoc 2014;3:e001179.
[352] Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane
DA. Dabigatran adherence in atrial fibrillation patients during the first
year after diagnosis: a nationwide cohort study. J Thromb Haemost
2015;13:495–504.
[353] Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin
for preventing stroke in patients with atrial fibrillation. Ann Intern Med
2007;147:590–592.
[354] Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al.
AVERROES Steering Committee Investigators. Apixaban in patients with
atrial fibrillation. N Engl J Med 2011;364:806–817.
[355] Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 Survey
of Atrial Fibrillation and Stroke: Gaps in Knowledge and Perspective,
Opportunities for Improvement. Heart Rhythm 2015;12:e105–113.
[356] Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ,
Schmitt J et al. Differences among western European countries in anti-
coagulation management of atrial fibrillation. Data from the PREFER IN
AF registry. Thromb Haemost 2014;111:833–841.
[357] O’Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR et al.
Physician practices regarding contraindications to oral anticoagulation
in atrial fibrillation: findings from the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J
2014;167:601–609.e1.
[358] Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N.
Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ
Cardiovasc Qual Outcomes 2010;3:624–631.
[359] Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y et al. Higher persis-
tence in newly diagnosed nonvalvular atrial fibrillation patients treated
with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:
567–574.
[360] Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J. Risk of falls
and major bleeds in patients on oral anticoagulation therapy. Am J Med
2012;125:773–778.
[361] Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrom-
botic therapy for elderly patients with atrial fibrillation who are at risk
for falls. Arch Intern Med 1999;159:677–685.
[362] Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY. BAFTA
investigators, Midland Research Practices Network (MidReC). Warfarin
versus aspirin for stroke prevention in an elderly community population
with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of
the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:
493–503.
[363] Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY et al.
AVERROES Steering Committee and Investigators. Apixaban versus
aspirin in patients with atrial fibrillation and previous stroke or transient
ischaemic attack: a predefined subgroup analysis from AVERROES, a
randomised trial. Lancet Neurol 2012;11:225–231.
[364] The SPAF III Writing Committee for the Stroke Prevention in Atrial
Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at
low risk of stroke during treatment with aspirin: Stroke Prevention in
Atrial Fibrillation III Study. JAMA 1998;279:1273–1277.
[365] Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ.
Validation of clinical classification schemes for predicting stroke:
results from the National Registry of Atrial Fibrillation. JAMA 2001;285:
2864–2870.
[366] van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL
et al. A clinical prediction rule to identify patients with atrial fibrillation
and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:
936–943.
[367] Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB et al. A
risk score for predicting stroke or death in individuals with new-onset
atrial fibrillation in the community: the Framingham Heart Study. JAMA
2003;290:1049–1056.
[368] Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk
stratification for predicting stroke and thromboembolism in atrial fibril-
lation using a novel risk factor-based approach: the euro heart survey
on atrial fibrillation. Chest 2010;137:263–272.
[369] Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. ESC
Committee for Practice Guidelines, European Heart Rhythm
Association, European Association for Cardio-Thoracic Surgery.
Guidelines for the management of atrial fibrillation: the Task Force for
the Management of Atrial Fibrillation of the European Society of
Cardiology (ESC). Europace 2010;12:1360–1420.
[370] Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, Camm AJ.
Atrial fibrillation guidelines across the Atlantic: a comparison of the cur-
rent recommendations of the European Society of Cardiology/European
Heart Rhythm Association/European Association of Cardiothoracic
Surgeons, the American College of Cardiology Foundation/American
Heart Association/Heart Rhythm Society, and the Canadian
Cardiovascular Society. Eur Heart J 2013;34:1471–1474.













[371] Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J
et al. Validation of risk stratification schemes for predicting stroke and
thromboembolism in patients with atrial fibrillation: nationwide cohort
study. BMJ 2011;342:d124.
[372] Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW et al. Should atrial
fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc
score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;
65:635–642.
[373] Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin,
or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk fac-
tor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:
1385–1394.
[374] Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F
et al. Oral Anticoagulation and the Risk of Stroke or Death in Patients
With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire
Valley Atrial Fibrillation Project. Chest 2016;149:960–968.
[375] Joundi RA, Cipriano LE, Sposato LA, Saposnik G. Stroke Outcomes
Research Working Group. Ischemic Stroke Risk in Patients With Atrial
Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and
Meta-Analysis. Stroke 2016;47:1364–1367.
[376] Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in
patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am
Coll Cardiol 2015;65:225–232.
[377] Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation
patients with none or one additional risk factor of the CHA2DS2-VASc
score. A comprehensive net clinical benefit analysis for warfarin, aspirin,
or no therapy. Thromb Haemost 2015;114:826–834.
[378] Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C,
Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a
nationwide cohort study. J Thromb Haemost 2012;10:1745–1751.
[379] Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for
stroke and thromboembolism in patients with atrial fibrillation? A sys-
tematic review and meta-analysis. QJM 2014;107:955–967.
[380] Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser
SH et al. Cardiac biomarkers are associated with an increased risk of
stroke and death in patients with atrial fibrillation: a Randomized
Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
Circulation 2012;125:1605–1616.
[381] Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C,
Ezekowitz J et al. N-terminal pro-B-type natriuretic peptide for risk
assessment in patients with atrial fibrillation: insights from the
ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With
Atrial Fibrillation). J Am Coll Cardiol 2013;61:2274–2284.
[382] Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM
et al. ARISTOTLE and STABILITY Investigators. The ABC (age, bio-
markers, clinical history) stroke risk score: a biomarker-based risk
score for predicting stroke in atrial fibrillation. Eur Heart J 2016;37:
1582–1590.
[383] Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW.
Clinical classification schemes for predicting hemorrhage: results from
the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:
713–719.
[384] Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel
user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding
in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:
1093–1100.
[385] Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N.
A new risk scheme to predict warfarin-associated hemorrhage: The
ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J
Am Coll Cardiol 2011;58:395–401.
[386] Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes
for ischaemic stroke and bleeding in 182 678 patients with atrial fibrilla-
tion: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:
1500–1510.
[387] Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW
et al. ARISTOTLE and RE-LY Investigators. The novel biomarker-based
ABC (age, biomarkers, clinical history)-bleeding risk score for patients
with atrial fibrillation: a derivation and validation study. Lancet 2016;
387:2302–2311.
[388] O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE et al.
The ORBIT bleeding score: a simple bedside score to assess bleeding
risk in atrial fibrillation. Eur Heart J 2015;36:3258–3264.
[389] Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an
updated systematic review and performance analysis of clinical predic-
tion rules. Ann Hematol 2011;90:1191–1200.
[390] Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C
et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: compar-
ison of two established bleeding prediction schemes in a nationwide
cohort. J Thromb Haemost 2011;9:1460–1467.
[391] Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of
risk stratification schemes for stroke in 79,884 atrial fibrillation patients
in general practice. J Thromb Haemost 2011;9:39–48.
[392] Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes
M et al. The HAS-BLED score has better prediction accuracy for major
bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated
patients with atrial fibrillation. J Am Coll Cardiol 2013;62:2199–2204.
[393] Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna
M et al. ARISTOTLE Investigators. Growth differentiation factor 15, a
marker of oxidative stress and inflammation, for risk assessment in
patients with atrial fibrillation: insights from the Apixaban for Reduction
in Stroke and Other Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE) trial. Circulation 2014;130:1847–1858.
[394] Raunso J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM et al.
Increased short-term risk of thrombo-embolism or death after interrup-
tion of warfarin treatment in patients with atrial fibrillation. Eur Heart J
2012;33:1886–1892.
[395] Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson
PJ. Safety and efficacy of well managed warfarin. A report from the
Swedish quality register Auricula. Thromb Haemost 2015;113:
1370–1377.
[396] Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR,
Levenson M et al. Cardiovascular, bleeding, and mortality risks in elderly
medicare patients treated with dabigatran or warfarin for nonvalvular
atrial fibrillation. Circulation 2015;131:157–164.
[397] Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality
of anticoagulation control among patients with atrial fibrillation on war-
farin: the SAMe-TT(2)R(2) score. Chest 2013;144:1555–1563.
[398] Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the
SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically
relevant bleeding, and mortality in patients with atrial fibrillation. Chest
2014;146:719–726.
[399] Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V. SAMe-
TT2R2 score, time in therapeutic range, and outcomes in anticoagulated
patients with atrial fibrillation. Am J Med 2014;127:1083–1088.
[400] Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP,
Mack MJ et al. RE-ALIGN Investigators. Dabigatran versus warfarin in
patients with mechanical heart valves. N Engl J Med 2013;369:
1206–1214.
[401] Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP
et al. Non-vitamin K antagonist oral anticoagulation agents in anticoa-
gulant naive atrial fibrillation patients: Danish nationwide descriptive
data 2011–2013. Europace 2015;17:187–193.
[402] Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM
et al. Major bleeding in patients with atrial fibrillation receiving apixa-
ban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation): Predictors,
Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014;63:
2141–2147.
[403] Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A
et al. Bleeding during treatment with aspirin versus apixaban in patients
with atrial fibrillation unsuitable for warfarin: the apixaban versus acetyl-
salicylic acid to prevent stroke in atrial fibrillation patients who have
failed or are unsuitable for vitamin K antagonist treatment (AVERROES)
trial. Stroke 2012;43:3291–3297.
[404] Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L.
Randomized Evaluation of Long-Term Anticoagulation Therapy
Investigators. Newly identified events in the RE-LY trial. N Engl J Med
2010;363:1875–1876.
[405] Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF
et al. Association between edoxaban dose, concentration, anti-Factor Xa
activity, and outcomes: an analysis of data from the randomised,
double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288–2295.
[406] Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C
et al. Rates, management, and outcome of rivaroxaban bleeding in
daily care: results from the Dresden NOAC registry. Blood 2014;124:
955–962.
[407] Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al.
XANTUS Investigators. XANTUS: a real-world, prospective, observational
study of patients treated with rivaroxaban for stroke prevention in atrial
fibrillation. Eur Heart J 2016;37:1145–1153.
e72 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[408] Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG
et al. RE-LY investigators. Efficacy and safety of dabigatran compared
with warfarin at different levels of international normalised ratio control
for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Lancet 2010;376:975–983.
[409] Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE
et al. ROCKET AF Investigators. Relationship between time in thera-
peutic range and comparative treatment effect of rivaroxaban and war-
farin: results from the ROCKET AF trial. J Am Heart Assoc 2014;3:
e000521.
[410] Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA et al. Stroke
and bleeding in atrial fibrillation with chronic kidney disease. N Engl J
Med 2012;367:625–635.
[411] Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip
GY. Risk of stroke or systemic embolism in atrial fibrillation patients
treated with warfarin: A systematic review and meta-analysis. Stroke
2013;44:1329–1336.
[412] Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrilla-
tion patients with moderate chronic kidney disease. Clin J Am Soc
Nephrol 2011;6:2599–2604.
[413] Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in
patients with atrial fibrillation and renal failure: the Swedish Atrial
Fibrillation Cohort study. Eur Heart J 2014:36:297–306.
[414] Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M et al. The
association between kidney function and major bleeding in older adults
with atrial fibrillation starting warfarin treatment: population based
observational study. BMJ 2015;350:h246.
[415] Del-Carpio Munoz F, Gharacholou SM, Munger TM, Friedman PA,
Asirvatham SJ, Packer DL. Meta-Analysis of Renal Function on the Safety
and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation. Am J
Cardiol 2016;117:69–75.
[416] Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W
et al. Updated European Heart Rhythm Association Practical Guide on
the use of non-vitamin K antagonist anticoagulants in patients with
non-valvular atrial fibrillation. Europace 2015;17:1467–1507.
[417] Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase
CM. Systematic review and meta-analysis of incidence, prevalence and
outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial
Transplant 2012;27:3816–3822.
[418] Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke pre-
vention in atrial fibrillation: implications for thromboprophylaxis and
bleeding risk. J Am Coll Cardiol 2011;57:1339–1348.
[419] Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB et al.
Atrial fibrillation in hemodialysis patients: clinical features and associa-
tions with anticoagulant therapy. Kidney Int 2010;77:1098–1106.
[420] Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates
with increased risk for stroke in hemodialysis patients with atrial fibrilla-
tion. J Am Soc Nephrol 2009;20:2223–2233.
[421] Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and
safety of warfarin initiation in older hemodialysis patients with incident
atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662–2668.
[422] Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ,
Rahme E et al. Warfarin use and the risk for stroke and bleeding in
patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:
1196–1203.
[423] Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K
et al. Net clinical benefit of antithrombotic therapy in patients with
atrial fibrillation and chronic kidney disease: a nationwide observational
cohort study. J Am Coll Cardiol 2014;64:2471–2482.
[424] Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran
and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Circulation 2015;131:972–979.
[425] Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom
JW et al. Efficacy and safety of dabigatran compared with warfarin in
relation to baseline renal function in patients with atrial fibrillation: a
RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy)
trial analysis. Circulation 2014;129:961–970.
[426] Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al.
Prevention of stroke and systemic embolism with rivaroxaban com-
pared with warfarin in patients with non-valvular atrial fibrillation and
moderate renal impairment. Eur Heart J 2011;32:2387–2394.
[427] Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M
et al. Efficacy of apixaban when compared with warfarin in relation to
renal function in patients with atrial fibrillation: insights from the
ARISTOTLE trial. Eur Heart J 2012;33:2821–2830.
[428] Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention
in Atrial Fibrillation Study. Final results. Circulation 1991;84:527–539.
[429] Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML et al.
Risks of thromboembolism and bleeding with thromboprophylaxis in
patients with atrial fibrillation: A net clinical benefit analysis using a ‘real
world’ nationwide cohort study. Thromb Haemost 2011;106:739–749.
[430] Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients
do not benefit from acetylsalicylic acid. Europace 2014;16:631–638.
[431] ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J,
Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus
aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrilla-
tion Clopidogrel Trial with Irbesartan for prevention of Vascular Events
(ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–1912.
[432] Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG
et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplate-
let therapy in atrial fibrillation depends on the quality of international nor-
malized ratio control achieved by centers and countries as measured by
time in therapeutic range. Circulation 2008;118:2029–2037.
[433] Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S.
ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients
with atrial fibrillation. N Engl J Med 2009;360:2066–2078.
[434] van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD et al.
Effect of age on stroke prevention therapy in patients with atrial fibrilla-
tion: the atrial fibrillation investigators. Stroke 2009;40:1410–1416.
[435] Olesen KH. The natural history of 271 patients with mitral stenosis
under medical treatment. Br Heart J 1962;24:349–357.
[436] Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A.
NASPEAF Investigators. Comparative effects of antiplatelet, anticoagu-
lant, or combined therapy in patients with valvular and nonvalvular
atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol
2004;44:1557–1566.
[437] Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis
without surgery: ten- and twenty-year perspectives. Ann Intern Med
1960;52:741–749.
[438] Wilson JK, Greenwood WF. The natural history of mitral stenosis. Can
Med Assoc J 1954;71:323–331.
[439] Cannegieter SC, van der Meer FJ, Briet E, Rosendaal FR. Warfarin and
aspirin after heart-valve replacement. N Engl J Med 1994;330:507–508;
author reply 508-509.
[440] Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH. Predictors of sys-
temic embolism in patients with mitral stenosis. A prospective study.
Ann Intern Med 1998;128:885–889.
[441] Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P et al.
Anticoagulation control and prediction of adverse events in patients
with atrial fibrillation: a systematic review. Circ Cardiovasc Qual
Outcomes 2008;1:84–91.
[442] Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb
JM. Warfarin treatment in patients with atrial fibrillation: observing out-
comes associated with varying levels of INR control. Thromb Res 2009;
124:37–41.
[443] Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of
stroke and mortality associated with suboptimal anticoagulation in atrial
fibrillation patients. Thromb Haemost 2011;106:968–977.
[444] De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H,
Bachmann F et al. Vitamin K antagonists in heart disease: current status
and perspectives (Section III). Position paper of the ESC Working Group
on Thrombosis—Task Force on Anticoagulants in Heart Disease. Thromb
Haemost 2013;110:1087–1107.
[445] Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M
et al. Concomitant use of antiplatelet therapy with dabigatran or war-
farin in the Randomized Evaluation of Long-Term Anticoagulation
Therapy (RE-LY) trial. Circulation 2013;127:634–640.
[446] Bajaj NS, Parashar A, Agarwal S, Sodhi N, Poddar KL, Garg A et al.
Percutaneous left atrial appendage occlusion for stroke prophylaxis in
nonvalvular atrial fibrillation: a systematic review and analysis of obser-
vational studies. JACC Cardiovasc Interv 2014;7:296–304.
[447] Lewalter T, Kanagaratnam P, Schmidt B, Rosenqvist M, Nielsen-Kudsk
JE, Ibrahim R et al. Ischaemic stroke prevention in patients with atrial
fibrillation and high bleeding risk: opportunities and challenges for per-
cutaneous left atrial appendage occlusion. Europace 2014;16:626–630.
[448] Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C. EHRA/
EAPCI expert consensus statement on catheter-based left atrial append-
age occlusion. Europace 2014;16:1397–1416.
[449] Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK et al.
Prospective randomized evaluation of the Watchman Left Atrial













Appendage Closure device in patients with atrial fibrillation versus
long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;
64:1–12.
[450] Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M et al.
Percutaneous closure of the left atrial appendage versus warfarin ther-
apy for prevention of stroke in patients with atrial fibrillation: a rando-
mised non-inferiority trial. Lancet 2009;374:534–542.
[451] Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K et al.
Percutaneous left atrial appendage closure for stroke prophylaxis in
patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF
(Watchman Left Atrial Appendage System for Embolic Protection in
Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720–729.
[452] Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P et al.
PROTECT AF Steering Committee and Investigators. Percutaneous left
atrial appendage closure vs warfarin for atrial fibrillation: a randomized
clinical trial. JAMA 2014;312:1988–1998.
[453] Holmes DR Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H et al. Left
Atrial Appendage Closure as an Alternative to Warfarin for Stroke
Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll
Cardiol 2015;65:2614–2623.
[454] Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J
et al. Left atrial appendage closure with the Watchman device in
patients with a contraindication for oral anticoagulation: the ASAP study
(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage
Closure Technology). J Am Coll Cardiol 2013;61:2551–2556.
[455] Santoro G, Meucci F, Stolcova M, Rezzaghi M, Mori F, Palmieri C et al.
Percutaneous left atrial appendage occlusion in patients with non-
valvular atrial fibrillation: implantation and up to four years follow-up of
the AMPLATZER Cardiac Plug. EuroIntervention 2016;11:1188–1194.
[456] Badheka AO, Chothani A, Mehta K, Patel NJ, Deshmukh A, Hoosien M
et al. Utilization and adverse outcomes of percutaneous left atrial
appendage closure for stroke prevention in atrial fibrillation in the
United States: influence of hospital volume. Circ Arrhythm
Electrophysiol 2015;8:42–48.
[457] Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstrom-
Lundqvist C. Left atrial appendage closure-indications, techniques, and
outcomes: results of the European Heart Rhythm Association Survey.
Europace 2015;17:642–646.
[458] Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A et al.
Early safety and efficacy of percutaneous left atrial appendage suture
ligation: results from the U.S. transcatheter LAA ligation consortium. J
Am Coll Cardiol 2014;64:565–572.
[459] Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E et al.
EWOLUTION investigators. Implant success and safety of left atrial
appendage closure with the WATCHMAN device: peri-procedural out-
comes from the EWOLUTION registry. Eur Heart J;doi:10.1093/
eurheartj/ehv730. Published online ahead of print27 January 2016.
[460] Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J
et al. Anticoagulant reversal, blood pressure levels, and anticoagulant
resumption in patients with anticoagulation-related intracerebral hem-
orrhage. JAMA 2015;313:824–836.
[461] Budera P, Straka Z, Osmancik P, Vanek T, Jelinek S, Hlavicka J et al.
Comparison of cardiac surgery with left atrial surgical ablation vs. car-
diac surgery without atrial ablation in patients with coronary and/or
valvular heart disease plus atrial fibrillation: final results of the PRAGUE-
12 randomized multicentre study. Eur Heart J 2012;33:2644–2652.
[462] Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH et al.
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized
controlled pilot study of left atrial appendage occlusion during coronary
bypass surgery in patients at risk for stroke. Am Heart J 2005;150:
288–293.
[463] Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD.
Surgical left atrial appendage occlusion during cardiac surgery for
patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg
2015;47:847–854.
[464] Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R et al.
Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol 2013;
29:1443–1447.
[465] Aryana A, Singh SK, Singh SM, GearoidO’Neill P, Bowers MR, Allen SL
et al. Association between incomplete surgical ligation of left atrial
appendage and stroke and systemic embolization. Heart Rhythm 2015;
12:1431–1437.
[466] Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine
P et al. CTSN Investigators. Surgical ablation of atrial fibrillation during
mitral-valve surgery. N Engl J Med 2015;372:1399–1409.
[467] Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A et al. Rationale
and design of the Left Atrial Appendage Occlusion Study (LAAOS) III.
Ann Cardiothorac Surg 2014;3:45–54.
[468] Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M
et al. Atrial fibrillation catheter ablation versus surgical ablation treat-
ment (FAST): a 2-center randomized clinical trial. Circulation 2012;125:
23–30.
[469] Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S et al.
Risk factors, outcome, and treatment in subtypes of ischemic stroke: the
German stroke data bank. Stroke 2001;32:2559–2566.
[470] Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic
attack: a systematic review and meta-analysis. Lancet Neurol 2007;6:
1063–1072.
[471] Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E et al.
Stroke Thrombolysis Trialists’ Collaborative Group. Effect of treatment
delay, age, and stroke severity on the effects of intravenous thromboly-
sis with alteplase for acute ischaemic stroke: a meta-analysis of individ-
ual patient data from randomised trials. Lancet 2014;384:1929–1935.
[472] Diener HC, Stanford S, Abdul-Rahim A, Christensen L, Hougaard KD,
Bakhai A et al. Anti-thrombotic therapy in patients with atrial
fibrillation and intracranial hemorrhage. Expert Rev Neurother 2014;14:
1019–1028.
[473] Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute
stroke in patients taking novel oral anticoagulants. Int J Stroke 2014;9:
627–632.
[474] Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM et al.
Risks of intracranial hemorrhage among patients with acute ischemic
stroke receiving warfarin and treated with intravenous tissue plasmino-
gen activator. JAMA 2012;307:2600–2608.
[475] Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein
RA et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015;373:
511–520.
[476] Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J
et al. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-
analysis. JAMA 2015;314:1832–1843.
[477] Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoa-
gulant treatment in acute cardioembolic stroke: a meta-analysis of
randomized controlled trials. Stroke 2007;38:423–430.
[478] Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J
et al. European Heart Rhythm Association Practical Guide on the use of
new oral anticoagulants in patients with non-valvular atrial fibrillation.
Europace 2013;15:625–651.
[479] Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S
et al. Dabigatran compared with warfarin in patients with atrial fibrilla-
tion and previous transient ischaemic attack or stroke: a subgroup anal-
ysis of the RE-LY trial. Lancet Neurol 2010;9:1157–1163.
[480] Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A
et al. ROCKET AF Steering Committee Investigators. Rivaroxaban com-
pared with warfarin in patients with atrial fibrillation and previous
stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Lancet Neurol 2012;11:315–322.
[481] Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L
et al. ARISTOTLE Committees and Investigators. Apixaban compared
with warfarin in patients with atrial fibrillation and previous stroke or
transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
Lancet Neurol 2012;11:503–511.
[482] Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-
K-antagonist oral anticoagulants in patients with atrial fibrillation and pre-
vious stroke or transient ischemic attack: a systematic review and meta-
analysis of randomized controlled trials. Stroke 2012;43:3298–3304.
[483] Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after
warfarin-associated cerebral haemorrhage in patients with atrial fibrilla-
tion? Thromb Haemost 2014;111:14–18.
[484] Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip
GY. Restarting Anticoagulant Treatment After Intracranial Hemorrhage
in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke,
Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 2015;
132:517–525.
[485] Weber R, Brenck J, Diener HC. Antiplatelet therapy in cerebrovascular
disorders. Handb Exp Pharmacol 2012:519–546.
[486] Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A
et al. Risks and benefits of combining aspirin with anticoagulant therapy
in patients with atrial fibrillation: an exploratory analysis of stroke pre-
vention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF)
trials. Am Heart J 2006;152:967–973.
e74 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[487] Yung D, Kapral MK, Asllani E, Fang J, Lee DS. Investigators of the
Registry of the Canadian Stroke Network. Reinitiation of anticoagulation
after warfarin-associated intracranial hemorrhage and mortality risk: the
Best Practice for Reinitiating Anticoagulation Therapy After Intracranial
Bleeding (BRAIN) study. Can J Cardiol 2012;28:33–39.
[488] Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients
with atrial fibrillation receiving vitamin K antagonists: a systematic review
of randomized and observational studies. Europace 2013;15:787–797.
[489] Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al.
2013 ESH/ESC guidelines for the management of arterial hypertension:
the Task Force for the Management of Arterial Hypertension of the
European Society of Hypertension (ESH) and of the European Society of
Cardiology (ESC). Eur Heart J 2013;34:2159–2219.
[490] Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS,
Oldgren J et al. Risk of bleeding with 2 doses of dabigatran compared
with warfarin in older and younger patients with atrial fibrillation: an
analysis of the randomized evaluation of long-term anticoagulant ther-
apy (RE-LY) trial. Circulation 2011;123:2363–2372.
[491] Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC
et al. ROCKET AF Investigators. Factors associated with major bleeding
events: insights from the ROCKET AF trial (rivaroxaban once-daily oral
direct factor Xa inhibition compared with vitamin K antagonism for pre-
vention of stroke and embolism trial in atrial fibrillation). J Am Coll
Cardiol 2014;63:891–900.
[492] Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointes-
tinal bleeding associated with oral anticoagulants: population based ret-
rospective cohort study. BMJ 2015;350:h1585.
[493] Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W.
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxa-
ban, and warfarin: population based cohort study. BMJ 2015;350:h1857.
[494] Bjo¨rck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Sj€alander A.
Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
JAMA Cardiology 2016;1:172–180.
[495] Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation
for stroke prevention in elderly patients with atrial fibrillation, including
those with falls and/or early-stage dementia: a single-center, retrospective,
observational study. Am J Geriatr Pharmacother 2009;7:159–166.
[496] Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history
of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial
Fibrillation Project. Am J Med 2014;127:972–978.
[497] Palareti G, Cosmi B. Bleeding with anticoagulation therapy – who is at
risk, and how best to identify such patients. Thromb Haemost 2009;102:
268–278.
[498] van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de
Boer A et al. Genotype-guided dosing of coumarin derivatives: the
European pharmacogenetics of anticoagulant therapy (EU-PACT) trial
design. Pharmacogenomics 2009;10:1687–1695.
[499] International Warfarin Pharmacogenetics Consortium, Klein TE, Altman
RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al. Estimation of the war-
farin dose with clinical and pharmacogenetic data. N Engl J Med 2009;
360:753–764.
[500] Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A
et al. Genetic determinants of response to warfarin during initial antico-
agulation. N Engl J Med 2008;358:999–1008.
[501] Tang T, Liu J, Zuo K, Cheng J, Chen L, Lu C et al. Genotype-Guided
Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized
Controlled Trials. J Cardiovasc Pharmacol Ther 2015;20:387–394.
[502] Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS
et al. BRIDGE Investigators. Perioperative Bridging Anticoagulation in
Patients with Atrial Fibrillation. N Engl J Med 2015;373:823–833.
[503] Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement
of the anticoagulant activity of the non-vitamin K oral anticoagulants. J
Am Coll Cardiol 2014;64:1128–1139.
[504] Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE et al.
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a
critical appraisal of available evidence and recommendations for clinical
management-a joint position paper of the European Society of
Cardiology Working Group on Cardiovascular Pharmacotherapy and
European Society of Cardiology Working Group on Thrombosis. Eur
Heart J;doi:10.1093/eurheartj/ehv676. Published online ahead of print
24 December 2015.
[505] Hanley JP. Warfarin reversal. J Clin Pathol 2004;57:1132–1139.
[506] Parry-Jones AR, Di Napoli M, Goldstein JN, Schreuder FH, Tetri S,
Tatlisumak T et al. Reversal strategies for vitamin K antagonists in acute
intracerebral hemorrhage. Ann Neurol 2015;78:54–62.
[507] Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug
BA. Four-factor prothrombin complex concentrate versus plasma for
rapid vitamin K antagonist reversal in patients needing urgent surgical
or invasive interventions: a phase 3b, open-label, non-inferiority, rando-
mised trial. Lancet 2015;385:2077–2087.
[508] Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL et al.
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J
Med 2015;373:2413–2424.
[509] Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: cur-
rent status and future potential. Arterioscler Thromb Vasc Biol 2015;35:
1736–1745.
[510] Staerk L, Lip GY, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN et al.
Stroke and recurrent haemorrhage associated with antithrombotic
treatment after gastrointestinal bleeding in patients with atrial fibrilla-
tion: nationwide cohort study. BMJ 2015;351:h5876.
[511] Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a
Cochrane Systematic review. J Hum Hypertens 2005;19:185–196.
[512] Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and
Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention
in Atrial Fibrillation and Secondary Prevention of Venous
Thromboembolism: Systematic Review and Meta-Analysis. Circulation
2015;132:194–204.
[513] Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J et al.
Anticoagulant and antiplatelet therapy use in 426 patients with atrial
fibrillation undergoing percutaneous coronary intervention and stent
implantation implications for bleeding risk and prognosis. J Am Coll
Cardiol 2008;51:818–825.
[514] Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J,
Gadsboll N et al. Risk of bleeding with single, dual, or triple therapy
with warfarin, aspirin, and clopidogrel in patients with atrial fibrilla-
tion. Arch Intern Med 2010;170:1433–1441.
[515] Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen
SL et al. Bleeding after initiation of multiple antithrombotic drugs,
including triple therapy, in atrial fibrillation patients following myocar-
dial infarction and coronary intervention: a nationwide cohort study.
Circulation 2012;126:1185–1193.
[516] Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014
ESC/EACTS Guidelines on myocardial revascularization: The Task Force
on Myocardial Revascularization of the European Society of Cardiology
(ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS). Developed with the special contribution of the European
Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur
Heart J 2014;35:2541–2619.
[517] Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA,
Alonso-Coello P et al. American College of Chest Physicians. Primary
and secondary prevention of cardiovascular disease: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest
2012;141:e637S–668S.
[518] Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marin F, Bhatt DL.
The optimal management of patients on oral anticoagulation under-
going coronary artery stenting. The 10th Anniversary Overview. Thromb
Haemost 2014;112:1080–1087.
[519] Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G. New
oral anticoagulants in addition to single or dual antiplatelet therapy
after an acute coronary syndrome: a systematic review and meta-analy-
sis. Eur Heart J 2013;34:1670–1680.
[520] Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM et al.
Management of antithrombotic therapy in atrial fibrillation patients
presenting with acute coronary syndrome and/or undergoing percuta-
neous coronary or valve interventions: a joint consensus document of
the European Society of Cardiology Working Group on Thrombosis,
European Heart Rhythm Association (EHRA), European Association of
Percutaneous Cardiovascular Interventions (EAPCI) and European
Association of Acute Cardiac Care (ACCA) endorsed by the Heart
Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).
Eur Heart J 2014;35:3155–3179.
[521] Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F
et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in
patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a rando-
mised, double-blind, phase II trial. Lancet 2009;374:29–38.
[522] Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D. Triple
therapy with aspirin, prasugrel, and vitamin K antagonists in patients
with drug-eluting stent implantation and an indication for oral anticoa-
gulation. J Am Coll Cardiol 2013;61:2060–2066.













[523] Jackson LR II, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW et al.
Outcomes of Patients With Acute Myocardial Infarction Undergoing
Percutaneous Coronary Intervention Receiving an Oral Anticoagulant
and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus
Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv
2015;8:1880–1889.
[524] Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL,
Herrman J-P et al. Use of clopidogrel with or without aspirin in patients
taking oral anticoagulant therapy and undergoing percutaneous coro-
nary intervention: an open-label, randomised, controlled trial. Lancet
2013;381:1107–1115.
[525] Braun O€O, Bico B, Chaudhry U, Wagner H, Koul S, Tyden P et al.
Concomitant use of warfarin and ticagrelor as an alternative to triple
antithrombotic therapy after an acute coronary syndrome. Thromb Res
2015;135:26–30.
[526] Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review
of medical heart rate control management. Postgrad Med J 2009;85:
303–312.
[527] Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation.
Cardiol Clin 2004;22:35–45.
[528] Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR
et al. The evidence regarding the drugs used for ventricular rate control.
In. J Fam Practice 2000; 49:47–59.
[529] Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial
fibrillation and flutter: intravenous diltiazem versus intravenous digoxin.
Ann Emerg Med 1997;29:135–140.
[530] Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is supe-
rior to intravenous amiodarone or digoxin for achieving ventricular rate
control in patients with acute uncomplicated atrial fibrillation. Crit Care
Med 2009;37:2174–2179; quiz 2180.
[531] Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS
et al. A randomized, double-blind comparison of intravenous diltiazem
and digoxin for atrial fibrillation after coronary artery bypass surgery.
Am Heart J 1998;135:739–747.
[532] Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C,
Heilbron B et al. Safety and efficiency of calcium channel blockers ver-
sus beta-blockers for rate control in patients with atrial fibrillation and
no acute underlying medical illness. Acad Emerg Med 2013;20:222–230.
[533] Darby AE, Dimarco JP. Management of atrial fibrillation in patients with
structural heart disease. Circulation 2012;125:945–957.
[534] Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998;
89:38–46.
[535] Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-
onset congestive heart failure in postinfarction patients with early
reduction in ejection fraction. The Adverse Experience Committee; and
the Multicenter Diltiazem Postinfarction Research Group. Circulation
1991;83:52–60.
[536] Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amio-
darone for acute heart rate control in the critically ill patient with atrial
tachyarrhythmias. Am J Cardiol 1998;81:594–598.
[537] Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M,
Gschwandtner M et al. Amiodarone versus diltiazem for rate control in
critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:
1149–1153.
[538] Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT. Acute treatment
of recent-onset atrial fibrillation and flutter with a tailored dosing regi-
men of intravenous amiodarone. A randomized, digoxin-controlled
study. Eur Heart J 1995;16:521–528.
[539] National Institute for Health and Care Excellence (NICE) guidelines.
Atrial fibrillation: management. http://www.nice.org.uk/guidance/
cg180/ (5 May 2016).
[540] Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG et al.
Beta-Blockers in Heart Failure Collaborative Group. Effect of age and
sex on efficacy and tolerability of b blockers in patients with heart fail-
ure with reduced ejection fraction: individual patient data meta-analy-
sis. BMJ 2016;353:i1855.
[541] Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M
et al. Comparison of four single-drug regimens on ventricular rate and
arrhythmia-related symptoms in patients with permanent atrial fibrilla-
tion. Am J Cardiol 2013;111:225–230.
[542] Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K.
Calcium channel blockers improve exercise capacity and reduce N-ter-
minal Pro-B-type natriuretic peptide levels compared with beta-
blockers in patients with permanent atrial fibrillation. Eur Heart J 2014;
35:517–524.
[543] Goldberger ZD, Alexander GC. Digitalis use in contemporary clinical
practice: refitting the foxglove. JAMA Intern Med 2014;174:151–154.
[544] The Digitalis Investigation Group. The effect of digoxin on mortality and
morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.
[545] Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW et al.
Effects of digoxin on morbidity and mortality in diastolic heart failure:
the ancillary digitalis investigation group trial. Circulation 2006;114:
397–403.
[546] Ziff OJ, Kotecha D. Digoxin: The good and the bad. Trends in
Cardiovascular Medicine; doi:10.1016/j.tcm.2016.03.011. Published
online ahead of print 30 March 2016.
[547] Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT
et al. Increased mortality associated with digoxin in contemporary
patients with atrial fibrillation: findings from the TREAT-AF study. J Am
Coll Cardiol 2014;64:660–668.
[548] Hallberg P, Lindback J, Lindahl B, Stenestrand U, Melhus H. Digoxin and
mortality in atrial fibrillation: a prospective cohort study. Eur J Clin
Pharmacol 2007;63:959–971.
[549] Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM
et al. Increased mortality among patients taking digoxin—analysis from
the AFFIRM study. Eur Heart J 2013;34:1481–1488.
[550] Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J,
Epstein AE et al. Lack of evidence of increased mortality among patients
with atrial fibrillation taking digoxin: findings from post hoc propensity-
matched analysis of the AFFIRM trial. Eur Heart J 2013;34:1489–1497.
[551] Flory JH, Ky B, Haynes K, S MB, Munson J, Rowan C et al. Observational
cohort study of the safety of digoxin use in women with heart failure.
BMJ Open 2012;2:e000888.
[552] Andrey JL, Romero S, Garcia-Egido A, Escobar MA, Corzo R, Garcia-
Dominguez G et al. Mortality and morbidity of heart failure treated with
digoxin. A propensity-matched study. Int J Clin Pract 2011;65:1250–1258.
[553] Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD
et al. ORBIT-AF Investigators. Digoxin Use and Subsequent Outcomes
Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll
Cardiol 2015;65:2691–2698.
[554] Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG.
Carvedilol alone or in combination with digoxin for the management of
atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;
42:1944–1951.
[555] Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate
control in chronic atrial fibrillation during daily activity and pro-
grammed exercise: a crossover open-label study of five drug regimens. J
Am Coll Cardiol 1999;33:304–310.
[556] Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH et al. Efficacy and
safety of digoxin alone and in combination with low-dose diltiazem or
betaxolol to control ventricular rate in chronic atrial fibrillation. Am J
Cardiol 1995;75:88–90.
[557] Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and
xamoterol on heart rate and exercise tolerance in digitalised patients
with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989;13:1–6.
[558] Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura
K. Rate control and quality of life in patients with permanent atrial fibril-
lation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. Circ J
2006;70:965–970.
[559] ClinicalTrials.gov. Rate Control Therapy Evaluation in Permanent Atrial
Fibrillation (RATE-AF). https://clinicaltrials.gov/ct2/show/NCT02391337
(5 May 2016).
[560] Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings
AM et al. RACE II Investigators. Lenient versus strict rate control in
patients with atrial fibrillation. N Engl J Med 2010;362:1363–1373.
[561] Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM,
Tijssen JG et al. RACE II Investigators. The effect of rate control on qual-
ity of life in patients with permanent atrial fibrillation: data from the
RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J
Am Coll Cardiol 2011;58:1795–1803.
[562] Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B,
Hagens VE. RACE and AFFIRM Investigators. Does intensity of rate-
control influence outcome in atrial fibrillation? An analysis of pooled
data from the RACE and AFFIRM studies. Europace 2006;8:935–942.
[563] Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace
revisited: long term survival and predictors of permanent atrial fibrilla-
tion. Heart 2003;89:1035–1038.
[564] Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M. Ablate
and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT
trial. Europace 2007;9:498–505.
e76 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[565] Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and
sudden death after radiofrequency catheter ablation of the atrioventric-
ular junction. Pacing Clin Electrophysiol 1997;20:343–348.
[566] Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF et al. Effect
of pacing method on risk of sudden death after atrioventricular node
ablation and pacemaker implantation in patients with atrial fibrillation.
Heart Rhythm 2013;10:696–701.
[567] Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry
NK, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-
analysis and systematic review. Circ Arrhythm Electrophysiol 2012;5:
68–76.
[568] Bradley DJ, Shen WK. Overview of management of atrial fibrillation in
symptomatic elderly patients: pharmacologic therapy versus AV node
ablation. Clin Pharmacol Ther 2007;81:284–287.
[569] Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical out-
comes after ablation and pacing therapy for atrial fibrillation : a meta-
analysis. Circulation 2000;101:1138–1144.
[570] Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF et al.
Long-term survival after ablation of the atrioventricular node and
implantation of a permanent pacemaker in patients with atrial fibrilla-
tion. N Engl J Med 2001;344:1043–1051.
[571] Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchroni-
zation therapy an antiarrhythmic therapy for atrial fibrillation? A sys-
tematic review and meta-analysis. Curr Cardiol Rep 2013;15:330.
[572] Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle
N. Effect of cardiac resynchronization on the incidence of atrial fibrilla-
tion in patients with severe heart failure. Circulation 2006;114:18–25.
[573] Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G,
Breithardt OA et al. 2013 ESC Guidelines on cardiac pacing and cardiac
resynchronization therapy: the Task Force on cardiac pacing and
resynchronization therapy of the European Society of Cardiology (ESC).
Developed in collaboration with the European Heart Rhythm
Association (EHRA). Eur Heart J 2013;34:2281–2329.
[574] Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP.
Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of
biventricular vs. right ventricular pacing mode. Eur J Heart Fail 2012;14:
661–667.
[575] Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate,
exercise tolerance and cardiac output in atrial fibrillation: the effects of
treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9:
777–781.
[576] Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings
M et al. RACE II Investigators. Digoxin in patients with permanent atrial
fibrillation: data from the RACE II study. Heart Rhythm 2014;11:
1543–1550.
[577] Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS et al. Comparative
study of efficacy and safety of low-dose diltiazem or betaxolol in combi-
nation with digoxin to control ventricular rate in chronic atrial fibrilla-
tion: randomized crossover study. Int J Cardiol 1995;52:167–174.
[578] Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic
rate versus rhythm-control strategies in atrial fibrillation: an updated
comprehensive review and meta-analysis. PACE 2013;36:122–133.
[579] de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs
rhythm control in patients with atrial fibrillation: a meta-analysis. Arch
Intern Med 2005;165:258–262.
[580] Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J.
Antiarrhythmics for maintaining sinus rhythm after cardioversion of
atrial fibrillation. Cochrane Database Syst Rev 2012;5:CD005049.
[581] Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M et al.
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial
of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913–920.
[582] Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. Rhythm
control versus rate control for atrial fibrillation and heart failure. N Engl
J Med 2008;358:2667–2677.
[583] Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A et al.
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or
flutter. N Engl J Med 2007;357:987–999.
[584] Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U
et al. Short-term versus long-term antiarrhythmic drug treatment after
cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised,
open-label, blinded endpoint assessment trial. Lancet 2012;380:
238–246.
[585] Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G,
Walfridsson H, Kongstad O et al. Radiofrequency ablation as initial ther-
apy in paroxysmal atrial fibrillation. N Engl J Med 2012;367:1587–1595.
[586] Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A
et al. ThermoCool AF Trial Investigators. Comparison of antiarrhythmic
drug therapy and radiofrequency catheter ablation in patients with par-
oxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;
303:333–340.
[587] Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P et al.
Atrial Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation
ablation pilot study: a European Survey on Methodology and results of
catheter ablation for atrial fibrillation conducted by the European Heart
Rhythm Association. Eur Heart J 2014;35:1466–1478.
[588] Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-
Pedersen C. Effect of dronedarone on cardiovascular events in atrial
fibrillation. N Engl J Med 2009;360:668–678.
[589] Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron
EB et al. A comparison of rate control and rhythm control in patients
with atrial fibrillation. N Engl J Med 2002;347:1825–1833.
[590] Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T
et al. Rate Control versus Electrical Cardioversion for Persistent Atrial
Fibrillation Study Group. A comparison of rate control and rhythm con-
trol in patients with recurrent persistent atrial fibrillation. N Engl J Med
2002;347:1834–1840.
[591] Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B,
Kolodziej P. Investigators of the Polish How to Treat Chronic Atrial
Fibrillation Study. Rate control vs rhythm control in patients with nonvalv-
ular persistent atrial fibrillation: the results of the Polish How to Treat
Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476–486.
[592] Kong MH, Shaw LK, O’Connor C, Califf RM, Blazing MA, Al-Khatib SM.
Is rhythm-control superior to rate-control in patients with atrial fibrilla-
tion and diastolic heart failure? Ann Noninvasive Electrocardiol 2010;15:
209–217.
[593] Kotecha D, Kirchhof P. Rate and rhythm control have comparable
effects on mortality and stroke in atrial fibrillation but better data are
needed. Evid Based Med 2014;19:222–223.
[594] ClinicalTrials.gov. Catheter Ablation vs Anti-arrhythmic Drug Therapy
for Atrial Fibrillation Trial (CABANA). https://clinicaltrials.gov/ct2/show/
NCT00911508 (5 May 2016).
[595] Khan IA. Oral loading single dose flecainide for pharmacological cardio-
version of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121–128.
[596] Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G,
Touboul P. Amiodarone versus placebo and class Ic drugs for cardiover-
sion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol
2003;41:255–262.
[597] Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amio-
darone for conversion of atrial fibrillation to sinus rhythm: a meta-anal-
ysis. Arch Intern Med 2003;163:777–785.
[598] Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological
cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;89:
239–248.
[599] Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V et al.
Rapid loading of sotalol or amiodarone for management of recent onset
symptomatic atrial fibrillation: a randomized, digoxin-controlled trial.
Am Heart J 2004;147:E3.
[600] Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA
et al. A randomized trial of prophylactic antiarrhythmic agents (amio-
darone and sotalol) in patients with atrial fibrillation for whom direct
current cardioversion is planned. Am Heart J 2006;151:863.e1–6.
[601] Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL et al.
Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:
1861–1872.
[602] Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S et al.
Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a
phase 3, randomized, placebo-controlled trial. Circulation 2008;117:
1518–1525.
[603] Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ et al.
Vernakalant hydrochloride for the rapid conversion of atrial fibrillation
after cardiac surgery: a randomized, double-blind, placebo-controlled
trial. Circ Arrhythm Electrophysiol 2009;2:652–659.
[604] Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC,
Mangal B. A randomized active-controlled study comparing the efficacy
and safety of vernakalant to amiodarone in recent-onset atrial fibrilla-
tion. J Am Coll Cardiol 2011;57:313–321.
[605] Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H et al.
Systematic review and meta-analysis of the efficacy of cardioversion by
vernakalant and comparators in patients with atrial fibrillation.
Cardiovasc Drugs Ther 2012;26:167–179.













[606] Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III
antiarrhythmic agent, for the termination of sustained atrial fibrillation
or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997;
29:385–390.
[607] Dankner R, Shahar A, Novikov I, Agmon U, Ziv A, Hod H. Treatment of
stable atrial fibrillation in the emergency department: a population-based
comparison of electrical direct-current versus pharmacological cardiover-
sion or conservative management. Cardiology 2009;112:270–278.
[608] Chen WS, Gao BR, Chen WQ, Li ZZ, Xu ZY, Zhang YH et al. Comparison
of pharmacological and electrical cardioversion in permanent atrial
fibrillation after prosthetic cardiac valve replacement: a prospective
randomized trial. J Int Med Res 2013;41:1067–1073.
[609] Gitt AK, Smolka W, Michailov G, Bernhardt A, Pittrow D, Lewalter T.
Types and outcomes of cardioversion in patients admitted to hospital
for atrial fibrillation: results of the German RHYTHM-AF Study. Clin Res
Cardiol 2013;102:713–723.
[610] Cristoni L, Tampieri A, Mucci F, Iannone P, Venturi A, Cavazza M.
Cardioversion of acute atrial fibrillation in the short observation unit:
comparison of a protocol focused on electrical cardioversion with sim-
ple antiarrhythmic treatment. Emerg Med J 2011;28:932–937.
[611] Bellone A, Etteri M, Vettorello M, Bonetti C, Clerici D, Gini G et al.
Cardioversion of acute atrial fibrillation in the emergency department: a
prospective randomised trial. Emerg Med J 2012;29:188–191.
[612] Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martin A et al.
Contemporary real life cardioversion of atrial fibrillation: Results from
the multinational RHYTHM-AF study. Int J Cardiol 2014;172:588–594.
[613] Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA et al.
Overtreatment and undertreatment with anticoagulation in relation to
cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol
2014;113:480–484.
[614] Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T et al.
Flecainide versus ibutilide for immediate cardioversion of atrial fibrilla-
tion of recent onset. Eur Heart J 2004;25:1318–1324.
[615] Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK,
VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibu-
tilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat
Dose Study Investigators. Circulation 1996;94:1613–1621.
[616] Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN.
Vernakalant: conversion of atrial fibrillation in patients with ischemic
heart disease. Int J Cardiol 2013;166:147–151.
[617] Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of
atrial fibrillation with vernakalant: evidence in support of the ESC
Guidelines. Europace 2014;16:162–173.
[618] Simon A, Niederdoeckl J, Skyllouriotis E, Schuetz N, Herkner H, Weiser
C et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in
patients with recent-onset atrial fibrillation: a randomized controlled
trial at the emergency department. Europace;doi:10.1093/europace/
euw052. Published online ahead of print 22 March 2016.
[619] Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E,
Gattermeier M et al. Prospective comparison of flecainide versus sotalol
for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:
1450–1454.
[620] Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L et al.
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-
the-pocket" approach. N Engl J Med 2004;351:2384–2391.
[621] Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.
Systematic review and cost-effectiveness evaluation of ‘pill-in-the-
pocket’ strategy for paroxysmal atrial fibrillation compared to episodic
in-hospital treatment or continuous antiarrhythmic drug therapy.
Health Technol Assess 2010;14:iii–iv, 1–75.
[622] Khan IA. Single oral loading dose of propafenone for pharmacological
cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001;
37:542–547.
[623] Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and
prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial
Investigators. Am J Cardiol 1997;79:418–423.
[624] Hughes C, Sunderji R, Gin K. Oral propafenone for rapid conversion of
recent onset atrial fibrillation—A review. Can J Cardiol 1997;13:839–842.
[625] Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intra-
venous ibutilide vs. propafenone for rapid termination of recent onset
atrial fibrillation. Int J Clin Pract 2005;59:1395–1400.
[626] Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ et al.
Transthoracic cardioversion of atrial fibrillation: comparison of rectilin-
ear biphasic versus damped sine wave monophasic shocks. Circulation
2000;101:1282–1287.
[627] Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH et al.
Anterior-posterior versus anterior-lateral electrode positions for exter-
nal cardioversion of atrial fibrillation: a randomised trial. Lancet 2002;
360:1275–1279.
[628] Kirchhof P, Monnig G, Wasmer K, Heinecke A, Breithardt G, Eckardt L. A
trial of self-adhesive patch electrodes and hand-held paddle electrodes
for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J
2005;26:1292–1297.
[629] Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice.
Heart 2015;101:1526–1530.
[630] Alp N, Rahman S, Bell J, Shahi M. Randomised comparison of antero-
lateral versus antero-posterior paddle positions for DC cardioversion of
persistent atrial fibrillation. Int J Cardiol 2000;75:211–216.
[631] Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion
for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the
SAFE-T trial. Heart Rhythm 2009;6:152–155.
[632] Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN et al. A
randomized placebo-controlled trial of pre-treatment and short- or
long-term maintenance therapy with amiodarone supporting DC cardi-
oversion for persistent atrial fibrillation. Eur Heart J 2004;25:144–150.
[633] Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA.
Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide
pretreatment. N Engl J Med 1999;340:1849–1854.
[634] Mussigbrodt A, John S, Kosiuk J, Richter S, Hindricks G, Bollmann A.
Vernakalant-facilitated electrical cardioversion: comparison of intrave-
nous vernakalant and amiodarone for drug-enhanced electrical cardio-
version of atrial fibrillation after failed electrical cardioversion. Europace
2016;18:51–56.
[635] Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects
of oral propafenone administration before electrical cardioversion of
chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol
1996;28:700–706.
[636] Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of
sinus rhythm with metoprolol CR initiated before cardioversion and
repeated cardioversion of atrial fibrillation: a randomized double-blind
placebo-controlled study. Eur Heart J 2007;28:1351–1357.
[637] Hemels ME, Van Noord T, Crijns HJ, Van Veldhuisen DJ, Veeger NJ,
Bosker HA et al. Verapamil versus digoxin and acute versus routine
serial cardioversion for the improvement of rhythm control for persis-
tent atrial fibrillation. J Am Coll Cardiol 2006;48:1001–1009.
[638] Villani GQ, Piepoli MF, Terracciano C, Capucci A. Effects of diltiazem
pretreatment on direct-current cardioversion in patients with persistent
atrial fibrillation: a single-blind, randomized, controlled study. Am Heart
J 2000;140:e12.
[639] De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F
et al. Pretreatment with verapamil in patients with persistent or chronic
atrial fibrillation who underwent electrical cardioversion. J Am Coll
Cardiol 1999;34:810–814.
[640] The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous
digoxin in acute atrial fibrillation. Results of a randomized, placebo-
controlled multicentre trial in 239 patients. Eur Heart J 1997;18:649–654.
[641] Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H.
Double-blind placebo-controlled trial of aprindine and digoxin for the
prevention of symptomatic atrial fibrillation. Circ J 2002;66:553–556.
[642] Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F.
Thromboembolic complications after cardioversion of acute atrial fibril-
lation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 2013;
62:1187–1192.
[643] Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH
et al. Thromboembolic risk in 16 274 atrial fibrillation patients under-
going direct current cardioversion with and without oral anticoagulant
therapy. Europace 2015;17:18–23.
[644] Schadlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U,
Stellbrink C. Economic evaluation of enoxaparin for anticoagulation in
early cardioversion of persisting nonvalvular atrial fibrillation: a statu-
tory health insurance perspective from Germany. Am J Cardiovasc
Drugs 2007;7:199–217.
[645] Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T,
Meurer J et al. Quality of anticoagulation with unfractionated heparin
plus phenprocoumon for the prevention of thromboembolic complica-
tions in cardioversion for non-valvular atrial fibrillation. Sub-analysis
from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Thromb Res 2007;119:27–34.
[646] Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath
P et al. Safety and efficacy of enoxaparin compared with unfractionated
e78 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
heparin and oral anticoagulants for prevention of thromboembolic
complications in cardioversion of nonvalvular atrial fibrillation: the
Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Circulation 2004;109:997–1003.
[647] Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to
cardioversion for acute atrial fibrillation and thromboembolic compli-
cations. JAMA 2014;312:647–649.
[648] Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW,
Black IW et al. Use of transesophageal echocardiography to guide cardi-
oversion in patients with atrial fibrillation. N Engl J Med 2001;344:
1411–1420.
[649] Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY
et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial
fibrillation. Eur Heart J 2014;35:3346–3355.
[650] Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB.
Recurrence of arrhythmia following short-term oral AMIOdarone after
CATheter ablation for atrial fibrillation: a double-blind, randomized,
placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014;35:
3356–3364.
[651] Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC
et al. Amiodarone in patients with congestive heart failure and asympto-
matic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in
Congestive Heart Failure. N Engl J Med 1995;333:77–82.
[652] Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede
torsades de pointes in long QT syndrome: a systematic electrocardio-
graphic analysis in patients with acquired and congenital QT prolonga-
tion. J Am Coll Cardiol 2009;54:143–149.
[653] Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard
HR. A practical guide for clinicians who treat patients with amiodarone:
2007. Heart Rhythm 2007;4:1250–1259.
[654] Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J
2009;16:43–48.
[655] Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL et al.
Continuous vs episodic prophylactic treatment with amiodarone for the
prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:
1784–1792.
[656] Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D.
Dronedarone for the control of ventricular rate in permanent atrial
fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of
ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;
156:527.e1–9.
[657] Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H
et al. Dronedarone Study Group. Increased mortality after dronedarone
therapy for severe heart failure. N Engl J Med 2008;358:2678–2687.
[658] Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J et al.
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med
2011;365:2268–2276.
[659] Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud
C. Effect of dronedarone on renal function in healthy subjects. Br J Clin
Pharmacol 2007;64:785–791.
[660] The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.
Preliminary report: effect of encainide and flecainide on mortality in a
randomized trial of arrhythmia suppression after myocardial infarction.
N Engl J Med 1989;321:406–412.
[661] Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M.
Mixed treatment comparison of dronedarone, amiodarone, sotalol, fle-
cainide, and propafenone, for the management of atrial fibrillation.
Europace 2011;13:329–345.
[662] Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L
et al. Multicenter study of the efficacy and safety of disopyramide in
obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:
1251–1258.
[663] Sirak TE, Sherrid MV. Oral disopyramide for the acute treatment of
severe outflow obstruction in hypertrophic cardiomyopathy in the ICU
setting. Chest 2008;133:1243–1246.
[664] Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL et al.
Treatment of obstructive hypertrophic cardiomyopathy symptoms and
gradient resistant to first-line therapy with beta-blockade or verapamil.
Circ Heart Fail 2013;6:694–702.
[665] Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF
et al. Effect of d-sotalol on mortality in patients with left ventricular dys-
function after recent and remote myocardial infarction. The SWORD
Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7–12.
[666] Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen
C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in
patients with reduced left ventricular function: a Danish investigations
of arrhythmia and mortality on dofetilide (diamond) substudy.
Circulation 2001;104:292–296.
[667] Shamiss Y, Khaykin Y, Oosthuizen R, Tunney D, Sarak B, Beardsall M
et al. Dofetilide is safe and effective in preventing atrial fibrillation recur-
rences in patients accepted for catheter ablation. Europace 2009;11:
1448–1455.
[668] Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR,
Antzelevitch C et al. The potential for QT prolongation and pro-
arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory impli-
cations. Report on a Policy Conference of the European Society of
Cardiology. Cardiovasc Res 2000;47:219–233.
[669] K€a€ab S, Hinterseer M, N€abauer M, Steinbeck G. Sotalol testing unmasks
altered repolarization in patients with suspected acquired long-QT-
syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J 2003;
24:649–657.
[670] Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac
drugs effects: individual pre-disposition and transient precipitating fac-
tors. Basic Clin Pharmacol Toxicol 2010;106:263–268.
[671] Choy AM, Darbar D, Dell’Orto S, Roden DM. Exaggerated QT prolongation
after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396–401.
[672] Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M et al.
Suppression of paroxysmal atrial tachyarrhythmias—results of the
SOPAT trial. Eur Heart J 2004;25:1395–1404.
[673] Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch
C. Atrial-selective prolongation of refractory period with AVE0118 is
due principally to inhibition of sodium channel activity. J Cardiovasc
Pharmacol 2012;59:539–546.
[674] Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K et al. Human
electrophysiological and pharmacological properties of XEN-D0101: a
novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol 2013;
61:408–415.
[675] Loose S, Mueller J, Wettwer E, Knaut M, Ford J, Milnes J. Effects of IKur
blocker MK-0448 on human right atrial action potentials from patients
in sinus rhythm and in permanent atrial fibrillation. Front Pharmacol
2014;5:26.
[676] Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S.
Ranolazine: ion-channel-blocking actions and in vivo electrophysiologi-
cal effects. Br J Pharmacol 2004;142:1300–1308.
[677] McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates
glucose oxidation in normoxic, ischemic, and reperfused ischemic rat
hearts. Circulation 1996;93:135–142.
[678] Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth
CM et al. Effect of ranolazine, an antianginal agent with novel electro-
physiological properties, on the incidence of arrhythmias in patients
with non ST-segment elevation acute coronary syndrome: results from
the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-
Elevation Acute Coronary Syndrome Thrombolysis in Myocardial
Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation
2007;116:1647–1652.
[679] Scirica BM, Belardinelli L, Chaitman BR, Waks JW, Volo S, Karwatowska-
Prokopczuk E et al. Effect of ranolazine on atrial fibrillation in patients
with non-ST elevation acute coronary syndromes: observations from
the MERLIN-TIMI 36 trial. Europace 2015;17:32–37.
[680] Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E,
Olmsted A et al, HARMONY Investigators. The HARMONY Trial:
Combined Ranolazine and Dronedarone in the Management of
Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Circ Arrhythm Electrophysiol 2015;8:1048–1056.
[681] Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris
P. Comparison of effectiveness of ranolazine plus amiodarone versus
amiodarone alone for conversion of recent-onset atrial fibrillation. Am J
Cardiol 2012;110:673–677.
[682] Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME,
Lenos A, Chryssagis K et al. Ranolazine enhances the antiarrhythmic
activity of amiodarone by accelerating conversion of new-onset atrial
fibrillation after cardiac surgery. Angiology 2014;65:294–297.
[683] Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine
enhances the efficacy of amiodarone for conversion of recent-onset
atrial fibrillation. Europace 2014;16:973–979.
[684] De Ferrari GM, Maier LS, Mont L, Schwartz PJ, Simonis G, Leschke M
et al. RAFFAELLO Investigators. Ranolazine in the treatment of atrial
fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial
Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm
2015;12:872–878.













[685] Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD.
Atrial fibrillation associated with ivabradine treatment: meta-analysis of
randomised controlled trials. Heart 2014;100:1506–1510.
[686] Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE et al.
Regression of electrocardiographic left ventricular hypertrophy and
decreased incidence of new-onset atrial fibrillation in patients with
hypertension. JAMA 2006;296:1242–1248.
[687] Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies
for management of atrial fibrillation: review of clinical evidence and
implications for European Society of Cardiology guidelines. Part II: sec-
ondary prevention. Europace 2011;13:610–625.
[688] Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA.
Use of metoprolol CR/XL to maintain sinus rhythm after conversion
from persistent atrial fibrillation: a randomized, double-blind, placebo-
controlled study. J Am Coll Cardiol 2000;36:139–146.
[689] Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T.
Preoperative statin therapy for patients undergoing cardiac surgery.
Cochrane Database Syst Rev 2012;4:Cd008493.
[690] Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH.
Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000
patients. Eur J Cardiothorac Surg 2014;45:17–26; discussion 26.
[691] Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q et al.
Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016;374:
1744–1753.
[692] Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW
et al. PROSPER Executive. Effect of statins on atrial fibrillation: collabora-
tive meta-analysis of published and unpublished evidence from rando-
mised controlled trials. BMJ 2011;342:d1250.
[693] Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflamma-
tion and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-meth-
ylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox
Signal 2014;20:1268–1285.
[694] Bianconi L, Calo L, Mennuni M, Santini L, Morosetti P, Azzolini P et al.
n-3 polyunsaturated fatty acids for the prevention of arrhythmia recur-
rence after electrical cardioversion of chronic persistent atrial fibrilla-
tion: a randomized, double-blind, multicentre study. Europace 2011;13:
174–181.
[695] Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy
and safety of prescription omega-3 fatty acids for the prevention of
recurrent symptomatic atrial fibrillation: a randomized controlled trial.
JAMA 2010;304:2363–2372.
[696] Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner
TJ et al. OPERA Investigators. Fish oil and postoperative atrial fibrillation:
the Omega-3 Fatty Acids for Prevention of Post-operative Atrial
Fibrillation (OPERA) randomized trial. JAMA 2012;308:2001–2011.
[697] Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H et al.
J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor
blocker vs. dihydropiridine calcium channel blocker in the treatment of
paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Europace 2011;13:473–479.
[698] Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J et al. GESICA
Investigators. Omega-3 fatty acids for the prevention of recurrent sympto-
matic atrial fibrillation: results of the FORWARD (Randomized Trial to
Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent
Atrial Fibrillation) trial. J Am Coll Cardiol 2013;61:463–468.
[699] Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska
A et al. Effect of combined spironolactone-b-blocker ± enalapril treat-
ment on occurrence of symptomatic atrial fibrillation episodes in
patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
Am J Cardiol 2010;106:1609–1614.
[700] Ito Y, Yamasaki H, Naruse Y, Yoshida K, Kaneshiro T, Murakoshi N et al.
Effect of eplerenone on maintenance of sinus rhythm after catheter
ablation in patients with long-standing persistent atrial fibrillation. Am J
Cardiol 2013;111:1012–1018.
[701] Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H
et al. EMPHASIS-Hf Study Investigators. Eplerenone and atrial fibrillation
in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone
in Mild Patients Hospitalization And SurvIval Study in Heart Failure)
study. J Am Coll Cardiol 2012;59:1598–1603.
[702] Coll-Vinent B, Sala X, Fernandez C, Bragulat E, Espinosa G, Miro O et al.
Sedation for cardioversion in the emergency department: analysis of
effectiveness in four protocols. Ann Emerg Med 2003;42:767–772.
[703] del Arco C, Martin A, Laguna P, Gargantilla P. Analysis of current man-
agement of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann
Emerg Med 2005;46:424–430.
[704] Scheuermeyer FX, Grafstein E, Heilbron B, Innes G. Emergency depart-
ment management and 1-year outcomes of patients with atrial flutter.
Ann Emerg Med 2011;57:564–571.e2.
[705] Goldner BG, Baker J, Accordino A, Sabatino L, DiGiulio M, Kalenderian
D et al. Electrical cardioversion of atrial fibrillation or flutter with
conscious sedation in the age of cost containment. Am Heart J 1998;
136:961–964.
[706] Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-
Gomez JM, Santos JM, Camacho C. Comparison of intravenous flecai-
nide, propafenone, and amiodarone for conversion of acute atrial fibril-
lation to sinus rhythm. Am J Cardiol 2000;86:950–953.
[707] Buccelletti F, Iacomini P, Botta G, Marsiliani D, Carroccia A, Gentiloni
Silveri N. Efficacy and safety of vernakalant in recent-onset atrial fibrilla-
tion after the European medicines agency approval: systematic review
and meta-analysis. J Clin Pharmacol 2012;52:1872–1878.
[708] Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY
et al. X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for
cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346–3355.
[709] Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH
et al. Dabigatran versus warfarin in patients with atrial fibrillation: an anal-
ysis of patients undergoing cardioversion. Circulation 2011;123:131–136.
[710] Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J et al.
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up
Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;
109:1973–1980.
[711] Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT,
Vesterlund T. Long-term follow-up of patients from a randomised trial
of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997;
350:1210–1216.
[712] Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM et al. Effects
of physiologic pacing versus ventricular pacing on the risk of stroke and
death due to cardiovascular causes. Canadian Trial of Physiologic
Pacing Investigators. N Engl J Med 2000;342:1385–1391.
[713] Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A et al.
Treatment of atrial fibrillation with antiarrhythmic drugs or radiofre-
quency ablation: two systematic literature reviews and meta-analyses.
Circ Arrhythm Electrophysiol 2009;2:349–361.
[714] Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA.
Reduced incidence of new-onset atrial fibrillation with angiotensin II
receptor blockade: the VALUE trial. J Hypertens 2008;26:403–411.
[715] Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012
HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical
Ablation of Atrial Fibrillation: recommendations for patient selection, pro-
cedural techniques, patient management and follow-up, definitions, end-
points, and research trial design. Europace 2012;14:528–606.
[716] Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A
et al. Gap-AF–AFNET 1 Investigators. Impact of Complete Versus
Incomplete Circumferential Lines Around the Pulmonary Veins During
Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the
Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network
1 Trial. Circ Arrhythm Electrophysiol 2016;9:e003337.
[717] Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X,
Arenal A et al. SARA investigators. Catheter ablation vs. antiarrhythmic
drug treatment of persistent atrial fibrillation: a multicentre, random-
ized, controlled trial (SARA study). Eur Heart J 2014;35:501–507.
[718] Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA
et al. Five-year follow-up after catheter ablation of persistent atrial fibril-
lation using the stepwise approach and prognostic factors for success.
Circ Arrhythm Electrophysiol 2015;8:308–317.
[719] Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton
SB et al. Five-year outcome of catheter ablation of persistent atrial fibril-
lation using termination of atrial fibrillation as a procedural endpoint.
Circ Arrhythm Electrophysiol 2015;8:18–24.
[720] Al Halabi S, Qintar M, Hussein A, Alraies MC, Jones DG, Wong T et al.
Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A
Meta-Analysis of Randomized Controlled Trials. JACC Clin
Electrophysiol 2015;1:200–209.
[721] Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency
ablation vs. antiarrhythmic drug therapy as first line treatment of symp-
tomatic atrial fibrillation: systematic review and meta-analysis. Europace
2015;17:370–378.
[722] Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J
et al. RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic
drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a
randomized trial. JAMA 2014;311:692–700.
e80 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[723] Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W
et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treat-
ment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;
293:2634–2640.
[724] Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr et al.
Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N
Engl J Med 2006;354:934–941.
[725] Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G
et al. Catheter ablation treatment in patients with drug-refractory atrial
fibrillation: a prospective, multi-centre, randomized, controlled study
(Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J
2006;27:216–221.
[726] Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S et al.
Catheter ablation of atrial fibrillation in patients with diabetes mellitus
type 2: results from a randomized study comparing pulmonary vein iso-
lation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol
2009;20:22–28.
[727] Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J et al.
Updated worldwide survey on the methods, efficacy, and safety of cathe-
ter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol
2010;3:32–38.
[728] Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS et al. Long-
term outcomes of catheter ablation of atrial fibrillation: a systematic
review and meta-analysis. J Am Heart Assoc 2013;2:e004549.
[729] McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S et al. A mini-
mal or maximal ablation strategy to achieve pulmonary vein isolation
for paroxysmal atrial fibrillation: a prospective multi-centre randomized
controlled trial (the Minimax study). Eur Heart J 2015;36:1812–1821.
[730] Verma A, Sanders P, Macle L, Deisenhofer I, Morillo CA, Chen J et al.
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial-
Part II (STAR AF II): design and rationale. Am Heart J 2012;164:1–6.e6.
[731] Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczotka A et al.
Relationship Between Pulmonary Vein Reconnection and Atrial
Fibrillation Recurrence. JACC Clin Electrophysiol;doi:10.1016/j.jacep.
2016.02.003. Published online ahead of print April 2016.
[732] Luik A, Radzewitz A, Kieser M, Walter M, Bramlage P, Hormann P et al.
Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients
With Paroxysmal Atrial Fibrillation: The Prospective, Randomized,
Controlled, Noninferiority FreezeAF Study. Circulation 2015;132:
1311–1319.
[733] Schmidt M, Dorwarth U, Andresen D, Brachmann J, Kuck KH, Kuniss M
et al. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation:
results from the German Ablation Registry. J Cardiovasc Electrophysiol
2014;25:1–7.
[734] Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR et al.
FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation
for Paroxysmal Atrial Fibrillation. N Engl J Med 2016;374:2235–2245.
[735] Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R et al.
STAR AF II Investigators. Approaches to catheter ablation for persistent
atrial fibrillation. N Engl J Med 2015;372:1812–1822.
[736] Dong JZ, Sang CH, Yu RH, Long DY, Tang RB, Jiang CX et al. Prospective
randomized comparison between a fixed ‘2C3L’ approach vs. stepwise
approach for catheter ablation of persistent atrial fibrillation. Europace
2015;17:1798–1806.
[737] Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L et al.
Maintenance of sinus rhythm with an ablation strategy in patients with
atrial fibrillation is associated with a lower risk of stroke and death.
Heart 2012;98:48–53.
[738] Providencia R, Lambiase PD, Srinivasan N, Ganesh Babu G, Bronis K,
Ahsan S et al. Is There Still a Role for Complex Fractionated Atrial
Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients
With Paroxysmal and Persistent Atrial Fibrillation? Meta-Analysis of 1415
Patients. Circ Arrhythm Electrophysiol 2015;8:1017–1029.
[739] Mohanty S, Gianni C, Mohanty P, Halbfass P, Metz T, Trivedi C et al.
Impact of Rotor Ablation in Non-Paroxysmal AF Patients: Results from a
Randomized Trial (OASIS). J Am Coll Cardiol;doi:10.1016/j.jacc.2016.04.
015. Published online ahead of print 6 May 2016.
[740] Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S et al. Tailored atrial
substrate modification based on low-voltage areas in catheter ablation
of atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:825–833.
[741] Shah AJ, Pascale P, Miyazaki S, Liu X, Roten L, Derval N et al. Prevalence
and types of pitfall in the assessment of mitral isthmus linear conduction
block. Circ Arrhythm Electrophysiol 2012;5:957–967.
[742] Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S et al.
ADVICE trial investigators. Adenosine-guided pulmonary vein isolation
for the treatment of paroxysmal atrial fibrillation: an international, mul-
ticentre, randomised superiority trial. Lancet 2015;386:672–679.
[743] Kobori A, Shizuta S, Inoue K, Kaitani K, Morimoto T, Nakazawa Y et al.
UNDER-ATP Trial Investigators. Adenosine triphosphate-guided pulmo-
nary vein isolation for atrial fibrillation: the UNmasking Dormant
Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial.
Eur Heart J 2015;36:3276–3287.
[744] Berntsen RF, Haland TF, Skardal R, Holm T. Focal impulse and rotor
modulation as a stand-alone procedure for treatment of paroxysmal
atrial fibrillation. A within-patient controlled study with implanted car-
diac monitoring. Heart Rhythm 2016;doi:10.1016/j.hrthm.2016.04.016.
[745] Lee G, Sparks PB, Morton JB, Kistler PM, Vohra JK, Medi C et al. Low risk
of major complications associated with pulmonary vein antral isolation
for atrial fibrillation: results of 500 consecutive ablation procedures in
patients with low prevalence of structural heart disease from a single
center. J Cardiovasc Electrophysiol 2011;22:163–168.
[746] Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of
catheter ablation for persistent atrial fibrillation: a systematic review and
meta-analysis of evidence from randomized and nonrandomized con-
trolled trials. Circ Arrhythm Electrophysiol 2014;7:841–852.
[747] Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM.
Shared decision making in atrial fibrillation: where we are and where
we should be going. Circulation 2014;129:704–710.
[748] Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K et al.
Complications of atrial fibrillation ablation in a high-volume center in
1,000 procedures: still cause for concern? J Cardiovasc Electrophysiol
2009;20:1014–1019.
[749] Deneke T, Jais P, Scaglione M, Schmitt R, L DIB, Christopoulos G et al.
Silent cerebral events/lesions related to atrial fibrillation ablation: a clini-
cal review. J Cardiovasc Electrophysiol 2015;26:455–463.
[750] Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC
et al. Complications of catheter ablation of atrial fibrillation: a systematic
review. Circ Arrhythm Electrophysiol 2013;6:1082–1088.
[751] Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J et al.
Delayed cardiac tamponade after radiofrequency catheter ablation of
atrial fibrillation: a worldwide report. J Am Coll Cardiol 2011;58:
2696–2697.
[752] Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and
ischemic stroke. Stroke 2012;43:265–270.
[753] Kosiuk J, Kornej J, Bollmann A, Piorkowski C, Myrda K, Arya A et al. Early
cerebral thromboembolic complications after radiofrequency catheter
ablation of atrial fibrillation: incidence, characteristics, and risk factors.
Heart Rhythm 2014;11:1934–1940.
[754] Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F et al.
Incidence of silent cerebral thromboembolic lesions after atrial fibrilla-
tion ablation may change according to technology used: comparison of
irrigated radiofrequency, multipolar nonirrigated catheter and cryobal-
loon. J Cardiovasc Electrophysiol 2011;22:961–968.
[755] Hsu LF, Jais P, Hocini M, Sanders P, Scavee C, Sacher F et al. Incidence
and prevention of cardiac tamponade complicating ablation for atrial
fibrillation. Pacing Clin Electrophysiol 2005;28:S106–109.
[756] Michowitz Y, Rahkovich M, Oral H, Zado ES, Tilz R, John S et al. Effects
of sex on the incidence of cardiac tamponade after catheter ablation of
atrial fibrillation: results from a worldwide survey in 34 943 atrial fibrilla-
tion ablation procedures. Circ Arrhythm Electrophysiol 2014;7:274–280.
[757] Nair KK, Shurrab M, Skanes A, Danon A, Birnie D, Morillo C et al. The
prevalence and risk factors for atrioesophageal fistula after percutane-
ous radiofrequency catheter ablation for atrial fibrillation: the Canadian
experience. J Interv Card Electrophysiol 2014;39:139–144.
[758] Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural
complications, rehospitalizations, and repeat procedures after catheter
ablation for atrial fibrillation. J Am Coll Cardiol 2012;59:143–149.
[759] Straube F, Dorwarth U, Schmidt M, Wankerl M, Ebersberger U,
Hoffmann E. Comparison of the first and second cryoballoon: high-
volume single-center safety and efficacy analysis. Circ Arrhythm
Electrophysiol 2014;7:293–299.
[760] Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R
et al. Periprocedural Stroke and Bleeding Complications in Patients
Undergoing Catheter Ablation of Atrial Fibrillation With Different
Anticoagulation Management: Results From the Role of Coumadin in
Preventing Thromboembolism in Atrial Fibrillation (AF) Patients
Undergoing Catheter Ablation (COMPARE) Randomized Trial.
Circulation 2014;129:2638–2644.
[761] Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S
et al. Feasibility and safety of uninterrupted periprocedural apixaban













administration in patients undergoing radiofrequency catheter ablation
for atrial fibrillation: Results from a multicenter study. Heart Rhythm
2015;12:1162–1168.
[762] Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate dur-
ing catheter ablation of atrial fibrillation: a meta-analysis of the litera-
ture. Europace 2013;15:1407–1411.
[763] Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC,
Santangeli P et al. Feasibility and safety of uninterrupted rivaroxaban for
periprocedural anticoagulation in patients undergoing radiofrequency
ablation for atrial fibrillation: results from a multicenter prospective
registry. J Am Coll Cardiol 2014;63:982–988.
[764] Providencia R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F
et al. Rivaroxaban and dabigatran in patients undergoing catheter abla-
tion of atrial fibrillation. Europace 2014;16:1137–1144.
[765] Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH et al.
Safety of new oral anticoagulants for patients undergoing atrial fibrilla-
tion ablation. J Interv Card Electrophysiol 2014;40:33–38.
[766] Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR
et al. Meta-analysis of efficacy and safety of rivaroxaban compared with
warfarin or dabigatran in patients undergoing catheter ablation for atrial
fibrillation. Am J Cardiol 2014;114:577–582.
[767] Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V et al.
Comparison of safety of left atrial catheter ablation procedures for atrial
arrhythmias under continuous anticoagulation with apixaban versus
phenprocoumon. Am J Cardiol 2015;115:47–51.
[768] Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber
DJ et al. VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. unin-
terrupted vitamin K antagonists for catheter ablation in non-valvular
atrial fibrillation. Eur Heart J 2015;36:1805–1811.
[769] Wu S, Yang YM, Zhu J, Wan HB, Wang J, Zhang H. Meta-Analysis of
Efficacy and Safety of New Oral Anticoagulants Compared With
Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter
Ablation for Atrial Fibrillation. Am J Cardiol 2016;117:926–934.
[770] Santarpia G, De Rosa S, Polimeni A, Giampa S, Micieli M, Curcio A.
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants
versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing
Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
PLoS One 2015;10:e0126512.
[771] Karasoy D, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt M
et al. Oral anticoagulation therapy after radiofrequency ablation of atrial
fibrillation and the risk of thromboembolism and serious bleeding:
long-term follow-up in nationwide cohort of Denmark. Eur Heart J
2015;36:307–314a.
[772] Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A et al.
The risk of thromboembolism and need for oral anticoagulation after suc-
cessful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735–743.
[773] Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS et al. Atrial
fibrillation ablation patients have long-term stroke rates similar to
patients without atrial fibrillation regardless of CHADS2 score. Heart
Rhythm 2013;10:1272–1277.
[774] Nedios S, Kornej J, Koutalas E, Bertagnolli L, Kosiuk J, Rolf S et al. Left
atrial appendage morphology and thromboembolic risk after catheter
ablation for atrial fibrillation. Heart Rhythm 2014;11:2239–2246.
[775] Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang
M. Health outcomes with catheter ablation or antiarrhythmic drug ther-
apy in atrial fibrillation: results of a propensity-matched analysis. Circ
Cardiovasc Qual Outcomes 2012;5:171–181.
[776] Gallo C, Battaglia A, Anselmino M, Bianchi F, Grossi S, Nangeroni G
et al. Long-term events following atrial fibrillation rate control or trans-
catheter ablation: a multicenter observational study. J Cardiovasc Med
(Hagerstown) 2016;17:187–193.
[777] Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D
et al. Ablation vs. Amiodarone for Treatment of Persistent Atrial
Fibrillation in Patients With Congestive Heart Failure and an Implanted
Device: Results From the AATAC Multicenter Randomized Trial.
Circulation;doi:10.1161/CIRCULATIONAHA.115.019406. Published
online ahead of print 30 March 2016.
[778] Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V et al. A
randomized controlled trial of catheter ablation versus medical treat-
ment of atrial fibrillation in heart failure (the CAMTAF trial). Circ
Arrhythm Electrophysiol 2014;7:31–38.
[779] MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw
M et al. Radiofrequency ablation for persistent atrial fibrillation in
patients with advanced heart failure and severe left ventricular systolic
dysfunction: a randomised controlled trial. Heart 2011;97:740–747.
[780] Dagres N, Varounis C, Gaspar T, Piorkowski C, Eitel C, Iliodromitis EK
et al. Catheter ablation for atrial fibrillation in patients with left ventricu-
lar systolic dysfunction. A systematic review and meta-analysis. J Card
Fail 2011;17:964–970.
[781] Piorkowski C, Kottkamp H, Tanner H, Kobza R, Nielsen JC, Arya A. Value
of different follow-up strategies to assess the efficacy of circumferential
pulmonary vein ablation for the curative treatment of atrial fibrillation. J
Cardiovasc Electrophysiol 2005;16:1286–1292.
[782] Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A et al.
Discerning the incidence of symptomatic and asymptomatic episodes
of atrial fibrillation before and after catheter ablation (DISCERN AF): a
prospective, multicenter study. JAMA Intern Med 2013;173:149–156.
[783] Cox JL, Boineau JP, Schuessler RB, Ferguson TB Jr., Cain ME, Lindsay BD
et al. Successful surgical treatment of atrial fibrillation. Review and clini-
cal update. JAMA 1991;266:1976–1980.
[784] Cox JL, Schuessler RB, D’Agostino HJ Jr, Stone CM, Chang BC, Cain ME
et al. The surgical treatment of atrial fibrillation. III. Development of a
definitive surgical procedure. J Thorac Cardiovasc Surg 1991;101:
569–583.
[785] Stulak JM, Suri RM, Burkhart HM, Daly RC, Dearani JA, Greason KL et al.
Surgical ablation for atrial fibrillation for two decades: are the results of
new techniques equivalent to the Cox maze III procedure? J Thorac
Cardiovasc Surg 2014;147:1478–1486.
[786] Basu S, Nagendran M, Maruthappu M. How effective is bipolar radiofre-
quency ablation for atrial fibrillation during concomitant cardiac sur-
gery? Interact CardioVasc Thorac Surg 2012;15:741–748.
[787] Lin Z, Shan ZG, Liao CX, Chen LW. The effect of microwave and bipolar
radio-frequency ablation in the surgical treatment of permanent atrial
fibrillation during valve surgery. Thorac Cardiovasc Surg 2011;59:460–464.
[788] McCarthy PM, Kruse J, Shalli S, Ilkhanoff L, Goldberger JJ, Kadish AH
et al. Where does atrial fibrillation surgery fail? Implications for increas-
ing effectiveness of ablation. J Thorac Cardiovasc Surg 2010;139:
860–867.
[789] Abreu Filho CA, Lisboa LA, Dallan LA, Spina GS, Grinberg M, Scanavacca
M et al. Effectiveness of the maze procedure using cooled-tip radiofre-
quency ablation in patients with permanent atrial fibrillation and rheu-
matic mitral valve disease. Circulation 2005;112:I20–25.
[790] Blomstrom-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM,
Thelin S et al. A randomized double-blind study of epicardial left atrial
cryoablation for permanent atrial fibrillation in patients undergoing
mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study
(SWEDMAF). Eur Heart J 2007;28:2902–2908.
[791] Chevalier P, Leizorovicz A, Maureira P, Carteaux JP, Corbineau H, Caus T
et al. Left atrial radiofrequency ablation during mitral valve surgery: a
prospective randomized multicentre study (SAFIR). Arch Cardiovasc Dis
2009;102:769–775.
[792] Deneke T, Khargi K, Grewe PH, Laczkovics A, von Dryander S, Lawo T
et al. Efficacy of an additional MAZE procedure using cooled-tip
radiofrequency ablation in patients with chronic atrial fibrillation and
mitral valve disease. A randomized, prospective trial. Eur Heart J 2002;
23:558–566.
[793] Doukas G, Samani NJ, Alexiou C, Oc M, Chin DT, Stafford PG et al. Left
atrial radiofrequency ablation during mitral valve surgery for continuous
atrial fibrillation: a randomized controlled trial. JAMA 2005;294:2323–2329.
[794] Schuetz A, Schulze CJ, Sarvanakis KK, Mair H, Plazer H, Kilger E et al.
Surgical treatment of permanent atrial fibrillation using microwave
energy ablation: a prospective randomized clinical trial. Eur J
Cardiothorac Surg 2003;24:475–480; discussion 480.
[795] Liu X, Tan HW, Wang XH, Shi HF, Li YZ, Li F et al. Efficacy of catheter
ablation and surgical CryoMaze procedure in patients with long-lasting
persistent atrial fibrillation and rheumatic heart disease: a randomized
trial. Eur Heart J 2010;31:2633–2641.
[796] Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G et al.
Surgical ablation for atrial fibrillation in cardiac surgery: a meta-analysis
and systematic review. Innovations (Phila) 2010;5:84–96.
[797] Barnett SD, Ad N. Surgical ablation as treatment for the elimination of
atrial fibrillation: a meta-analysis. J Thorac Cardiovasc Surg 2006;131:
1029–1035.
[798] Ad N, Henry L, Massimiano P, Pritchard G, Holmes SD. The state of sur-
gical ablation for atrial fibrillation in patients with mitral valve disease.
Curr Opin Cardiol 2013;28:170–180.
[799] Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr,
O’Brien SM et al. Atrial fibrillation correction surgery: lessons from the
Society of Thoracic Surgeons National Cardiac Database. Ann Thorac
Surg 2008;85:909–914.
e82 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[800] Chen MC, Chang JP, Chang HW. Preoperative atrial size predicts the
success of radiofrequency maze procedure for permanent atrial fibrilla-
tion in patients undergoing concomitant valvular surgery. Chest 2004;
125:2129–2134.
[801] Sunderland N, Maruthappu M, Nagendran M. What size of left atrium
significantly impairs the success of maze surgery for atrial fibrillation?
Interact CardioVasc Thorac Surg 2011;13:332–338.
[802] Chaiyaroj S, Ngarmukos T, Lertsithichai P. Predictors of sinus rhythm
after radiofrequency maze and mitral valve surgery. Asian Cardiovasc
Thorac Ann 2008;16:292–297.
[803] Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG,
Navia JL et al. Surgery for permanent atrial fibrillation: impact of patient
factors and lesion set. Ann Thorac Surg 2006;82:502–513; discussion
513–504.
[804] Beukema WP, Sie HT, Misier AR, Delnoy PP, Wellens HJ, Elvan A.
Predictive factors of sustained sinus rhythm and recurrent atrial fibrilla-
tion after a radiofrequency modified Maze procedure. Eur J
Cardiothorac Surg 2008;34:771–775.
[805] Gillinov AM, Bakaeen F, McCarthy PM, Blackstone EH, Rajeswaran J,
Pettersson G et al. Surgery for paroxysmal atrial fibrillation in the setting
of mitral valve disease: a role for pulmonary vein isolation? Ann Thorac
Surg 2006;81:19–26; discussion 27–18.
[806] Onorati F, Mariscalco G, Rubino AS, Serraino F, Santini F, Musazzi A
et al. Impact of lesion sets on mid-term results of surgical ablation pro-
cedure for atrial fibrillation. J Am Coll Cardiol 2011;57:931–940.
[807] Saint LL, Bailey MS, Prasad S, Guthrie TJ, Bell J, Moon MR et al. Cox-
Maze IV results for patients with lone atrial fibrillation versus concomi-
tant mitral disease. Ann Thorac Surg 2012;93:789–794; discussion 794–
785.
[808] Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS. A
minimally invasive Cox maze IV procedure is as effective as sternotomy
while decreasing major morbidity and hospital stay. J Thorac Cardiovasc
Surg 2014;148:955–961; discussion 962–952.
[809] Edgerton JR, Brinkman WT, Weaver T, Prince SL, Culica D, Herbert MA.
Pulmonary vein isolation and autonomic denervation for the manage-
ment of paroxysmal atrial fibrillation by a minimally invasive surgical
approach. J Thorac Cardiovasc Surg 2010;140:823–828.
[810] McClelland JH, Duke D, Reddy R. Preliminary results of a limited thora-
cotomy: new approach to treat atrial fibrillation. J Cardiovasc
Electrophysiol 2007;18:1289–1295.
[811] Castella M, Pereda D, Mestres CA, Gomez F, Quintana E, Mulet J.
Thoracoscopic pulmonary vein isolation in patients with atrial fibrilla-
tion and failed percutaneous ablation. J Thorac Cardiovasc Surg 2010;
140:633–638.
[812] Krul SP, Driessen AH, van Boven WJ, Linnenbank AC, Geuzebroek GS,
Jackman WM et al. Thoracoscopic video-assisted pulmonary vein
antrum isolation, ganglionated plexus ablation, and periprocedural con-
firmation of ablation lesions: first results of a hybrid surgical-
electrophysiological approach for atrial fibrillation. Circ Arrhythm
Electrophysiol 2011;4:262–270.
[813] La Meir M, Gelsomino S, Lorusso R, Luca F, Pison L, Parise O et al. The
hybrid approach for the surgical treatment of lone atrial fibrillation:
one-year results employing a monopolar radiofrequency source. J
Cardiothorac Surg 2012;7:71.
[814] Wang S, Liu L, Zou C. Comparative study of video-assisted thoraco-
scopic surgery ablation and radiofrequency catheter ablation on treat-
ing paroxysmal atrial fibrillation: a randomized, controlled short-term
trial. Chin Med J (Engl) 2014;127:2567–2570.
[815] Phan K, Phan S, Thiagalingam A, Medi C, Yan TD. Thoracoscopic surgi-
cal ablation versus catheter ablation for atrial fibrillation. Eur J
Cardiothorac Surg 2016;49:1044–1051.
[816] Hu QM, Li Y, Xu CL, Han J, Zhang HB, Han W. Analysis of risk factors for
recurrence after video-assisted pulmonary vein isolation of lone atrial
fibrillation-results of 5 years of follow-up. J Thorac Cardiovasc Surg
2014;148:2174–2180.
[817] Edgerton JR, Edgerton ZJ, Weaver T, Reed K, Prince S, Herbert MA.
Minimally invasive pulmonary vein isolation and partial autonomic
denervation for surgical treatment of atrial fibrillation. Ann Thorac Surg
2008;86:35–38; discussion 39.
[818] Wang J, Li Y, Shi J, Han J, Xu C, Ma C. Minimally invasive surgical versus
catheter ablation for the long-lasting persistent atrial fibrillation. PLoS
One 2011;6:e22122.
[819] Wang JG, Xin M, Han J, Li Y, Luo TG, Wang J et al. Ablation in selective
patients with long-standing persistent atrial fibrillation: medium-term
results of the Dallas lesion set. Eur J Cardiothorac Surg 2014;46:213–220.
[820] Sirak JH, Schwartzman D. Interim results of the 5-box thoracoscopic
maze procedure. Ann Thorac Surg 2012;94:1880–1884.
[821] Kasirajan V, Spradlin EA, Mormando TE, Medina AE, Ovadia P,
Schwartzman DS et al. Minimally invasive surgery using bipolar radio-
frequency energy is effective treatment for refractory atrial fibrillation.
Ann Thorac Surg 2012;93:1456–1461.
[822] Weimar T, Vosseler M, Czesla M, Boscheinen M, Hemmer WB, Doll KN.
Approaching a paradigm shift: endoscopic ablation of lone atrial fibrilla-
tion on the beating heart. Ann Thorac Surg 2012;94:1886–1892.
[823] La Meir M, Gelsomino S, Luca F, Pison L, Parise O, Colella A et al.
Minimally invasive surgical treatment of lone atrial fibrillation: early
results of hybrid versus standard minimally invasive approach employ-
ing radiofrequency sources. Int J Cardiol 2013;167:1469–1475.
[824] Gelsomino S, Van Breugel HN, Pison L, Parise O, Crijns HJ, Wellens F
et al. Hybrid thoracoscopic and transvenous catheter ablation of atrial
fibrillation. Eur J Cardiothorac Surg 2014;45:401–407.
[825] Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid
thoracoscopic surgical and transvenous catheter ablation of atrial fibril-
lation. J Am Coll Cardiol 2012;60:54–61.
[826] De Maat GE, Van Gelder IC, Rienstra M, Quast AF, Tan ES, Wiesfeld AC
et al. Surgical vs. transcatheter pulmonary vein isolation as first invasive
treatment in patients with atrial fibrillation: a matched group compari-
son. Europace 2014;16:33–39.
[827] Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY.
Atrial flutter and thromboembolic risk: a systematic review. Heart 2015;
101:1446–1455.
[828] Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM 3rd, Schaff HV. Left
ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm
by the Cox-maze procedure significantly improves systolic function and
functional status. Ann Thorac Surg 2006;82:494–501.
[829] Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY et al. Pacing or abla-
tion: which is better for paroxysmal atrial fibrillation-related tachycardia-
bradycardia syndrome? Pacing Clin Electrophysiol 2014;37:403–411.
[830] Khaykin Y, Marrouche NF, Martin DO, Saliba W, Schweikert R, Wexman
M et al. Pulmonary vein isolation for atrial fibrillation in patients with
symptomatic sinus bradycardia or pauses. J Cardiovasc Electrophysiol
2004;15:784–789.
[831] Ad N, Henry L, Hunt S. Current role for surgery in treatment of lone
atrial fibrillation. Semin Thorac Cardiovasc Surg 2012;24:42–50.
[832] Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL. The
cox-maze procedure for lone atrial fibrillation: a single-center experience
over 2 decades. Circ Arrhythm Electrophysiol 2012;5:8–14.
[833] Ad N, Henry L, Hunt S, Holmes SD. Do we increase the operative risk by
adding the Cox Maze III procedure to aortic valve replacement and cor-
onary artery bypass surgery? J Thorac Cardiovasc Surg 2012;143:
936–944.
[834] Prakash A, Saksena S, Krol RB, Filipecki A, Philip G. Catheter ablation of
inducible atrial flutter, in combination with atrial pacing and antiarrhyth-
mic drugs (hybrid therapy) improves rhythm control in patients with
refractory atrial fibrillation. J Interv Card Electrophysiol 2002;6:165–172.
[835] Tai CT, Chiang CE, Lee SH, Chen YJ, Yu WC, Feng AN et al. Persistent atrial
flutter in patients treated for atrial fibrillation with amiodarone and prop-
afenone: electrophysiologic characteristics, radiofrequency catheter abla-
tion, and risk prediction. J Cardiovasc Electrophysiol 1999;10:1180–1187.
[836] Stabile G, De Simone A, Turco P, La Rocca V, Nocerino P, Astarita C
et al. Response to flecainide infusion predicts long-term success of
hybrid pharmacologic and ablation therapy in patients with atrial fibril-
lation. J Am Coll Cardiol 2001;37:1639–1644.
[837] Anastasio N, Frankel DS, Deyell MW, Zado E, Gerstenfeld EP, Dixit S
et al. Nearly uniform failure of atrial flutter ablation and continuation of
antiarrhythmic agents (hybrid therapy) for the long-term control of
atrial fibrillation. J Interv Card Electrophysiol 2012;35:57–61.
[838] Garcia Seara J, Raposeiras Roubin S, Gude Sampedro F, Balboa Barreiro
V, Martinez Sande JL, Rodriguez Manero M. Failure of hybrid therapy
for the prevention of long-term recurrence of atrial fibrillation. Int J
Cardiol 2014;176:74–79.
[839] Saksena S, Prakash A, Ziegler P, Hummel JD, Friedman P, Plumb VJ et al.
Improved suppression of recurrent atrial fibrillation with dual-site right
atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol 2002;
40:1140–1150; discussion 1151–1142.
[840] Wharton JM, Sorrentino RA, Campbell P, Gonzalez-Zuelgaray J, Keating
E, Curtis A et al. Effect of pacing modality on atrial tachyarrhythmia
recurrence in the tachycardia-bradycardia syndrome: preliminary
results of the Pacemaker Atrial Tachycardia Trial. Circulation 1998;
98:I–494.













[841] Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor
for stroke in atrial fibrillation patients: implications for thromboprophy-
laxis. J Am Coll Cardiol 2010;56:827–837.
[842] Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW.
Adverse outcomes and predictors of underuse of antithrombotic ther-
apy in medicare beneficiaries with chronic atrial fibrillation. Stroke
2000;31:822–827.
[843] Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M et al.
ESC Thrombosis Working Group. Antithrombotic therapy in the elderly:
expert position paper of the European Society of Cardiology Working
Group on Thrombosis. Eur Heart J 2015;36:3238–3249.
[844] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M,
Camm J et al. 2015 ESC Guidelines for the management of patients with
ventricular arrhythmias and the prevention of sudden cardiac death: The
Task Force for the Management of Patients with Ventricular Arrhythmias
and the Prevention of Sudden Cardiac Death of the European Society of
Cardiology (ESC). Endorsed by: Association for European Paediatric and
Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–2867.
[845] Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P
et al. 2014 ESC Guidelines on diagnosis and management of hypertro-
phic cardiomyopathy: the Task Force for the Diagnosis and
Management of Hypertrophic Cardiomyopathy of the European Society
of Cardiology (ESC). Eur Heart J 2014;35:2733–2779.
[846] Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ.
Prevalence of early-onset atrial fibrillation in congenital long QT syn-
drome. Heart Rhythm 2008;5:704–709.
[847] Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H et al.
Prolonged atrial action potential durations and polymorphic atrial
tachyarrhythmias in patients with long QT syndrome. J Cardiovasc
Electrophysiol 2003;14:1027–1033.
[848] Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J
et al. Atrial Arrhythmias in long-QT syndrome under daily life condi-
tions: a nested case control study. J Cardiovasc Electrophysiol 2009;20:
401–407.
[849] Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL et al.
ECG T-wave patterns in genetically distinct forms of the hereditary long
QT syndrome. Circulation 1995;92:2929–2934.
[850] Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C
et al. Genotype-phenotype correlation in the long-QT syndrome: gene-
specific triggers for life-threatening arrhythmias. Circulation 2001;103:
89–95.
[851] Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T et al.
Brugada syndrome and supraventricular tachyarrhythmias: a novel asso-
ciation? J Cardiovasc Electrophysiol 2001;12:680–685.
[852] Kaufman ES. Mechanisms and clinical management of inherited chan-
nelopathies: long QT syndrome, Brugada syndrome, catecholaminergic
polymorphic ventricular tachycardia, and short QT syndrome. Heart
Rhythm 2009;6:S51–55.
[853] Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC,
Aizawa Y et al. Loss-of-function mutations in the cardiac calcium channel
underlie a new clinical entity characterized by ST-segment elevation, short
QT intervals, and sudden cardiac death. Circulation 2007;115:442–449.
[854] London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S et al.
Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L)
decreases cardiac Na+ current and causes inherited arrhythmias.
Circulation 2007;116:2260–2268.
[855] Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott
JJ et al. Sodium channel beta1 subunit mutations associated with
Brugada syndrome and cardiac conduction disease in humans. J Clin
Invest 2008;118:2260–2268.
[856] Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M et al.
Sudden death associated with short-QT syndrome linked to mutations
in HERG. Circulation 2004;109:30–35.
[857] Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R et al.
Short QT Syndrome: a familial cause of sudden death. Circulation 2003;
108:965–970.
[858] Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P
et al. Short QT syndrome: clinical findings and diagnostic-therapeutic
implications. Eur Heart J 2006;27:2440–2447.
[859] Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT,
Wiesfeld AC, Alders M et al. Expanding spectrum of human RYR2-
related disease: new electrocardiographic, structural, and genetic fea-
tures. Circulation 2007;116:1569–1576.
[860] Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic
polymorphic ventricular tachycardia. Heart Rhythm 2007;4:675–678.
[861] Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiologi-
cal bases of catecholaminergic polymorphic ventricular tachycardia. J
Cardiovasc Electrophysiol 2007;18:791–797.
[862] Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and out-
comes of hypertrophic cardiomyopathy in Taiwan—a tertiary center
experience. Clin Cardiol 2007;30:177–182.
[863] Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D’Alessandro G
et al. Determinants of atrial fibrillation development in patients with
hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895–900.
[864] Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP et al.
Clinical profile of stroke in 900 patients with hypertrophic cardiomyop-
athy. J Am Coll Cardiol 2002;39:301–307.
[865] Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L.
Novel PRKAG2 mutation responsible for the genetic syndrome of ven-
tricular preexcitation and conduction system disease with childhood
onset and absence of cardiac hypertrophy. Circulation 2001;104:
3030–3033.
[866] Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels
VM, Ilgun A et al. A gain-of-function TBX5 mutation is associated with
atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. Circ
Res 2008;102:1433–1442.
[867] Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ven-
tricular cardiomyopathy: a practical guide for physicians. J Am Coll
Cardiol 2013;61:1945–1948.
[868] Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with
arrhythmogenic right ventricular cardiomyopathy/dysplasia and ven-
tricular tachycardia. Am J Cardiol 2010;106:720–722.
[869] Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H,
Camm AJ et al. European Society of Cardiology Committee, NASPE-
Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of
patients with supraventricular arrhythmias—executive summary. a
report of the American college of cardiology/American heart associa-
tion task force on practice guidelines and the European society of cardi-
ology committee for practice guidelines (writing committee to develop
guidelines for the management of patients with supraventricular
arrhythmias) developed in collaboration with NASPE-Heart Rhythm
Society. J Am Coll Cardiol 2003;42:1493–1531.
[870] Tischenko A, Fox DJ, Yee R, Krahn AD, Skanes AC, Gula LJ. When should
we recommend catheter ablation for patients with the Wolff-Parkinson-
White syndrome? Curr Opin Cardiol 2008;23:32–37.
[871] Kibos A, Deharo JC, Adoubi A, Assouan X, Djianeb P. [Clinical and elec-
trophysiological study of asymptomatic Wolff-Parkinson-White syn-
drome]. Ann Cardiol Angeiol (Paris) 2007;56:237–240.
[872] Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini
G et al. A randomized study of prophylactic catheter ablation in asymp-
tomatic patients with the Wolff-Parkinson-White syndrome. N Engl J
Med 2003;349:1803–1811.
[873] Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of
acute atrial fibrillation in the Wolff-Parkinson-White syndrome by pro-
cainamide and propafenone: importance of atrial fibrillatory cycle
length. J Am Coll Cardiol 1990;16:1408–1414.
[874] O’Nunain S, Garratt CJ, Linker NJ, Gill J, Ward DE, Camm AJ. A compari-
son of intravenous propafenone and flecainide in the treatment of
tachycardias associated with the Wolff-Parkinson-White syndrome.
Pacing Clin Electrophysiol 1991;14:2028–2034.
[875] Manolis AS, Estes NA III. Supraventricular tachycardia. Mechanisms and
therapy. Arch Intern Med 1987;147:1706–1716.
[876] Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superi-
ority of amiodarone for rate control in Wolff-Parkinson-White and atrial
fibrillation. Intern Emerg Med 2010;5:421–426.
[877] Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM.
Atrial fibrillation and thromboembolism in patients with hypertrophic
cardiomyopathy: systematic review. Heart 2014;100:465–472.
[878] Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact
of atrial fibrillation on the clinical course of hypertrophic cardiomyop-
athy. Circulation 2001;104:2517–2524.
[879] Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ.
Prognostic value of non-sustained ventricular tachycardia and the
potential role of amiodarone treatment in hypertrophic cardiomyop-
athy: assessment in an unselected non-referral based patient popula-
tion. Heart 1998;79:331–336.
[880] Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM
et al. Substrate and procedural predictors of outcomes after catheter
ablation for atrial fibrillation in patients with hypertrophic cardiomyop-
athy. J Cardiovasc Electrophysiol 2008;19:1009–1014.
e84 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[881] Di Donna P, Olivotto I, Delcre SD, Caponi D, Scaglione M, Nault I et al.
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardio-
myopathy: impact of age, atrial remodelling, and disease progression.
Europace 2010;12:347–355.
[882] Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A
et al. Usefulness and safety of transcatheter ablation of atrial fibrillation
in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007;99:
1575–1581.
[883] Kilicaslan F, Verma A, Saad E, Themistoclakis S, Bonso A, Raviele A et al.
Efficacy of catheter ablation of atrial fibrillation in patients with hyper-
trophic obstructive cardiomyopathy. Heart Rhythm 2006;3:275–280.
[884] McCready JW, Smedley T, Lambiase PD, Ahsan SY, Segal OR, Rowland E
et al. Predictors of recurrence following radiofrequency ablation for per-
sistent atrial fibrillation. Europace 2011;13:355–361.
[885] Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S et al.
Chromosome 4q25 variants are genetic modifiers of rare ion channel
mutations associated with familial atrial fibrillation. J Am Coll Cardiol
2012;60:1173–1181.
[886] Mann SA, Otway R, Guo G, Soka M, Karlsdotter L, Trivedi G et al.
Epistatic effects of potassium channel variation on cardiac repolarization
and atrial fibrillation risk. J Am Coll Cardiol 2012;59:1017–1025.
[887] Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E
et al. Atrial fibrillation in a large population with Brugada electrocardio-
graphic pattern: prevalence, management, and correlation with progno-
sis. Heart Rhythm 2014;11:259–265.
[888] Darbar D, Kannankeril PJ, Donahue BS, Kucera G, Stubblefield T, Haines
JL et al. Cardiac sodium channel (SCN5A) variants associated with atrial
fibrillation. Circulation 2008;117:1927–1935.
[889] Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ et al.
Sodium channel mutations and susceptibility to heart failure and atrial
fibrillation. JAMA 2005;293:447–454.
[890] Ellinor PT, Moore RK, Patton KK, Ruskin JN, Pollak MR, Macrae CA.
Mutations in the long QT gene, KCNQ1, are an uncommon cause of
atrial fibrillation. Heart 2004;90:1487–1488.
[891] Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C et al. Executive
summary: HRS/EHRA/APHRS expert consensus statement on the diag-
nosis and management of patients with inherited primary arrhythmia
syndromes. Europace 2013;15:1389–1406.
[892] Antz M, Weiss C, Volkmer M, Hebe J, Ernst S, Ouyang F. Risk of sudden
death after successful accessory atrioventricular pathway ablation in
resuscitated patients with Wolff-Parkinson-White syndrome. J
Cardiovasc Electrophysiol 2002;13:231–236.
[893] Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A,
Wellens HJ. Aborted sudden death in the Wolff-Parkinson-White syn-
drome. Am J Cardiol 1995;76:492–494.
[894] Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and
electrophysiologic characterization of accessory pathways on manage-
ment strategies to reduce sudden death among children with Wolff-
Parkinson-White syndrome. J Am Coll Cardiol 1996;27:690–695.
[895] Al-Khatib SM, Arshad A, Balk EM, Das SR, Hsu JC, Joglar JA. Risk stratifi-
cation for arrhythmic events in patients with asymptomatic pre-
excitation: A systematic review for the 2015 ACC/AHA/HRS guideline
for the management of adult patients with supraventricular tachycardia:
A Report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines and the Heart
Rhythm Society. Heart Rhythm 2016;13:e222–237.
[896] Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS.
Hypertrophic cardiomyopathy: present and future, with translation
into contemporary cardiovascular medicine. J Am Coll Cardiol 2014;64:
83–99.
[897] Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD,
McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a lon-
gitudinal study. J Am Coll Cardiol 1990;15:1279–1285.
[898] Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and
incidence of atrial fibrillation in older adults: the cardiovascular health
study. Circulation 2008;118:800–807.
[899] Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E et al.
Sport practice and the risk of lone atrial fibrillation: a case-control study.
Int J Cardiol 2006;108:332–337.
[900] Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R et al.
Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002;
23:477–482.
[901] Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes
than in the general population? A systematic review and meta-analysis.
Europace 2009;11:1156–1159.
[902] Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S
et al. Resting heart rate and physical activity as risk factors for lone atrial
fibrillation: a prospective study of 309,540 men and women. Heart
2013;99:1755–1760.
[903] Wilhelm M, Roten L, Tanner H, Wilhelm I, Schmid JP, Saner H. Atrial
remodeling, autonomic tone, and lifetime training hours in nonelite ath-
letes. Am J Cardiol 2011;108:580–585.
[904] Guasch E, Benito B, Qi X, Cifelli C, Naud P, Shi Y et al. Atrial fibrillation
promotion by endurance exercise: demonstration and mechanistic
exploration in an animal model. J Am Coll Cardiol 2013;62:68–77.
[905] Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson
K. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a
cohort study. Eur Heart J 2013;34:3624–3631.
[906] Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibril-
lation in vigorously exercising middle aged men: case-control study.
BMJ 1998;316:1784–1785.
[907] Biffi A, Maron BJ, Culasso F, Verdile L, Fernando F, Di Giacinto B et al.
Patterns of ventricular tachyarrhythmias associated with training,
deconditioning and retraining in elite athletes without cardiovascular
abnormalities. Am J Cardiol 2011;107:697–703.
[908] Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E et al.
Efficacy of circumferential pulmonary vein ablation of atrial fibrillation
in endurance athletes. Europace 2010;12:30–36.
[909] Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van
Casteren L et al. Efficacy of radiofrequency catheter ablation in athletes
with atrial fibrillation. Europace 2011;13:1386–1393.
[910] Heidbuchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A,
Delise P et al. Recommendations for participation in leisure-time physical
activity and competitive sports in patients with arrhythmias and poten-
tially arrhythmogenic conditions Part I: Supraventricular arrhythmias and
pacemakers. Eur J Cardiovasc Prev Rehabil 2006;13:475–484.
[911] Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC.
Recurrence rates of arrhythmias during pregnancy in women with pre-
vious tachyarrhythmia and impact on fetal and neonatal outcomes. Am
J Cardiol 2006;97:1206–1212.
[912] Salam AM, Ertekin E, van Hagen IM, Al Suwaidi J, Ruys TPE, Johnson MR
et al. Atrial Fibrillation or Flutter During Pregnancy in Patients With
Structural Heart Disease: Data From the ROPAC (Registry on Pregnancy
and Cardiac Disease). JACC Clin Electrophysiol 2015;1:284–292.
[913] Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE,
Galie N et al. ESC Guidelines for the management of grown-up congeni-
tal heart disease (new version 2010). Eur Heart J 2010;31:2915–2957.
[914] Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995;
130:871–876.
[915] Magee LA, Duley L. Oral beta-blockers for mild to moderate hyperten-
sion during pregnancy. Cochrane Database Syst Rev 2003;3:CD002863.
[916] Mitani GM, Steinberg I, Lien EJ, Harrison EC, Elkayam U. The pharmaco-
kinetics of antiarrhythmic agents in pregnancy and lactation. Clin
Pharmacokinet 1987;12:253–291.
[917] Gowda RM, Khan IA, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac
arrhythmias in pregnancy: clinical and therapeutic considerations. Int J
Cardiol 2003;88:129–133.
[918] Joint Formulary Committee. British National Formulary (online). http://
www.medicinescomplete.com (2 December 2014).
[919] Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone
administration during pregnancy on neonatal thyroid function and sub-
sequent neurodevelopment. J Endocrinol Invest 2001;24:116–130.
[920] Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur SA, Rammeloo L et al.
Comparison of transplacental treatment of fetal supraventricular
tachyarrhythmias with digoxin, flecainide, and sotalol: results of a non-
randomized multicenter study. Circulation 2011;124:1747–1754.
[921] Tromp CHN, Nanne ACM, Pernet PJM, Tukkie R, Bolte AC. Electrical
cardioversion during pregnancy: safe or not? Neth Heart J 2011;19:
134–136.
[922] Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of
maternal supraventricular tachycardias during pregnancy: a review of
the literature. J Obstet Gynaecol Can 2011;33:17–23.
[923] Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik
PO. American College of Chest Physicians. VTE, thrombophilia, antithrom-
botic therapy, and pregnancy: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines. Chest 2012;141:e691S–736S.
[924] Ahlsson AJ, Bodin L, Lundblad OH, Englund AG. Postoperative atrial
fibrillation is not correlated to C-reactive protein. Ann Thorac Surg
2007;83:1332–1337.













[925] Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM.
Interventions for preventing post-operative atrial fibrillation in patients
undergoing heart surgery. Cochrane Database Syst Rev 2013;1:
Cd003611.
[926] Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD et al. A
multicenter risk index for atrial fibrillation after cardiac surgery. JAMA
2004;291:1720–1729.
[927] Steinberg BA, Zhao Y, He X, Hernandez AF, Fullerton DA, Thomas KL
et al. Management of postoperative atrial fibrillation and subsequent
outcomes in contemporary patients undergoing cardiac surgery:
insights from the Society of Thoracic Surgeons CAPS-Care Atrial
Fibrillation Registry. Clin Cardiol 2014;37:7–13.
[928] Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery
bypass grafting (CABG) atrial fibrillation: efficacy of prophylactic beta-
blockers in the modern era: a meta-analysis of latest randomized con-
trolled trials. Ann Noninvasive Electrocardiol 2013;18:58–68.
[929] Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-
operative atrial fibrillation and its complications after cardiac surgery: a
meta-analysis. Eur Heart J 2006;27:2846–2857.
[930] Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and
route of amiodarone for prevention of postoperative atrial fibrillation
after cardiac surgery: a network regression meta-analysis. Pacing Clin
Electrophysiol 2013;36:1017–1023.
[931] Zhu J, Wang C, Gao D, Zhang C, Zhang Y, Lu Y. Meta-analysis of amio-
darone versus beta-blocker as a prophylactic therapy against atrial
fibrillation following cardiac surgery. Intern Med J 2012;42:1078–1087.
[932] Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation:
systematic review and updated meta-analysis of published randomized
controlled trials. Curr Opin Cardiol 2013;28:7–18.
[933] Zheng H, Xue S, Hu ZL, Shan JG, Yang WG. The use of statins to
prevent postoperative atrial fibrillation after coronary artery bypass
grafting: a meta-analysis of 12 studies. J Cardiovasc Pharmacol 2014;64:
285–292.
[934] Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q et al.
Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016;374:
1744–1753.
[935] Cook RC, Yamashita MH, Kearns M, Ramanathan K, Gin K, Humphries
KH. Prophylactic magnesium does not prevent atrial fibrillation after
cardiac surgery: a meta-analysis. Ann Thorac Surg 2013;95:533–541.
[936] De Oliveira GS Jr, Knautz JS, Sherwani S, McCarthy RJ. Systemic magne-
sium to reduce postoperative arrhythmias after coronary artery bypass
graft surgery: a meta-analysis of randomized controlled trials. J
Cardiothorac Vasc Anesth 2012;26:643–650.
[937] Costanzo S, di Niro V, Di Castelnuovo A, Gianfagna F, Donati MB, de
Gaetano G. Prevention of postoperative atrial fibrillation in open heart
surgery patients by preoperative supplementation of n-3 polyunsatu-
rated fatty acids: an updated meta-analysis. J Thorac Cardiovasc Surg
2013;146:906–911.
[938] Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA
et al. Effect of dietary fish oil on atrial fibrillation after cardiac surgery.
Am J Cardiol 2011;108:851–856.
[939] Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V,
Gottskalksson G et al. Does treatment with n-3 polyunsaturated fatty
acids prevent atrial fibrillation after open heart surgery? Europace 2010;
12:356–363.
[940] Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D et al. N-3
polyunsaturated fatty acids to prevent atrial fibrillation: updated system-
atic review and meta-analysis of randomized controlled trials. J Am
Heart Assoc 2013;2:e005033.
[941] Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J,
Villalabeitia E et al. A randomized controlled trial to prevent post-
operative atrial fibrillation by antioxidant reinforcement. J Am Coll
Cardiol 2013;62:1457–1465.
[942] Saravanan P, Bridgewater B, West AL, O’Neill SC, Calder PC, Davidson
NC. Omega-3 fatty acid supplementation does not reduce risk of atrial
fibrillation after coronary artery bypass surgery: a randomized, double-
blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol
2010;3:46–53.
[943] Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS et al.
Plasma phospholipid omega-3 fatty acids and incidence of postopera-
tive atrial fibrillation in the OPERA trial. J Am Heart Assoc 2013;2:
e000397.
[944] Xin W, Wei W, Lin Z, Zhang X, Yang H, Zhang T et al. Fish oil and atrial
fibrillation after cardiac surgery: a meta-analysis of randomized con-
trolled trials. PLoS One 2013;8:e72913.
[945] Zhang B, Zhen Y, Tao A, Bao Z, Zhang G. Polyunsaturated fatty acids for
the prevention of atrial fibrillation after cardiac surgery: an updated
meta-analysis of randomized controlled trials. J Cardiol 2014;63:53–59.
[946] Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A et al.
COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy
syndrome and postoperative atrial fibrillation: the COPPS-2 randomized
clinical trial. JAMA 2014;312:1016–1023.
[947] Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM,
Paparella D. Protective effects of steroids in cardiac surgery: a meta-
analysis of randomized double-blind trials. J Cardiothorac Vasc Anesth
2011;25:156–165.
[948] Viviano A, Kanagasabay R, Zakkar M. Is perioperative corticosteroid
administration associated with a reduced incidence of postoperative
atrial fibrillation in adult cardiac surgery? Interact CardioVasc Thorac
Surg 2014;18:225–229.
[949] Kaleda VI, McCormack DJ, Shipolini AR. Does posterior pericardiotomy
reduce the incidence of atrial fibrillation after coronary artery bypass
grafting surgery? Interact CardioVasc Thorac Surg 2012;14:384–389.
[950] Dunning J, Treasure T, Versteegh M, Nashef SA. Guidelines on the pre-
vention and management of de novo atrial fibrillation after cardiac and
thoracic surgery. Eur J Cardiothorac Surg 2006;30:852–872.
[951] LaPar DJ, Speir AM, Crosby IK, Fonner E Jr, Brown M, Rich JB et al.
Investigators for the Virginia Cardiac Surgery Quality Initiative.
Postoperative atrial fibrillation significantly increases mortality, hospital
readmission, and hospital costs. Ann Thorac Surg 2014;98:527–533; dis-
cussion 533.
[952] Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE.
Usefulness of postoperative atrial fibrillation as an independent predic-
tor for worse early and late outcomes after isolated coronary artery
bypass grafting (multicenter Australian study of 19,497 patients). Am J
Cardiol 2012;109:219–225.
[953] Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS.
Perioperative atrial fibrillation and the long-term risk of ischemic stroke.
JAMA 2014;312:616–622.
[954] Ahlsson A, Bodin L, Fengsrud E, Englund A. Patients with postoperative
atrial fibrillation have a doubled cardiovascular mortality. Scand
Cardiovasc J 2009;43:330–336.
[955] Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrilla-
tion in patients undergoing aortocoronary bypass surgery carries an
eightfold risk of future atrial fibrillation and a doubled cardiovascular
mortality. Eur J Cardiothorac Surg 2010;37:1353–1359.
[956] Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P
et al. Atrial fibrillation after isolated coronary surgery affects late sur-
vival. Circulation 2008;118:1612–1618.
[957] Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M et al.
Postoperative atrial fibrillation and mortality after coronary artery
bypass surgery. J Am Coll Cardiol 2004;43:742–748.
[958] Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial
fibrillation following coronary bypass surgery predicts long-term mor-
tality: a systematic review and meta-analysis. Eur J Cardiothorac Surg
2015;48:817–824.
[959] El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA
et al. New-onset atrial fibrillation predicts long-term mortality after cor-
onary artery bypass graft. J Am Coll Cardiol 2010;55:1370–1376.
[960] Anderson E, Dyke C, Levy JH. Anticoagulation strategies for the
management of postoperative atrial fibrillation. Clin Lab Med 2014;34:
537–561.
[961] Heldal M, Atar D. Pharmacological conversion of recent-onset atrial
fibrillation: a systematic review. Scand Cardiovasc J Suppl 2013;47:2–10.
[962] Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish
ME et al. CTSN. Rate Control versus Rhythm Control for Atrial
Fibrillation after Cardiac Surgery. N Engl J Med 2016;374:1911–1921.
[963] Triedman JK. Arrhythmias in adults with congenital heart disease. Heart
2002;87:383–389.
[964] Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA,
Friedman PA et al. Outcome of direct current cardioversion for atrial
arrhythmias in adults with congenital heart disease. Int J Cardiol 2012;
154:270–274.
[965] Greason KL, Dearani JA, Theodoro DA, Porter CB, Warnes CA, Danielson
GK. Surgical management of atrial tachyarrhythmias associated with
congenital cardiac anomalies: Mayo Clinic experience. Semin Thorac
Cardiovasc Surg Pediatr Card Surg Annu 2003;6:59–71.
[966] Payne L, Zeigler VL, Gillette PC. Acute cardiac arrhythmias following sur-
gery for congenital heart disease: mechanisms, diagnostic tools, and
management. Crit Care Nurs Clin North Am 2011;23:255–272.
e86 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
[967] Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ
et al. Sudden cardiac death in adult congenital heart disease. Circulation
2012;126:1944–1954.
[968] Jensen AS, Idorn L, Norager B, Vejlstrup N, Sondergaard L.
Anticoagulation in adults with congenital heart disease: The who, the
when and the how? Heart 2014;101:424–429.
[969] Fujita S, Takahashi K, Takeuchi D, Manaka T, Shoda M, Hagiwara N et al.
Management of late atrial tachyarrhythmia long after Fontan operation.
J Cardiol 2009;53:410–416.
[970] Feltes TF, Friedman RA. Transesophageal echocardiographic detection
of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias
and congenital heart disease. J Am Coll Cardiol 1994;24:1365–1370.
[971] Nagao K, Tsuchihashi K, Tanaka S, Iimura O. [Studies on atrial arrhyth-
mias in atrial septal defect. The influences of aging on atrial fibrillation].
Nihon Ronen Igakkai Zasshi 1995;32:27–32.
[972] Giamberti A, Chessa M, Abella R, Butera G, Negura D, Foresti S et al.
Surgical treatment of arrhythmias in adults with congenital heart
defects. Int J Cardiol 2008;129:37–41.
[973] Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen
EH, Utens EM et al. Excellent survival and low incidence of arrhythmias,
stroke and heart failure long-term after surgical ASD closure at young
age. A prospective follow-up study of 21-33 years. Eur Heart J 2003;24:
190–197.
[974] Yamada T, McElderry HT, Muto M, Murakami Y, Kay GN. Pulmonary
vein isolation in patients with paroxysmal atrial fibrillation after direct
suture closure of congenital atrial septal defect. Circ J 2007;71:
1989–1992.
[975] Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, Paelinck B,
Morissens M. The importance of pulmonary artery pressures on late
atrial arrhythmia in transcatheter and surgically closed ASD type secun-
dum. Int J Cardiol 2011;152:192–195.
[976] de Salle P, Goenen M, Lecron J, Jaumin P, Tremouroux J. [Rhythm disor-
ders occurring after surgical closure of the interatrial communication].
Acta Cardiol 1975;30:239–249.
[977] Scaglione M, Caponi D, Ebrille E, Di Donna P, Di Clemente F, Battaglia A
et al. Very long-term results of electroanatomic-guided radiofrequency
ablation of atrial arrhythmias in patients with surgically corrected atrial
septal defect. Europace 2014;16:1800–1807.
[978] Kanter RJ, Garson A Jr. Atrial arrhythmias during chronic follow-up of
surgery for complex congenital heart disease. Pacing Clin Electrophysiol
1997;20:502–511.
[979] Porter CJ, Garson A. Incidence and management of dysrhythmias after
Fontan procedure. Herz 1993;18:318–327.
[980] Gelatt M, Hamilton RM, McCrindle BW, Gow RM, Williams WG, Trusler
GA. Risk factors for atrial tachyarrhythmias after the Fontan operation. J
Am Coll Cardiol 1994;24:1735–1741.
[981] Peters NS, Somerville J. Arrhythmias after the Fontan procedure. Br
Heart J 1992;68:199–204.
[982] Kwak JG, Kim WH, Lee JR, Kim YJ. Surgical therapy of arrhythmias in
single-ventricle patients undergoing Fontan or Fontan conversion. J
Card Surg 2009;24:738–741.
[983] Backer CL, Tsao S, Deal BJ, Mavroudis C. Maze procedure in single ven-
tricle patients. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu
2008;11:44–48.
[984] Deal BJ, Mavroudis C, Backer CL. The role of concomitant arrhythmia
surgery in patients undergoing repair of congenital heart disease. Pacing
Clin Electrophysiol 2008;31:S13–16.
[985] Gandhi SK. Atrial arrhythmia surgery in congenital heart disease. J Interv
Card Electrophysiol 2007;20:119–125.
[986] Correa R, Sherwin ED, Kovach J, Mah DY, Alexander ME, Cecchin F et al.
Mechanism and ablation of arrhythmia following total cavopulmonary
connection. Circ Arrhythm Electrophysiol 2015;8:318–325.
[987] Khairy P, Aboulhosn J, Gurvitz MZ, Opotowsky AR, Mongeon FP, Kay J
et al. Alliance for Adult Research in Congenital Cardiology. Arrhythmia
burden in adults with surgically repaired tetralogy of Fallot: a multi-
institutional study. Circulation 2010;122:868–875.
[988] Kobayashi J, Yamamoto F, Nakano K, Sasako Y, Kitamura S, Kosakai Y.
Maze procedure for atrial fibrillation associated with atrial septal defect.
Circulation 1998;98:II399–402.
[989] Shim H, Yang JH, Park PW, Jeong DS, Jun TG. Efficacy of the maze pro-
cedure for atrial fibrillation associated with atrial septal defect. Korean J
Thorac Cardiovasc Surg 2013;46:98–103.
[990] Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyar-
rhythmias and the Cox-maze procedure in congenital heart disease.
Congenit Heart Dis 2013;8:434–439.
[ 991] Sherwin ED, Triedman JK, Walsh EP. Update on interventional electro-
physiology in congenital heart disease: evolving solutions for complex
hearts. Circ Arrhythm Electrophysiol 2013;6:1032–1040.
[992] Wellens HJ. Contemporary management of atrial flutter. Circulation
2002;106:649–652.
[993] Bertaglia E, Zoppo F, Bonso A, Proclemer A, Verlato R, Coro L et al.
Long term follow up of radiofrequency catheter ablation of atrial flut-
ter: clinical course and predictors of atrial fibrillation occurrence.
Heart 2004;90:59–63.
[994] Seara JG, Roubin SR, Gude Sampedro F, Barreiro VB, Sande JM,
Manero MR et al. Risk of atrial fibrillation, stroke, and death after
radiofrequency catheter ablation of typical atrial flutter. Clin Res
Cardiol 2014;103:543–552.
[995] Brembilla-Perrot B, Girerd N, Sellal JM, Olivier A, Manenti V, Villemin T
et al. Risk of atrial fibrillation after atrial flutter ablation: impact of AF his-
tory, gender, and antiarrhythmic drug medication. J Cardiovasc
Electrophysiol 2014;25:813–820.
[996] Bronis K, Metaxa S, Koulouris S, Manolis AS. Vernakalant: review of a
novel atrial selective antiarrhythmic agent and its place in current
treatment of atrial fibrillation. Hosp Chronicles 2012;7:171–181.
[997] Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardio-
version of atrial flutter and fibrillation. J Am Board Fam Med 2011;24:
86–92.
[998] Reisinger J, Gstrein C, Winter T, Zeindlhofer E, Hollinger K, Mori M
et al. Optimization of initial energy for cardioversion of atrial tachyar-
rhythmias with biphasic shocks. Am J Emerg Med 2010;28:159–165.
[999] Pinski SL, Sgarbossa EB, Ching E, Trohman RG. A comparison of 50-J
versus 100-J shocks for direct-current cardioversion of atrial flutter.
Am Heart J 1999;137:439–442.
[1000] Manolis AS, Dragazis I, Kapelakis I, Papadimitriou P, Sakellaris N.
Transesophageal overdrive pacing: A simple and versatile tool. Hosp
Chronicles 2013;8:143–145.
[1001] Poulidakis E, Manolis AS. Transvenous temporary cardiac pacing.
Rhythmos 2014;9:20–27.
[1002] Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A et al.
Meta-analysis of ablation of atrial flutter and supraventricular tachy-
cardia. Am J Cardiol 2009;104:671–677.
[1003] Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA
et al. Acute and long-term results of radiofrequency ablation of common
atrial flutter and the influence of the right atrial isthmus ablation on the
occurrence of atrial fibrillation. Eur Heart J 2003;24:956–962.
[1004] Bandini A, Golia P, Caroli E, Biancoli S, Galvani M. Atrial fibrillation
after typical atrial flutter ablation: a long-term follow-up. J Cardiovasc
Med (Hagerstown) 2011;12:110–115.
[1005] Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clini-
cal outcomes after catheter ablation of atrial flutter. PLoS One 2014;9:
e100509.
[1006] Esato M, Hindricks G, Sommer P, Arya A, Gaspar T, Bode K et al. Color-
coded three-dimensional entrainment mapping for analysis and treat-
ment of atrial macroreentrant tachycardia. Heart Rhythm 2009;6:
349–358.
[1007] Huo Y, Schoenbauer R, Richter S, Rolf S, Sommer P, Arya A et al. Atrial
Arrhythmias Following Surgical AF Ablation: Electrophysiological
Findings, Ablation Strategies, and Clinical Outcome. J Cardiovasc
Electrophysiol 2014;25:725–738.
[1008] Institute of Medicine Committee on Quality of Health Care in America.
Crossing the Quality Chasm: A New Health System for the 21st
Century. Washington (DC): National Academies Press (US); 2001.
[1009] Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for
patients with chronic illness. JAMA 2002;288:1775–1779.
[1010] Hibbard JH, Greene J. What the evidence shows about patient activa-
tion: better health outcomes and care experiences; fewer data on costs.
Health Aff (Millwood) 2013;32:207–214.
[1011] McCabe PJ. Self-management of atrial fibrillation: a new frontier for
nursing research. Prog Cardiovasc Nurs 2008;23:37–40.
[1012] Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differen-
ces in patient perceptions of atrial fibrillation and anticoagulation ther-
apy: the West Birmingham Atrial Fibrillation Project. Stroke 2002;33:
238–242.
[1013] Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural
interventions for anticoagulant therapy in patients with atrial fibrilla-
tion. Cochrane Database Syst Rev 2013;6:Cd008600.
[1014] Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational interven-
tion improves anticoagulation control in atrial fibrillation patients: the
TREAT randomised trial. PLoS One 2013;8:e74037.













[1015] Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an
Educational intervention on patients’ knowledge of Atrial fibrillation
and anticoagulant therapy, INR control, and outcome of Treatment
with warfarin (TREAT). BMC Cardiovasc Disord 2010;10:21.
[1016] Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP et al.
Warfarin knowledge in patients with atrial fibrillation: implications for
safety, efficacy, and education strategies. Cardiology 2010;116:61–69.
[1017] Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE. Atrial
Fibrillation AWareness and Risk Education group [comprising the Atrial
Fibrillation Association (AFA), the European Heart Rhythm Association
(EHRA), Stroke Alliance for Europe (SAFE), and the World Heart
Federation (WHF)]. An international survey of physician and patient
understanding, perception, and attitudes to atrial fibrillation and its
contribution to cardiovascular disease morbidity and mortality.
Europace 2010;12:626–633.
[1018] Hendriks JM, Crijns HJ, Tieleman RG, Vrijhoef HJ. The atrial fibrillation
knowledge scale: development, validation and results. Int J Cardiol
2013;168:1422–1428.
[1019] McCabe PJ. What patients want and need to know about atrial fibrilla-
tion. J Multidiscip Healthc 2011;4:413–419.
[1020] Lorig KR, Holman H. Self-management education: history, definition,
outcomes, and mechanisms. Ann Behav Med 2003;26:1–7.
[1021] Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F,
Montori VM et al. Shared decision making: really putting patients at
the centre of healthcare. BMJ 2012;344:e256.
[1022] Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB et al.
Decision aids for people facing health treatment or screening deci-
sions. Cochrane Database Syst Rev 2014;1:CD001431.
[1023] Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley
P et al. Shared decision making: a model for clinical practice. J Gen
Intern Med 2012;27:1361–1367.
[1024] Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ,
Brundel B et al. Progress toward the prevention and treatment of atrial
fibrillation: A summary of the Heart Rhythm Society Research Forum
on the Treatment and Prevention of Atrial Fibrillation, Washington,
DC, December 9-10, 2013. Heart Rhythm 2015;12:e5–e29.
[1025] van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel
GJ, van Gelder IC et al. APACHE-AF Investigators. Apixaban versus
Antiplatelet drugs or no antithrombotic drugs after anticoagulation-
associated intraCerebral HaEmorrhage in patients with Atrial
Fibrillation (APACHE-AF): study protocol for a randomised controlled
trial. Trials 2015;16:393.
[1026] Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen
JE. Arrhythmic complications after electrical cardioversion of acute
atrial fibrillation: the FinCV study. Europace 2013;15:1432–1435.
[1027] Tse HF, Lau CP. Does sinus rhythm beget sinus rhythm? Effects of
prompt cardioversion on the frequency and persistence of recurrent
atrial fibrillation. Card Electrophysiol Rev 2003;7:359–365.
[1028] Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation:
a rationale for early restoration and maintenance of sinus rhythm.
Europace 2006;8:943–949.
[1029] Liu ZJ, Fu WG, Guo ZY, Shen LG, Shi ZY, Li JH. Updated systematic
review and meta-analysis of randomized clinical trials comparing caro-
tid artery stenting and carotid endarterectomy in the treatment of car-
otid stenosis. Ann Vasc Surg 2012;26:576–590.
[1030] Taylor DW, Barnett HJM, Haynes RB, Ferguson GG, Sackett DL, Thorpe
KE et al. ASA and Carotid Endarterectomy (ACE) trial collaborators. Low-
dose and high-dose acetylsalicylic acid for patients undergoing carotid
endarterectomy: a randomised controlled trial. Lancet 1999;353:
2179–2184.
[1031] Watanabe M, Chaudhry SA, Adil MM, Alqadri SL, Majidi S, Semaan E.
The effect of atrial fibrillation on outcomes in patients undergoing car-
otid endarterectomy or stent placement in general practice. J Vasc
Surg 2015;61:927–932.
[1032] Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP,
Stevens SR et al. ROCHET AF Steering Committee & Investigators.
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in
patients with non-valvular atrial fibrillation but underlying native
mitral and aortic valve disease participating in the ROCKET AF trial. Eur
Heart J 2014;35:3377–3385.
[1033] Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A,
Babuty D et al. Prognostic value of CHA2DS2-VASc score in
patients with ‘non-valvular atrial fibrillation’ and valvular heart disease:
the Loire Valley Atrial Fibrillation Project. Eur Heart J 2015;36:
1822–1830.
[1034] Breithardt G, Baumgartner H. Valvular heart disease among non-
valvular atrial fibrillation: a misnomer, in search of a new term. Eur
Heart J 2015;36:1794–1797.
[1035] Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB Jr.
Video-assisted bilateral pulmonary vein isolation and left atrial
appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg
2005;130:797–802.
[1036] Yilmaz A, Van Putte BP, Van Boven WJ. Completely thoracoscopic
bilateral pulmonary vein isolation and left atrial appendage
exclusion for atrial fibrillation. J Thorac Cardiovasc Surg 2008;136:
521–522.
[1037] Salzberg SP, Plass A, Emmert MY, Desbiolles L, Alkadhi H,
Grunenfelder J. Left atrial appendage clip occlusion: early clinical
results. J Thorac Cardiovasc Surg 2010;139:1269–1274.
[1038] Papworth Hospital NHS Foundation Trust. A randomised controlled
trial to investigate the clinical and cost effectiveness of adding an abla-
tion device-based maze procedure as a routine adjunct to elective car-
diac surgery for patients with pre-existing atrial fibrillation. http://
www.isrctn.com/ISRCTN82731440 (5 May 2016).
[1039] Amit G, Nyong J, Morillo CA, Casas JP, Adler AJ, Owolabi OO, Perel P,
Prieto-Merino D, Lambiase P. Efficacy and safety of ablation for
patients with non-paroxysmal atrial fibrillation. Cochrane Database of
Systematic Reviews 2016; 8: CD012088. DOI: 10.1002/
14651858.CD012088.pub2.
[1040] Huffman MD, Karmali KN, Berendsen MA, Andrei A-C, Kruse J,
McCarthy PM, Malaisrie CS. Concomitant atrial fibrillation surgery
for people undergoing cardiac surgery. Cochrane Database of
Systematic Reviews 2016; 8: CD011814. DOI: 10.1002/14651858.
CD011814.pub2.
[1041] Allen V, Banerjee A, SHah AD, Patel, R, Denaxas S, Casas J-P,
Hemingway H. Net clinical benefit of warfarin in individuals with atrial
fibrillation across stroke risk and acros primary and secondary care.
Heart, http://dx.doi.org/10.1136/heartjnl-2016-309910.
[1042] Kirchhof P, Calkins H. Catheter ablation in patients with persistent
atrial fibrillation. Eur Heart J 2016;10.1093/eurheartj/ehw260.
e88 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
